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Abstract 
 
The work described herein concerns the effect on the anticancer activity and the 
ability to reach their possible intracellular targets of certain steroidal metallodrugs and 
metallosupramolecular cylinders. Chapter 1 surveys the background to the project, 
surveying different DNA-binding modes, explaining their importance in the anticancer 
properties of metallodrugs and showing an overview of the different strategies used for 
enhanced delivery of these metallodrugs. 
In Chapter 2 the synthesis of new steroidal DNA covalent-binding platinum(II) 
complexes together with techniques to purify previously synthesised steroidal 
complexes are presented. Their cytotoxicity, cellular uptake and biomolecular 
interaction are investigated, showing that the coupling of the steroid confers activity to 
otherwise inactive complexes, modifying their DNA binding mode and cellular uptake 
and distribution.  
Chapter 3 explores the coupling of similar steroidal delivery vectors to non-covalent 
metallodrugs, presenting simple synthetic pathways to create such complexes in a single 
step. Their anticancer activity and DNA-binding affinity are investigated: surprisingly 
showing that this coupling has negative effects. 
In Chapter 4 the cytoxicity and cellular behaviour of metallosupramolecular 
cylinders are studied. It is shown that these complexes can cross the cellular membrane, 
concentrating in the nuclei where they can interact with cellular DNA. 
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Chapter 1: Introduction 
 
DNA is the most important molecule in the cell. Its contents encode all the genetic 
data (in most organisms) which is ultimately responsible for most of the functions, 
actions and physical traits of the organism. The genetic information is processed 
through transcription into RNA, which is then used to synthesise specific amino-acidic 
sequences, leading to desired proteins. Alternatively the RNA itself may have regulative 
functions of other genes or proteins. This means that through regulation of DNA, the 
whole cellular activity can be controlled. Changes in the DNA sequence or defective 
genetic information can produce protein actions that are the origin of many diseases. To 
avoid this, cells have processes that lead to programmed death in case of important 
changes in the genomic DNA. Some organisms make use of this dependence on DNA 
and turn it to their own advantage with defensive or pathogenic intentions. Good 
examples of this are the viruses; they can introduce their own genetic material into the 
cellular genomic DNA to control the whole cell and reproduce within the infected 
organism. Other examples are the productions of antibiotics, toxins or other compounds 
that act through a direct interaction with the target organism DNA providing an 
advantage to the organism that synthesises them. For these reasons, cellular DNA is 
interesting as a medicinal target with the potential of control diseases, parasites or 
viruses. 
 
1.1 Modes of DNA interaction 
It has been demonstrated that synthetic molecules can target DNA using four 
different binding modes: Major and minor groove binding, intercalation, and base 
covalent binding (Fig. 1.1)
1
. Recently two new modes of ligand-DNA interaction have 
been described; phosphate binding and junction binding (Fig. 1.1)
1-3
. Most of these 
modes have been observed in nature and synthetic molecules have been created to 
imitate the natural products. The major groove has been successfully targeted with 
synthetic peptides or oligonucleotides containing Zinc fingers
4
 or forming triple 
stranded DNA
5-6
 respectively. These oligonucleotides form the triplex DNA through the 
formation of Hoogsteen or reverse Hoogsteen base pairing, which confers certain 
sequence-specificity, making them interesting for gene regulation
5-7
. Peptide nucleic 
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acids (PNAs) have been synthesised as well with the same aim of the oligonucleotides. 
These molecules replace the sugar backbone of DNA/RNA by a neutral polymeric chain 
of aminoacids, removing the negative charge of the oligonucleotides that will reduce 
their binding to anionic double helical DNA
8
. Recently, metallosupramolecular 
cylinders able to target the DNA double helix in the major groove (Fig. 1.2 A) have 
been reported. They are the first truly synthetic agents to target only the major groove
1
. 
 
Figure 1.1. Synthetic molecules targeting the major groove (A; synthetic oligonucleotide; PDB ref. 149D), minor 
groove (B; DAPI, Fig 1.2; 1D30), intercalate between DNA bases (C; Doxorubicin, Fig. 1.2; 1D12), binding to bases 
(D; cisplatin, Fig. 1.5; 1AIO) phospate backbone (E; TriplatinNC, Fig. 1.7; 2DYW) and three way junction (F; iron 
supramolecular helicate Fig 1.8; 2ETO). 
B 
A 
C 
D E 
F 
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Figure 1.2. Metallodrugs that bind in the major groove (A) or intercalate between DNA bases (B); non-covalent 
DNA Three Way Junction binding (C, taken from Olesky et al2) and Phospate binding (D, TriplatinNC, taken from 
Komeda et al3).  
The DNA double helix minor groove, on the other hand, can be targeted with organic 
synthetic molecules (Fig. 1.3 B,C)
1
. Such agents are usually small arc shaped cationic 
structures with selectivity towards AT regions (due to the narrower size of the minor 
groove when compared with GC sequences, making them fit tighter), such as 
diarylamides (DAPI, berenil and pentamidine) and bis-benzimidazoles (Hoechst 
family)
1
. They are used as anticancer, antiprotozoal, antiviral and antibacterial agents,
9
 
and some of them show interesting fluorescent abilities (increased when bound to 
DNA), and are widely used as imaging molecules and DNA stains
1
. Another example is 
Distamycin A, a natural antibiotic used commercially against bacterial and viral 
infections. As the previous synthetic examples it is a cationic long molecule with 
methylpyrroles that bind specifically in AT rich regions
10. Dervan’s group have 
modified the basic structure with different pyrrole/imidazole sequences that allow the 
recognition of different DNA sequences via the minor groove
10
.The resulting molecules 
D 
C 
B 
A 
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are the pre-eminent example of sequence specific synthetic DNA binding agents (Fig. 
1.3C). 
 
Figure 1.3. Synthetic molecules targeting the major groove (A), minor groove (B, C), intercalate between DNA 
bases (D), binding to bases (E). 
A third way of binding is intercalation. This involves the introduction of planar 
aromatic molecules between the bases
1
 (Fig. 1.3D) and was first proposed in the 
1960s
11
. Intercalation can happen from either major and minor grooves, opening the gap 
between stacked base pairs and producing unwinding of the DNA double helix. 
Intercalators have a maximum loading of a molecule per 2 gaps
12
; this is due to the fact 
that the backbone is not flexible enough to have molecules intercalated in adjacent gaps. 
An example of a molecule with intercalative properties is ethidium bromide, a 
carcinogenic compound used in normal molecular biology and biochemistry techniques 
that increases its fluorescent properties when intercalated between the bases of the 
DNA
13
. An example of a clinically used intercalator is the antibiotic doxorubicin and its 
family (antrhacycline antibiotics), a group of planar organic molecules that have been 
widely used as anticancer drugs since 1960s
14
.  
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Finally, the last of the conventional modes of DNA binding is covalent binding to the 
nucleobases, mainly to the N7 atoms of G or A bases
1
. These covalent bonds produce 
modifications in the structure of the DNA leading to lesions in the genetic code that not 
always can be repaired, finishing usually in programmed cellular death. Nitrogen 
mustards such as melphalan (Fig. 1.3E), platinum complexes such as cisplatin
15
, 
nitrosoureas and cross linking agents such as mitomycin C
16
, are in clinical use as 
anticancer agents. 
 
Figure 1.4. Hydrogen bonds with the DNA phosphate backbone observed in the arginine fork (A) and with 
Farrell’s TriplatinNC (B). 
All of these modes of interaction with DNA have been known since the 1960s and in 
40 years no substantial new ways of DNA binding have been described. This has 
changed recently and in the last 5 years two new modes of DNA binding have been 
described: binding to DNA junctions (especially three way junctions)
2
 and binding to 
the phosphate backbone of the DNA
3
. Phosphate binding has been observed in the 
nature previously: Proteins can bind this region through hydrogen bonds from cationic 
residues, especially arginine, which forms the known arginine forks (Fig. 1.4 A). Alkali 
metals of the groups I and II can bind to DNA in this area as well
1
. Recently Farrell 
synthesised a non-natural compound that could bind to the DNA phosphate backbone in 
similar way to the arginine residues
3
. The synthesised compound is a cationic trinuclear 
Pt complex, without Pt-Cl groups that would allow covalent binding to the DNA (Fig. 
1.2, TriplatinNC). The positive charge, absence of leaving groups and presence of 
several amino groups allow the complex to bind to the phosphate groups of the 
backbone through hydrogen bonds (Fig. 1.4 B), forming similar structures to arginine 
forks. Single crystal X-Ray diffraction of DNA and ligand reveals that the complex can 
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both track along the backbone of a single strand or stretch across the minor groove 
making contacts with the phosphate backbones on each strand
3
. 
The second new DNA binding mode occurs through the recognition of DNA 
junctions. These structures are formed by RNAs or DNAs in different situations, the 
common structures being the connective points of three or four double stranded chains. 
Some of these can be observed in different structural types of RNA, replication forks (a 
kind of three way junction) or during the recombination process (the four way or 
Holliday junction). Until recently, compounds aimed at these structures were just 
bifunctional agents that target two of the B-DNA arms involved in the junction. Thus 
bis-intercalators and bis-minor groove binders were synthesised and showed the ability 
to recognize these structures, but still bind to the DNA in their usual way
1
. Recently, the 
Hannon group described the structure of a cationic metallosupramolecular complex that 
could bind in the internal cavity of a three way junction (Fig. 1.2)
2
. This dimetallic 
triple-stranded complex has a cylindrical shape and similar size to Zinc fingers and is 
able to target the major groove of the DNA double helix producing dramatic coiling
17
. 
Single crystal X-Ray diffraction of the complex with a palindromic DNA sequence 
showed that the cylindrical compound could recognise as well the structure of a three 
way junction (TWJ). The compound was perfectly inserted in the cavity created by the 
TWJ structure, without alterations to the DNA structure or the complex. The fit was so 
perfect that the two internal aromatic phenyls of each strand of the complex stack with 
the two bases of one of the strands of the TWJ. The three pyridine rings of the end of 
the cylinder that protrude into the TWJ bind in the minor grooves of the three strands of 
the structure in a similar way to the minor groove binders described before
2
. This 
recognition was unprecedented and of high interest since opens the possibility to target 
replication or transcription forks. 
 
1.2 Metallic complexes as anticancer drugs 
The popular image of a medicine corresponds to organic molecules with complicated 
structures. These molecules would be cleverly designed, aiming at incredibly specific 
targets and would provide great activity and low side effects. Reality is different and 
inorganic formulated drugs (especially coordination complexes of the metallic transition 
elements) represent a major part of the pharmaceutical industry
18-19
. The best example 
 18 
of this is cisplatin, a platinum (II) square planar coordination complex that presents two 
ammine groups and two chloride atoms in cis configuration bound to the metallic centre 
(Fig. 1.5)
15
. This complex was first synthesised by Peyrone in 1844
20
, but was not until 
the 1960s that Rosenberg discovered its antibacterial
21
 and cytotoxic
22
 abilities. 
Cisplatin was accepted as a clinical anti-cancer drug in 1978 and since then has been 
used broadly alone or in combination against different cancers presenting a business of 
two billion US dollar per year
23-24
.  
 
Figure 1.5. Structure of cisplatin (A), carboplatin (B), oxaliplatin (C), nedaplatin (D). 
It is commonly accepted that cisplatin interacts not only with DNA but also with 
plasma proteins
25
, enzymes
26
, serum albumin
27
, and with sulphur containing molecules 
such as glutathione, the latter taking part in a deactivation processes
28
. It can also 
interact with lipids and intermembrane proteins, while it is trying to enter into the cell
29
. 
The cellular uptake process was believed for a long time to occur by passive diffusion
30-
34
, but recent works suggest other possible routes: some copper transporters can regulate 
the amount of platinum inside the cell
35
. However, DNA is the target that leads to 
cisplatin activity
23, 36
. 
Cisplatin is not thought to be the active agent once the drug is inside the body and 
partial or complete hydrolysis in the intracellular environment is thought responsible for 
activation
37
. This hydrolysis affords cationic compounds that interact with DNA, mainly 
through bonding to the N
7
 of purine bases, with Guanine preferred over Adenine (90% 
of all Pt-DNA bonds). Binding to N
1
 of Adenine or N
3
 of Cytosine is possible as well, 
but not so common. Cisplatin-DNA interactions appear mainly as bifunctional 
adducts
38
, being the intrastrand 1,2 GpG the most common (formed in 65% of the 
occasions). Intrastrand 1,2 ApG cross links can be detected as well on 25% of the 
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lesions, with a 5% of 1,3 GpXpG
39
. Finally, small amount of interstrand adducts 
(mainly GG) and monofunctional adducts can be detected
40
. As might be expected, the 
various bonding arrangements found in Pt-DNA adducts result in different distortions to 
the DNA helix. The major intrastrand 1,2 GpG lesion is located in the major groove, 
and produce the DNA double strand to unwind by 13º
41
. It also bends (kinks), the DNA 
by 45º towards the site of platination
42
. This bent DNA is recognized by nuclear HMG 
proteins
39, 43
, binding to the DNA and protecting the lesion from DNA repair
 44
. If 
enough of these adducts are produced without repair (normally through nucleotide 
excision repair), the cell will die through apoptotic process.  
 
Figure 1.6. XRay structure of cisplatin DNA interaction (left; PDB ref. 1AIO), and being recognised by HMG 
proteins (right; 1CKT). 
The trans isomer of cisplatin, by contrast, does not show any activity against 
carcinogenic cells. This could be due to the non formation of bifunctional 1-2 GpG 
intrastrand adducts: transplatin only forms 1,3 GpXpG intrastrand crosslinks. These 
adducts are quite unstable and evolve to 1,1’ GC interstrand adducts45, unwinding the 
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DNA double helix by 9º and not being recognised by HMG domain proteins. Another 
possibility for this low activity could be the higher life time of the mono-functional 
adducts and the low formation of bi-functional adducts compared with cisplatin
46
. DNA 
adducts and structural modifications different to cisplatin’s could explain the inactive 
nature observed for trans platinum compounds. This shows the importance of DNA 
binding in the cellular behaviour of platinum complexes.  For that reason it was 
postulated that for a platinum drug to be active, it needed to present two good leaving 
groups in cis geometry. 
However, this process is not selective: cisplatin interacts with non-cancerous cells 
and other bio-molecules (such us proteins) producing secondary effects that limit the 
dose that can be administered. In addition, some tumours are resistant towards the drug 
and others can develop resistance after the treatment
15
. For that reason a second 
generation of complexes was developed and three of such compounds are already on the 
market (Carboplatin, Oxaliplatin and Nedaplatin) (Fig. 1.5)
23
. These new complexes 
allowed the solution of some of the problems previously described: respectively lower 
side effects, broader activity and the ability to overcome some types of resistance, lower 
neuro and nefrotoxicity. Carboplatin (Fig. 1.5B) has a cyclobutane,1-1,dicarboxylate as 
leaving group instead of the chlorides of cisplatin. This increases the stability of the 
complex, showing lower interaction with non-wanted molecules
15
, leading to lower 
secondary effects and cytotoxicity. For that reason carboplatin is administered to 
patients with other weaknesses or illness. However, no activity is observed when 
cisplatin resistant tumours are treated with this derivative
36
. Oxaliplatin (Fig. 1.5C), on 
the other hand, shows a different activity spectrum to cisplatin. It is quite effective 
against tumours that develop resistance as result of the treatment with cisplatin
47
. The 
mechanism of action is the same as cisplatin, but it seems not to be recognised by the 
HMG proteins as result of the bulkiness of its DNA adduct (the DACH ligand remains 
on the lesion rather than two ammonias)
48
. None of these drugs have addressed all of the 
problems, probably due to their similarity to cisplatin in their structure and thus their 
mode of action. 
All second generation complexes bind to DNA in a similar way to cisplatin, 
providing similar activity. Complexes that bind differently from cisplatin to the DNA 
can lead to activity through different mechanisms that could circumvent cisplatin 
problems. For that reason, further generations of compounds have been explored, 
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searching for different interactions with the cellular DNA. This class of agents is broad 
and includes many “non-conventional” structures such trans geometries38, 49-51, 
polymetallic
52-54
, monofunctional
55-57
 or platinum (IV) complexes (targeting oral 
administration)
15
. None of these has yet arrived on the market, although some have 
entered clinical trials. 
Complexes with trans geometry can be activated by modification of the coordination 
sphere. Three main types of compounds can be observed here: trans platinum 
complexes activated by bulky aromatic substituents, by aliphatic amino groups and 
finally by iminoethers (Fig. 1.7A-E)
38, 58
. All of them show different DNA binding 
abilities and produce different distortions to the DNA structure compared with 
transplatin and cisplatin 
38, 58
. When one or both amino groups are substituted by bulky 
aromatic rings, the new compounds show activities at least one order of magnitude 
better than transplatin. The complexes are as cytotoxic as their cis isomers and cisplatin, 
presenting good activity against cisplatin and oxaliplatin resistant cell lines
38, 58
. They 
show higher cellular uptake, slower reaction binding rates to glutathione and twice as 
many interstrand adducts compared with transplatin. These interstrand adducts are 
formed quicker than for transplatin and present a similar structure to the ones observed 
in cisplatin, being 1,2’ GG instead of 1,1’ GC (as observed for transplatin). The 
presence of the aromatic ring changes the DNA unwinding structure/ability relationship, 
17º for the trans against 13º of cisplatin, 9º of transplatin and 4º of their cis derivatives. 
It is interesting to note that complexes with a single aromatic in the coordinative sphere 
also show in vivo anti-leukeamic activity, not observed for the bisubstituted compounds, 
may be due to the high number of monofunctional adducts observed for this complexes. 
These adducts produce local conformational distortions in the DNA very similar to the 
ones produced by the 1,2 GpG intrastrand cisplatin adducts (perhaps due to a partial 
intercalation of the aromatic ring between the adjacent bases), and are recognized by 
HMG proteins and cisplatin-specific antibodies. The poor solubility problem presented 
for these complexes was solved changing the chloride leaving groups by acetate groups. 
This change makes them the trans equivalent of carboplatin, providing them with high 
water solubility, but maintaining the same activity as the original compounds
59
. 
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Figure 1.7. Examples of non-conventional platinum complexes: planar aromatic trans complexes (A), aliphatic 
amines trans complexes (B), piperidine/piperazine-aliphatic amine trans complexes (C), iminoether trans complexes 
(D), multimetallic BBR3464 (E) and platinum(IV) Satraplatin (F). 
A second example of trans activation can be observed when the N donor amino 
groups are substituted by one or two aliphatic amines (Fig. 1.7B, C). These complexes 
show similar activity to cisplatin in sensitive cell lines and higher against cisplatin 
resistant
38, 58
. The improved activity in resistant cell lines again can be due to a 
particularly high percentage of monofunctional and interstrand adducts, with this adduct 
found in the form of 1,2’ GG crosslinks. This leads to higher efficiencies than cisplatin 
and transplatin in blocking DNA in vitro synthesis and lower levels of repair of the 
lesions observed
38, 58
. These two modes for activate trans geometries are mixed when 
one of the amines or ammonia is substituted by a positively charged non planar 
piperidine or piperazine molecule (Fig. 1.7C). The toxicity of these new complexes 
decreases compared with the original compounds, but they present better response 
towards cisplatin resistance mechanisms
58
. These cationic complexes show a high 
percentage of interstrand crosslinks, but lower than previous compounds, and extremely 
high double stranded DNA unwinding abilities, showing around 30º compared to 13º of 
cisplatin and 17º showed by the trans aromatic complexes
60
. Cis derivatives, in contrast, 
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unwind the DNA double helix by 13º (the same as cisplatin) and present normal 
cisplatin like interstrand adducts percentages, showing lower toxicities compared to the 
trans complexes
61
.  
The third way to activate trans geometries is through the use of N donor iminoether 
groups (Fig. 1.7D)
38, 58
. Contrary to the previous examples, the main DNA adduct is not 
an interstrand crosslink, rather a higher percentage of monofunctional adducts are 
formed with preference for sequences pyrimidine-Guanine-pyrimidine (py-G-py). Even 
though, they show in vitro anticancer activities similar to cisplatin (with a better 
response towards resistance mechanisms) and present in vivo activity (having interesting 
lipophilic properties that make possible potential oral administration). These 
monofunctinal lesions unwind the DNA double helix 6º
38, 58
, as seen in previous non-
active monofunctional complexes
62
 (against 13º for cisplatin and higher values for 
aromatic trans complexes). However, they do not denature the DNA double helix as 
transplatin or other monofunctionally binding complexes, and they force a 21º DNA 
bend towards the minor groove (against the 45º towards the major groove of cisplatin). 
Not being recognised by HMG domain proteins, they can be removed by nuclear 
excision repair (NER); but formation of protein-DNA crosslinks inhibits both the DNA 
synthesis and NER systems
58
.  
Interestingly, monofunctional adducts caused by biologically inactive
63-64
 
[Pt(NH3)3Cl]Cl and [Pt(dien)Cl]Cl cause relatively few DNA structural changes. They 
bind monofunctionally to N7 of guanine, producing 6º of unwinding to the double helix 
without visible bending of the DNA
62
. When bulkier amines are attached to the 
platinum
55
, monofunctional adducts are still formed without any trace of bifunctional 
adducts
56, 65
 (although some of this have been observed with triammines with 2-
diazapyrenium
66-67
). They still produce minor distortions to DNA compared to 
cisplatin
68
, unwinding the double helix to a similar extent to non-bulky amines
57
 without 
visible bending of the structure
69
. This ability to distort DNA may be co-related to why 
such complexes possess poor cytotoxicity. Unlike cisplatin they don’t seem to undergo 
hydrolysis before binding to guanine
70
, and show low sensitivity to the excision repair 
mechanism
66
. However, triammines do inhibit DNA replication, with an increased 
effectivity when bulky substituents are introduced
56
. As with cisplatin, trans isomers 
seem to produce less effect on the DNA
71
, being less active than the cis isomers. 
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These are not the only compounds specifically designed to yield adducts different to 
the ones produced by cisplatin, with the idea that different DNA interaction would lead 
to broader anti-cancer activity; multimetallic complexes have been studied as well. Of 
particular note are Farrell’s trans platinum multimetallic complexes52, especially 
BBR3464 (which underwent phase II clinical trials; Fig. 1.7E), that show increased 
intracellular accumulation, and dramatic in vivo and in vitro activity against cisplatin 
sensitive and resistant tumours
72
. These compounds could produce a whole series of 
different DNA adducts, including 1,2 , 1,3 and 1,5 intrastrand and 1,2’ , 1,4’ and 1,6’ 
interstrand crosslinks adducts. None of the intrastrand lesions are recognised by HMG 
proteins and can be repaired by nuclear excision repair proteins (NER proteins) more 
easily than cisplatin 1,2 GpG adducts. However, a high level (20%) of interstrand 
crosslinks are detected (against 3% of cisplatin) that unwind by 14º the double helix of 
DNA and are able to span 6-8 bases the DNA
73
. These interstrand crosslinks are not 
recognised by HMG proteins, and the 1,4’ adduct is particularly interesting, as it cannot 
be repaired by NER proteins
74
.  
Finally, using octahedral platinum(IV) centres (Fig. 1.7F), two more ligands can be 
added to the metallic centre, this can lead to higher lipophilicities and water solubilities. 
Compounds in this oxidation state are more inert, lowering the reactivity with 
biomolecules leading to fewer side effects
75
. These two factors (improved 
solubility/lipophilicity and higher inertness) made them the perfect molecules to attempt 
oral administration. They show high stability in the gastro-intestinal track and are 
incorporated into the blood stream
76
. Once inside the organism they are reduced by 
proteins like GSH or even Fe(II) containing proteins
77
 (heme groups), producing 
platinum(II) derivatives, which are believed to be the DNA interacting active species
78
. 
Currently the major challenge of these compounds is to minimize the possible plasmatic 
reduction (3 s t1/2 in blood for tetraplatin
78
 and 6.3 min for satraplatin
75
), which could 
lead to unwanted secondary effects and to the loss of platinum(IV) potential advantages.  
Biological activities have been discovered for complexes of other metals, giving the 
possibility to attack different targets that maybe would resolve the problems created by 
platinum drugs
18-19
. The most effective of these are ruthenium complexes of which two 
are currently in clinical trials; the ruthenium (III) derivatives KP1019
79
 and NAMI-A
80-
81
 (Fig. 1.8). The first of these, KP1019, uses the iron transporting proteins Ferritin and 
Albumin to be transported through the blood and into the cells, where it interacts (in 
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some form) with DNA, showing activity against colon carcinoma and a variety of 
human primary tumours. NAMI-A seems to act in a totally different way since it 
doesn’t show any activity towards primary tumours. However, it has very interesting 
antiangiogenetic and antiinvasive properties, making it particularly active against 
metastasic stages of cancer. Complexes with similar (primary or anti-metastatic) 
activities have been developed with the use of arenes and ruthenium (II) as the metallic 
centre
82-85
. Other metals like iron
86-88
, titanium
89-92
 or gallium
93-94
 have been studied as 
well, with complexes of the last two also entering clinical trials. 
 
Figure 1.8. Structures of NAMI-A (A) and KP1019 (B). 
All of these drugs were designed with a view to obtaining activity through covalent 
binding of the metallic centre to its target (DNA). Non-covalent interactions with DNA 
and other macromolecules are observed in the nature, and are of great importance. 
Examples of this can be seen in the fields of recognition
95
 or antibiotics
14
, and it is also 
of potential interest for the development of new medicines. Two major ways of non-
covalent DNA binding have been known for the last forty years; groove binding (major 
and minor) and intercalation
1
. Two more has been added recently; junction
2
 and 
phosphate binding
3
. Metallodrugs binding to DNA through all four ways has been 
developed (Fig. 1.2), and indeed the last two modes have been discovered through the 
use of coordination complexes (Fig. 1.2C, D)
1
. Although promising results have been 
observed, the use of this kind of compounds as anticarcinogenic drugs is still under its 
first steps.  
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1.3 Delivery strategies for metallodrugs 
Although important breakthroughs in tumour active metallodrugs have taken place in 
the last 20 years, some of the problems formerly presented by cisplatin are common to 
almost all of the new compounds and remain unsolved. A different way of tackling the 
problem is the use of delivery systems
96
 and here two main paths have been followed: 
the use of systems that deliver the selected drug slowly, usually relying for targeting on 
the EPR (enhanced permeability and retention) effect
97
 (caused by the increased 
production of permeability mediators and angiogenesis, together with the decrease of 
the lymphatic drainage in tumour tissues); or the chemical modification of the drug 
targeting a direct feature of the selected tumour
96
, stopping the action in healthy cells. 
Herein we present an overview of the strategies used for the delivery and selective 
administration of existing anticancer metallodrugs.  
1.3.1 Delivery through covalent modification 
 Since cisplatin’s discovery, chemists have been trying to improve its abilities or 
solve its problems through covalent modification of its structure
15, 23, 38, 96, 98
. Side 
effects or resistance have been partially solved with new chemically formulated drugs 
and the same has been explored targeting or delivery
96, 98
. A variety of different ideas 
have been explored ranging from binding to biomolecules, to the use of prodrug 
techniques. An example of a biomolecule strategy was the attachment of the drug to a 
cysteine binding molecule (Fig. 1.9)
99
. The aim was to bind to blood transport proteins 
and thereby localize it using the EPR effect. Formulations of this complex achieved 
90% binding with human serum albumine (HSA) in 15 minutes of reaction. In vitro cell 
tests showed a 5-8 fold decrease in activity against lung carcinoma; however, the agents 
presented improved activity when treating in vivo tumours in mice. A similar tethering-
to-HSA strategy has also been used for ruthenium organometallic complexes
100
. This 
gave a 20 fold increase of the activity in ovarian cell lines compared with the parent 
complex
100
. 
  
Figure 1.9. Example of Pt(II) complex with cysteine binding domain. 
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As we will see in this chapter, carriers can be directed toward specific organs or 
receptors by attaching biomolecules that target them
101-104
. Metallodrugs have been 
targeted against liver or bones and estrogen or folate receptors using similar ideas
96
. 
Galactose or bile acid molecules have been use to target platinum drugs to the liver, 
taking advantage of physiological properties (galactose receptors are expressed highly 
in liver and bile acids are synthesised and effectively recycled and reused by the same 
organ). Natural
105
 and synthetic oestrogenic molecules
106
 have been attached to 
platinum or organometallic drugs and imaging systems to target oestrogen receptor (Fig. 
1.10A). Endocytotic delivery has been sought by attaching folic acid molecules to 
platinum drugs
107
. This acid displays high affinity for Folate Receptors (FR) that 
introduces the drug inside the cell through an endocytotic process. Moreover FR is 
expressed highly in human cancer cells, especially in ovarian and endometrial cancers 
and is absent in most of normal cells
108
. The ostoetropic (bone seeking) abilities 
presented by bisphosphonate molecules have been used to target bone tumours and 
ossifying metastases. Platinum molecules were attached to bisphosphonates (Fig. 
1.10B), acting as leaving groups. These molecules have interesting cytotoxicity values 
and in vivo experiments showed strong inhibition of primary tumours and prolonged 
survival
96
.  
 
Figure 1.10. Examples of oestrogen receptor directed Pt(II) estradiol derivative (A), and bone directed Pt(II) 
complex (B). 
A way of reducing side effects of platinum drugs would be to better target them to 
the nuclear DNA. To explore this metallodrugs have been bound to molecules with high 
binding affinity for DNA or that are known to localize in the nuclei
98
. Oligonucleotides 
or peptide nucleic acid (PNA) have been attached to platinum (II) and (IV) compounds 
and have shown some ability to overcome cisplatin resistance (perhaps by dual, and 
more specific, binding) and sequence specific inhibition of specific oncogens
98
. A level 
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of sequence specificity could also be achieved with the use of minor groove binders. 
Sequence selective chains of pyrolles and imidazoles can target the platinum complex 
towards certain sequences (Fig. 1.11)
109-110
. Intercalators posses high binding affinity 
towards DNA and have also been explored. Some complexes including intercalative 
ligands show impressive cytotoxic abilities and act in different ways to cisplatin
111-113
, 
making such agents interesting against cisplatin resistant cell lines. Some intercalators 
show fluorescence properties and this has been used for cellular tracking of the 
complex
114-115
. Such nuclear targeting is less attractive than tissue targeting but might 
nevertheless prove useful.  
 
Figure 1.11. Example of nuclear DNA directed Pt (II) complex. 
Prodrugs have also been explored. A prodrug is an inert compound that can be turned 
into an active drug upon selective modification at a given site, thereby delivering the 
active complex only at the desired target. Different strategies have been used for the 
activation of metallo-prodrugs but probably the most successful to date is the use of 
compounds that can undergo reduction. Platinum (IV) is a chemical form of platinum 
that present much lower activity than platinum (II). However, these platinum (IV) 
compounds can undergo intra or extracellular reduction releasing active platinum (II) 
species
23
. Platinum (IV) complexes have, also, octahedral coordination sphere, giving 
the possibility to attach extra ligands that could increase the water solubility, making 
possible the oral administration. Different platinum (IV) complexes have entered 
clinical trials
23
, the most effective to date being Satraplatin (Fig. 1.12A). Satraplatin 
usually is administered orally and reached phase III trials although it appears to have 
been unsuccessful in the final stage and has not (at this time) been approved by the 
FDA
116
. Complexes that are modified under low pH conditions (Fig. 1.12B)
96
 or can be 
photoactivated (Fig. 1.12C)
117
 have been studied as well. Carcinogenic cells present 
lower pH than its normal counterparts, as a result of the hypoxia produced by the low 
irrigation. For this reason platinum (II) complexes have been synthesised and 
considered for their pH dependent reactivity and cytotoxicity
96
. Local effects can also 
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be obtained using inactive drugs that are modified and activated by external irradiation 
with light of certain wavelength
117
. Some initial studies have looked at molecules that 
could be cleaved by specific enzymes. Sugars and esters have been attached to platinum 
molecules aiming at cleavage bye β-glucuronidases or esterases98. Although to date the 
cleavage seems to be aimed at altering the cellular permeability of such complexes 
rather than the inherent activity of the platinum unit. 
 
Figure 1.12. Examples of Platinum (IV) complex (Satraplatin, A), pH activated Pt(II) prodrug (B), photoactivated 
Pt(IV) prodrug (C), and enzymatically activated Pt(II) prodrug (D). 
1.3.2 Ceramic materials 
The usual method of cisplatin chemotherapy is through intravenous administration as 
a short-term infusion. This method yields a big concentration of complex in the 
injection area in the short initial time and the drug is then removed quickly to the rest of 
the organism. This leads to high side effects both in the treated organ and in the rest of 
the organism. An early attempt to control this release was the surgical implantation of 
solid material close to the tumour that would release slowly the drug for a long period 
reducing the side effects
118-119
. Different materials have been used in this role
120-121
, but 
due to their similarity with bone structures Calcium Phosphates (CaPs) were extensively 
studied
118, 119, 122-123
. First formulations consisted of packed solids, hydroxyapatite 
ceramic or solid phase cement that included the drugs in solid state
121-122
. When these 
systems were used it was shown that implantation close to the tumour could inhibit its 
growth and decrease the side effects produced by cisplatin
123
. Passage into the tumour 
was a complex event, a function of solubilization of the drug, adsorption to the CaPs 
ceramic and diffusion gradients in the organism
124
.  
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More recently crystals of CaPs have attracted attention due to their physical and 
chemical properties, high surface interaction properties and their biocompatibility
125
. 
Examples using hydroxyapatite or tricalcium phosphate ceramics showed that these 
systems could be used to deliver Steroids
126
, proteins
127
, hormones
128
, anticancer 
drugs
119, 122, 129
 and other molecules
130-132
. Carbonated hydroxyapatite (HA) crystals 
were especially interesting due to their similarities to the crystals found in bones. The 
compounds were adsorbed in the crystals instead of being included as solids. This 
adsorption depended on the physical and chemical characteristic of the HA crystals such 
as the chemical composition, the structure and porosity, the surface area or the size
124, 
128, 133-134
. Initial studies loading cisplatin in HA crystals showed that the adsorption and 
release of the drug was dependent on temperature, chloride concentration in the medium 
and crystallinity of the HA
124, 135
. This last factor indicated that lower crystallinity lead 
towards higher adsorption and slower release. Initial in vitro tests showed cytotoxicity 
in these systems
135
. 
 
Figure 1.13. TEM images of synthetic plate (A) or needle shaped (B) HA crystals. Taken from Palazzo et al136. 
Later studies demostrated that shape of the HA crystals is important as well. In 2007 
Natile et al showed that cisplatin molecules and bisphosphonate platinum derivatives 
could be loaded into the porous structures of bone like plate or needle shaped HA 
crystals (Fig. 1.13)
136
. The different crystalline structures showed similar Ca/P bulk 
ratios, but different surface area and Ca/P surface ratio (higher for plate shaped). 
Cisplatin was adsorbed better on needle shaped crystals, where the lower amount of 
Calcium in the surface allowed easier loading of the positively charged aquated cisplatin 
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molecules. The bisphosphonate derivative did not show any preference, presenting 
similar adsorption in both structures. However, release of the platinum agent was slower 
from the plate shaped crystals. By contrast cisplatin release was the same for both 
shaped HA crystals.  
1.3.3 Carbon Nanotubes  
Carbon nanotubes have been recently started to be explored for delivery of drugs due 
to their unique physical, chemical and physiological properties
136
. They have proved to 
be able to transport a wide range of molecules across membranes and into living cells
137-
140
. In addition, their structural stability may prolong the circulation time and the 
bioavailability of the loaded molecules. Ajima et al in 2005
141
 used single-walled 
carbon nanohorns (SWNHs) for the delivery of cisplatin. These are a kind of single-
walled nanotube (SWNTs) that do not exist alone, but instead several hundred assemble 
to form a spherical structure between 80 and 100 nm, presenting an adequate size for 
delivery through EPR. SWNHs were loaded with cisplatin through a selective 
precipitation process using DMF, showing a Pt/C ratio of 1/100 and incorporating 
around 15% of the cisplatin. The complex appeared unaltered and the system presented 
a low release rate retaining 40% of the complex  withing the nanotubes after 48 hours 
and 20% after 14 days. The formulation kept activity similar to cisplatin in a period of 
time of 48 hours. When the selective precipitation was made from water, the amount of 
complex incorporated increased to 46%
142
. Over 48 hours 100% was released. Finally 
systems generated in this way showed better in vitro and in vivo antitumour activity 
compared with cisplatin, maintaining the activity in mice for long times (25 days). 
Similar techniques have also been used for the drug Zinc phthalocyanine (ZnPc) with 
good results showing the flexibility of this kind of system. Encapsulated drug lead to the 
almost complete disappearance of tumours in mice when irradiated at 670 nm
143
, this 
effect was not observed when ZnPc or the SWNHs were administered alone.  
More recently SWNTs were functionalized with Platinum (IV) molecules by Lippard 
through covalent tethering (Fig. 1.14). The SWNTs were expected to internalize the 
drug and release the platinum payload once inside the cell
144
. An average of 65 
molecules of platinum was attached to each SWNT and they were shown to enter the 
cell through an endocytotic process, introducing higher levels of platinum in the cell 
than the untethered complex or cisplatin. They showed high toxicity in testicular cancer 
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improving 25 fold the activity of the parent complex (and 2.5 fold greater than 
cisplatin). These structures were further functionalized by adding folic acid (FA) to the 
platinum (IV) unit after preparation
101
. This was hoped to target the SWNTs towards 
FR+ cell lines and indeed proved to increase the selectivity. Toxicity was increased in 
these cell lines compared to FR- lines, giving 9 fold greater activity compared with 
cisplatin. 
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Figure 1.14. SWNTs-Pt(IV) tethered conjugated. 
Platinum (II) conjugates of SWNTs have been synthesised as well
102
. These 
conjugates have been targeted with an epithelial growing factor (EGF) towards its 
receptor (EGFR). The studies showed that the constructs entered the cell through EGFR 
directed endocytosis, as proven by the lack of uptake when EGF was not attached or the 
EGFR was knocked out.  This uptake was observed in both in vivo and in vitro systems 
and the SWNTs were detected close to the nuclei. Increases in the cytotoxicity 
compared with cisplatin and the untargeted Pt-SWNTs were observed, proving that 
activity was EGFR directed. Similar results were obtained for tumour growth in mice, 
with lower growth and higher accumulation observed in the tumour when targeted. No 
data about the way the platinum moiety is released have been provided but nevertheless 
this was the first example of selective tumour targeting of SWNTs in vivo.  
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1.3.4 Liposomes and nanocapsules 
The use of liposomes as delivery vectors involves the inclusion of the drug inside a 
lipidic bilayer biodegradable particle. It is especially useful if low solubility and poor 
stability are an issue and the liposomes have the advantage that they can be targeted by 
the EPR effect
96
. Formulations of cisplatin in liposomes failed initially, with only low 
amounts of the drug encapsulated due to its low lipophilicity
145
. These liposomes had a 
low cisplatin to lipid ratio, and showed low DNA platination and activity
146
. Two 
different strategies have been used to improve the encapsulation ratio. The first was the 
use of lipophilic derivatives of cisplatin that would help the increase of complex inside 
the bilayer. An example of this is Aroplatin, a formulation of a mixture of at least 18 
compounds with different length chain alkyl ammines that recently have reported 
positive results from phase II trials
147
. A second attempt modified the composition of 
the liposome itself (using mixtures of dipalmitoyl phosphatidyl glycerol, soy 
phosphatidyl choline, cholesterol, and methoxy-polyethyleneglycol-distearoyl 
phosphatidylethanolamine) obtaining high encapsulation efficacy
148
. Lipoplatin, as the 
formulation between this lipidic mixture and cisplatin is called, is expected to enter 
phase III of clinical trials and formulations with carboplatin are ready to start clinical 
trials
96
.  
 
Figure 1.15. Example of molecular organization of cisplatin nanocapsules taken from Chupin et al150. 
A new technique for the introduction of cisplatin in liposomes has also been 
developed, providing interesting results
149
. Following a procedure of hydratation, thaw 
freezing and centrifugation, bean shape particles with a lipidic bilayer were created (Fig. 
1.15). These particles increased the drug to lipid ratio by two or three orders of 
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magnitude compared with previous examples, and activity against ovarian cell lines 
were up to thousand fold better compared with cisplatin. Inside these nanocapsules, 
solid particles without water were detected. In principle it was thought that these 
particles were created by solid cisplatin covered by positively charged aquated species 
that would attract the negatively charged lipids. However, further studies showed that, 
while 90% of the particles were formed by precipitated cisplatin, the remaining 10% 
was formed by chlorobridged cisplatin molecules
150
. Increase of toxicity was thought to 
be due to protection from inactivation and increase uptake compared with normal 
cisplatin. 
The possibility of using the same technique with different drugs has been proven and 
lanthanides and different platinum based complexes have been introduced
149
. The 
results with carboplatin in particular were interesting
151
. Encapsulation strongly 
improved its cytotoxicity towards a panel of human cancer cell lines, showing IC50s up 
to three orders of magnitude lower than those of the free drug. When uptake was 
studied, similar results were found for cells treated with solutions of 20 nM of the 
nanocapsules and 1 µM of the free platinum drug. This improved uptake did not 
however explain all the increase in cytotoxicity, indicating that the increased activity 
was not due solely to improved uptake by cells.  
1.3.5 Nanoparticles 
The use of polymeric nanoparticles as sequential release vector for antitumour drugs 
is a well established method
152-154
. It allows protection of the loaded compound from the 
exterior environment, increasing the blood circulation time of the active dose before 
reaching its target. This not only protects the drug from body fluids, but the body will 
also be isolated from undesired chemical consequences of the drug, allowing 
minimisation of dose-dependent side effects. Encapsulation of cisplatin in nanoparticles 
presents a challenge because of its physico-chemical properties. Cisplatin is insoluble in 
organic solvents, and partially soluble in water. Only low loading ratios of cisplatin are 
achieved
154
 within the hydrophobic interiors of such polymer nanoparticles and the 
partial solubility makes difficult to obtain cisplatin polymer nanoparticle systems that 
maintain the adequate concentration for long time periods
156
. Tests have shown 
accumulation in unwanted (non-target) organs
157
 and low cytotoxicity compared with 
the free drug
158
. A strategy to incorporate platinum (IV) units with coordinated groups 
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that increase their hydrophobicity and organic solubility has been recently explored 
(Fig. 1.16A)
103
. This increased the internalisation of the platinum moiety in the 
nanoparticle, arriving at a maximum loading of around 20% of the provided drug. 
Controlled release of the complex was achieved for a period of 60 hours, releasing the 
unmodified loaded compound. Nanoparticles loaded with this complex showed IC50 
values one order of magnitude lower than the parent compound and presenting better 
activity than cisplatin. 
 
Figure 1.16. Synthesis of encapsulated Pt (IV) nanoparticles (A, Dhar et al103) and Pt(IV)/Tb3+ nanoparticles (B, 
Rieter et al104). 
The particles could be targeted towards prostate cancer by conjugation of the prostate 
specific membrane antigen aptamer (PSMA) and this did not modify the loading or 
releasing pattern of the platinum agent. Cytotoxicity in PSMA- cell lines was not 
affected by the targeting, but a four fold increase of toxicity in PSMA+ cell lines were 
as observed, yielding overall toxicities around 80 times better than the parent prodrug. 
This selectivity towards PSMA + cell lines was produced by a receptor mediated 
endocytosis that allowed the introduction of the targeted nanoparticles in times as short 
as 2 hours and gave rise to 1,2 GpG intrastrand crosslinks in those cells after 12 hours.  
A different way to circumvent the identified problems has been explored by Rieter et 
all (Fig. 1.16B)
104
. Instead of using polymeric nanoparticles with a hydrophobic interior, 
they formed the nanoparticle from precipitation of the same platinum moiety. 
Nanoparticles of platinum (IV) and Tb
3+
 ions were precipitated, giving a 2-3 Tb
3+
-Pt 
(IV) ratio. These systems released half of the payload drug in times as short as 1 hour. 
However, if they were coated with amorphous silica shells, this half-release time was 
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increased to 5.5 or 9 hours, depending of the size of the coating (2 nm or 7 nm 
respectively). Cytotoxicity was similar to cisplatin for breast cancer, but the compound 
was inactive against integrin expressing colon carcinomas. Upon conjugation of 
peptides with high binding affinity towards integrin the toxicity was increased in the 
colon cancers to slightly better activity than cisplatin.  
Non-platinum metallodrugs had also been targeted using the same techniques. 
Organometallic ferrocenyl tamoxifen derivatives were loaded into polymeric 
nanoparticles with the aim of increase their bioavailability and to reduce the removal 
from the physiological medium
158
. Cell results showed that loaded compounds retained 
their ability to stop the ER mediated transcription. However, encapsulation of the 
compounds increased the number of apoptotic cells observed compared with the free 
complexes. Similar strategies have also been used for the delivery of MRI and 
fluorescent imaging agents
160
. 
1.3.6 Biomolecules 
The previous examples for protection and release are based on systems with non-
physiological carriers. Recently, a strategy which uses proteins with internal cavities as 
delivery vectors has been developed. It is based in the use of apoferritin, the unloaded 
state of the natural iron (II) storage protein Ferritin
161
. It presents an inner cage formed 
by the assembly of its 24 protein subunits that leave 8 hydrophilic channels. Ferritin can 
be internalized by some tumour tissues through endocytosis directed by membrane-
specific receptors
162-163
. Gadolinium III
164
, metal ions
165
 or nanoparticles of iron salts
166
 
have been internalised in the apoferritin cavity, and this strategy has been used to 
deliver anticancer drugs to the brain
167
. In order to introduce a platinum drug inside the 
protein cage two procedures were used (Fig. 1.17)
168
. In the first one, molecules of 
cisplatin or carboplatin were added in solution together with apoferritin. The pH was 
dropped to 2 in order to dissociate the protein, opening the cage. The process was then 
reversed to make the apoferritine associate again entrapping the drugs. Both cisplatin 
and carboplatin were succesfully internalized, although only low amounts of them were 
included: only 2 molecules of cisplatin or 3 of carboplatin per ferritin 
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Figure 1.17. Cisplatin or carboplatin loaded apoferritin through unfolding-refolding method (A) or in situ 
generation method (B). Taken from Yang et al168. 
In the second method apoferritin in its natural conformation was treated with anionic 
[PtCl4]
2-
 salts (K2PtCl4). Being negatively charged, these platinum molecules entered 
into the internal cavity. The mixture was then treated with ammonium groups forming 
neutral diammonium dichloride platinum (II) complexes. Thirty such compounds were 
detected per cavity, a big increase compared with the 2 or 3 internalized molecules in 
the first method. This is significant even if only 15 of them correspond to cisplatin 
(mixed with transplatin). Preliminary studies against rat cell lines showed that both 
systems presented increased toxic abilities compared with the apoferritin control. 
Proteins loaded following the second procedure showed higher toxicity than the ones 
loaded under the first procedure. No comparison with cisplatin or carboplatin was 
presented since no data about release of the payload was available. 
1.3.7 Small molecular carriers 
Encapsulation, as seen previously, is commonly used by many of the delivery 
systems, and often involves several drug molecules in a single delivery unit
142, 149, 103, 
168
. Lately a new strategy for encapsulation has been developed, including a single drug 
molecule in each delivery device. Platinum molecules were encapsulated in 
macrocycles with the intention of delivery into cell lines first in 2004
169
. A dinuclear 
platinum molecule was included in a cucurbi[7]til macrocycle without showing any 
significant effect in the cytotoxicity. Cucurbit[n]urils are small barrel shaped 
macrocycles with an internal hydrophobic cavity and hydrophilic exterior and can host 
A 
B 
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different molecules
170
. Later studies showed that they could also be used as delivery 
vectors for a wide range of platinum compounds (Fig. 1.18), showing mixed effects 
depending on the compound
171
. The size of the cavity and the binding affinity was 
important on the cytoxicity. In oxaliplatin-derived intercalators, small changes of 
macrocycle size could decrease activity or give small improvements (up to 2.5 fold)
172
. 
Unfortunately binding affinity could not be measured, making impossible to fully 
understand the interactions between macrocycles and drugs. 
 
Figure 1.18. Representation of oxaliplatin derivatives intercalators encapsulated in calyx(4)arene macrocycles (A, 
taken from Benghuzzi et al131) and molecular representation of triplatin encapsulated in two cucurbit[8]uril 
macrocycles (B, taken from Wheathe et al171). 
The decrease in the activity seen for some of the compounds could be a result of the 
protective effects that the macrocycles have on their encapsulated molecules. The 
reaction ratio with mononucleotides decreased upon encapsulation, and the number of 
DNA-Pt adducts also decreased
171
. On the other hand, glutathione deactivation was 
drastically reduced, showing that encapsulation could protect these molecules from 
intracellular degradation
173
. Finally when the complexes were tested in mice, data 
showed the tolerated dose doubled compared with non-macrocycle treated drugs
171
.  
The same technique has been used with different macrocycles such as calyx(4)arenes 
(Fig. 1.18A) and β-cyclodextrins174. When the oxaliplatin-derived intercalators used 
before were encapsulated in these macrocycles they increased their stability to 
glutathione three fold. Cytotoxicity (as also seen with cucurbit[n]uril) was not modified. 
A B 
0 
4- 
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These macrocycles could find use as delivery vectors especially against cisplatin 
resistant cell lines with increased expression of Glutathione. 
1.3.8 Polymers 
The previous examples mainly deal encapsulation of the drug inside the carrier
142, 149, 
103, 168, 171
. Another approach is to use polymeric molecules that bind covalently to the 
platinum instead of encapsulating it
175
. This is an alternative way to protect the 
complexes from degradation, giving as well the opportunity for a chemically controlled 
release. As a polymeric system, accumulation at cancer cells is expected by the EPR 
effect. There are various ways to interpret this basic design, the most important being 
the Platinum-Polymer complexes, the Platinum-Dendrimer complexes and the Micellar-
Platinum systems
175
.  
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Figure 1.19. Structure of platinum-polymer AP5280. 
The first and maybe the most simple of these are the Platinum-Polymer complexes. 
Different polymers can be used, from poly(aminoacids) to more complicated 
poly(amidoamine) (PAMAM) or poly (N-(2-hydroxypropyl)-methacrylamide) 
(PHPMA) polymers. They allow the presence of linking groups that can be cleavaged 
under desired conditions, providing a certain level of specificity
175
. Different examples 
are described in the literature, but by far the most successful are the ones using 
PHPMA
176
. Two of such complexes, AP5280
177
 and AP5346
178
, are in clinical trials. 
Both contain pH sensitive peptide side chains where the platinum molecule would bind 
and a molecule of cisplatin or oxaliplatin respectively bound to it. AP5280 (Fig. 1.19) 
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entered phase I trials but presented dose limiting side effects of vomiting and nausea
177
. 
AP5346 on the other hand advanced through phase I. A phase II study in patients with 
recurrent ovarian cancer has recently been completed under the commercial name of 
Prolindac
TM. 179
.  
Dendrimers are highly branched polymers with multiple end groups. Examples like 
PAMAM are commercially available and have been studied as delivery vectors for 
several drugs
180
. PAMAM with carboxylic end groups showed high platinum loading, 
but as well the possibility of formation of crosslinks
181
. PAMAM dendrimers have high 
plasma stability, and are expected to accumulate in the tumours by the EPR effect. Low 
release of the platinum payloads in plasma-like conditions was observed, with less than 
1% of the charge released in 72 hours. However, these compounds present between 250 
and 550 times less systemic toxicities compared with cisplatin, with activities that 
reduced by 40% the mass of the tumours
181
.  
Micellar systems are aggregates of surfactant molecules in solution, formed above 
the critical micelle concentration. They are generally used to increase the aqueous 
solubility of hydrophobic complexes
182
. As described in 1.3 the main problem to use 
such formulations with platinum drugs is their intrinsic hydrophobic/hydrophilic 
properties
167
. This has been addressed by the use of diblock polymers that could bind to 
cisplatin and then self assemble into micellar structures. As for previous examples of 
polymers, the payload liberation was dependent of the concentration of ionic chloride. 
Several examples show high tumour accumulation and similar or slightly improved 
cytotoxic properties compared with cisplatin. In addition some present lower 
nephrotoxicity than the parent drug
183
. 
 
1.4 Final Remarks 
As we have seen delivery vectors can have a big impact on the effects of drug release 
or targeting. Some of them can increase cellular uptake, increasing the activity, protect 
the compounds against extra and intracellular deactivation, or help to overcome 
resistance. Some can localize drugs in selected tumours through the EPR effect, through 
physiological properties or through targeting to specific biomolecules. They can also 
increase the circulation time of the drug in the blood or control the release of the drugs 
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allowing longer times of treatment and lower side effects due to the low concentrations. 
Together this body of work represents an extremely exciting way to overcome known 
metallodrug problems, allowing better administration strategies and decreasing the 
unwanted secondary effects. However, the focus has been only at a small subset of 
known active metallo-drug designs (principally cisplatin and derivatives). Non-
conventional metallodrugs are also an important tool to overcome some of the 
drawbacks presented by cisplatin, mainly because of the different actions at the 
molecular level. The combination of these delivery strategies with interesting non-
platinum or non-conventional complexes could lead to new and successful strategies in 
the fight against cancer. 
Three different points will be addressed in this thesis. First we will study how the 
introduction of a delivery vector through covalent modification can affect the activity 
and behaviour of the metallodrug in the cell. To do this, previously synthesised active 
non-conventional estradiol- and testosterone-functionalized platinum(II) 
monofunctional complexes (targeting oestrogen or androgen receptors) will be 
compared with the equivalent inactive non-steroidal complexes. In order to know where 
the activity of such complexes came from, toxicity of the free steroidal ligands and 
effect of addition of free steroids to non-steroidal complexes will be studied. Cellular 
uptake, DNA interaction and protein interaction will be studied as well, to see how the 
presence of the steroid can alter their cellular and macromolecular binding behaviour. 
Finally we will explore possible synthetic routes that could allow the standardization of 
the coupling of steroids to existent metallodrugs. 
In the second chapter the coupling of these steroidal delivery vectors to non-covalent 
metallodrugs will be explored. New non-conventional metallo-intercalators will be 
designed and synthesised from well known and simply synthesised metallodrugs and 
commercially available steroids. We will study their anticancer activity, testing them 
against different cancers with different steroidal dependence and comparing them with 
both steroidal and non-steroidal control complexes. Again, the cellular uptake and 
interaction with macromolecules (especially with DNA) of these new complexes will be 
studied, searching for a possible explanation for the origin of their cellular behaviour. 
This should allow us to compare the results of the coupling of a steroidal delivery vector 
in the behaviour of covalent and non-covalent DNA metallo-binders. 
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Finally in the third and last chapter we will investigate the anticancer activity of 
supramolecular dimetallic cylinders previously synthesised in our laboratory. These 
agents present the interesting ability to bind to the DNA in the major groove or in the 
internal cavity of a three way junction, and preliminary experiments show certain 
anticancer activity in levels close to carboplatin. Studies of the dependence of this 
activity to the structure of the cylinders (using complexes with small and big structural 
modification and with different metals inside the structure) and cellular distribution will 
be undertaken; to know if they can reach the nuclei and interact with the genomic DNA, 
possible target of their activity. 
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Chapter 2: Steroidal covalent metallodrugs 
 
2.1 Introduction 
Platinum metallo-drugs are among the most effective clinical agents for the treatment 
of cancer and three such agents (cisplatin, carboplatin and oxaliplatin) are in widespread 
use. These agents are believed to act by binding to DNA, with the three structurally-
related drugs having similar molecular-level actions
1-6
. Clinical challenges include 
circumventing acquired resistance to cisplatin and widening the spectrum of cancers 
which can be treated; this requires chemists to explore new metallo-drugs which are 
distinct from the traditional cisplatin structure and which will have different molecular-
level interactions. Other challenges include minimizing the side-effects which arise 
because of the action of the drugs in other sites in the body and with other bio-
molecules such as proteins.  More effective targeting of the drugs to specific organs or 
tumour types is thus desirable, as is maximising the delivery of the cytotoxic agent into 
the cell and on to the (nuclear) DNA. In the search of a “magic bullet” (a drug that is 
aimed precisely at a disease site and that would not harm healthy tissues) the use of 
carriers that would take the drug to the target and release it there has been explored. 
Ideally, this delivery-vector needs to take the drug into physical contact with its 
physiological target only in the desired anatomical location of the body. It should be 
retained at the site of action for a long enough period of time and not be removed from 
circulation too rapidly
7
. Different bio-molecules have been used in the last years as 
delivery vectors with varying degree of success
8-10
. Sex hormones such as oestrogens 
and testosterone are interesting because of their importance in reproductive system 
cancers
11-13
. 
Breast cancer is a major cause of cancer death for women in the western world and 
cisplatin is not useful against it. It is known that 60-75% of breast cancer tumours over-
express oestrogen receptors (ER)
14
. For that reason, rhenium and 
99m
technetium units for 
imaging have been attached to oestrogen-based ligands
15-16
 to enhance delivery, aiming 
for selective uptake in cells displaying elevated levels of the oestrogen receptor (ER). 
Steroid mimics have been attempted as well, by replacing part of the steroidal skeleton 
with rhenium (V), but this type of approach led to unstable complexes
17
. It has been 
suggested that an organometallic substrate (or any other type of ER targeted complex), 
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would need to posses a binding affinity of at least 1% relative to oestrogen towards the 
ER for selective uptake of the substrate into cells to occur
18
. Cytotoxic metallo-drugs 
have also been conjugated to steroids or synthetic oestrogens (Fig. 2.1). Jaouen et al 
synthesized a series of organo-metallic ferrocene-functionalized tamoxifens and 
hydroxy-tamoxifens
19
, showing similar activity to tamoxifen in ERα+ cell lines, but 
increased activity in ERβ+ (compared to tamoxifen). However, when oxaliplatin-like 
molecules were attached to tamoxifen no effect on the activity of the free synthetic 
oestrogen was observed
20
. Three-substituted oestrogen-based platinum(II) complexes 
have been reported as well, showing cytotoxic activity in MCF-7 tumour cells 
comparable to cisplatin
21-22
. Unfortunately these compounds posses extremely low 
relative binding affinity (RBA) towards the ER due to removal of the OH in 3 position, 
which is important for the recognition by the receptor.   
 
Figure 2.1.  A. Conjugate of the anti-oestrogen tamoxifen with platinum(II). B. Structure of 3-substituted oestrogen 
conjugate with potentially cytotoxic platinum(II).    
Recently Osella synthesised 17α-substituted oestrogens with bidentate ligands based 
on ethylenediammine-type chelates (Fig. 2.2 A). Malonate-platinum(II) moeities were 
coordinated to the ligands to provide better water solubility
23
. Unfortunately stability 
problems and low RBAs meant they were not suitable for cell tests. In an attempt to 
solve this problem oestrogens were functionalised with chelates linked through benzyl 
spacers
24
. The platinum(II) complexes showed an estimated RBA of aproximately 2%. 
However cell tests in ER+ and hormone independent cell lines did not show growth 
inhibition at treated concentrations (while cisplatin showed almost 50% growth 
inhibition). Berube used a different strategy. He synthesised a series of oestrogens 
coupled to platinum units through the 16 position (Fig. 2.2 B). The resulting complexes 
showed high cytotoxicity and indeed a higher RBA than estradiol, but they didn’t show 
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any specificity towards ER+ cell lines
25-26
. Lippard has explored steroidal platinum(IV) 
compounds (Fig. 2.2 C) after discovering oestrogen sensitises cancer cells to 
platinum(II) cytotoxic agents
27
.  In this approach the steroid is released from the metal 
prior to DNA binding; again these complexes showed high toxicity but not specificity
28
. 
Non-conventional drugs have been attached as well: Hannon et al attached a 
monofunctional platinum-terpyridine derivative (Fig. 2.2 D), that showed the capacity 
to bind to DNA and proteins at the same time
29
. 
 
Figure 2.2.  Recent examples of steroids coordinated to platinum drugs. 
2.1.1 Steroid coupled platinum(II) triammines 
All these previous examples have three things in common: an active metallodrug has 
been coupled to the carrier; estradiol or a synthetic oestrogen has been used with the 
goal of targeting the ER; and a relatively complicated synthesis is required. Previously 
no steroidal metal complexes have targeted the androgen receptor (AR) with the aim of 
localising cytotoxic drugs
30
. The androgen receptor (AR) is the predominant sex-steroid 
nuclear receptor in malignant tissue and found over-expressed in ~80 % of breast
31-33
,
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74-90 % of ovarian
34-36
 and substantially all prostate tumours
37-39
. Recently, colleagues 
in our group (Martin Huxley and Michael J. Browning) developed a simple procedure to 
attach non-conventional metallodrugs to steroids
40-42
. Using simple coupling reactions 
between commercially available steroids and arylhalides estradiol and testosterone 
derived ligands were created and coordinated to triammine cationic platinum(II) 
monofunctional centres (Fig. 2.2E, Fig 2.3)
40-41
. This allowed the creation of a small 
library of steroidal complexes, both estradiol and testosterone, in just two simple steps.  
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Figure 2.3.  Steroid linked non-conventional cationic platinum(II) complexes previously synthesised. EE and ET 
indicate estradiol (EE) or testosterone (ET) derived ligands and complexes. 
The anti-cancer properties of the testosterone coupled pyridine, quinoline and 
isoquinoline derivatives were tested
40, 42
. The complexes were subject to in vitro testing 
in two cancer cell lines, ovarian line SK-OV-3 (AR-), and breast line T-47D (AR+). The 
results (Fig. 2.4), showed that non-steroidal complexes were inactive or presented very 
low activity
43-45
, whilst the steroidal platinum(II) conjugates all show between 2 and 12-
fold improved toxicity
40,42
. It was also remarkable that the cis-complexes all displayed a 
2-3 fold higher activity compared with trans isomers, indicating geometry as well as the 
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steroidal linkage influences cytotoxicity. The origin of this cytotoxicity cannot be 
ascribed solely to the platinum moiety (IC50 values of 115 μM and 197 μM for SK-O-
V3 and T-47D). There appears to exist a synergistic effect; upon conjugation of an 
testosterone-based ligand to an inactive non-conventional cationic platinum(II) centre a 
potent new compound is created. At the moment, no data have been provided of the 
estradiol analogues’ toxicities. 
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Figure 2.4.  IC50 values of testostene coupled and non-steroidal platinum(II) compounds in the tumor cells lines T-
47D and SK-OV-3. 
As presented in previous chapter (Chapter 1.2) platinum complex activity is related 
with the mode of binding to DNA and the distortions produced to the double helix. 
Non-conventional platinum drugs have been created, designed to yield adducts different 
to the ones produced by cisplatin, with the idea that different DNA interaction would 
lead to broader anti-cancer activity. Steroid delivery has been used before to try to 
improve activity of Pt drugs against breast cancer by targeting the Estrogen Receptor 
(ER)
23-28
. However, none of the studies has explored how the presence of the steroid 
affects the DNA binding of the Pt unit, simply reporting cytotoxicity data. From our 
own laboratories, a monofunctional platinum-terpyridine estrogen derivative was 
prepared and shown to be able to bind to DNA and proteins at the same time; however 
no detailed information about the interactions was obtained
29
. Studies with our library 
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of compounds showed that the presence of a steroid, attached to an aromatic ring of a 
non-conventional and inactive platinum(II) complex has a significant and dramatic 
effect on the interaction of monofunctional complexes with DNA
40-41, 46
. The presence 
of the steroid increases the ability of the compounds to bend and unwind the DNA 
greatly (Table 2.1)
40,46
. This is remarkable, compared with small unwinding abilities and 
no bending shown by inactive monofunctional complexes (Section 1.2). 
 Unwinding Angle  Unwinding Angle 
trans-[Pt(2ET)Cl(NH3)2]
+ 19º trans-[Pt(1EE)Cl(NH3)2]
+ 11º 
trans-[Pt(3ET)Cl(NH3)2]
+ 11º trans-[Pt(2EE)Cl(NH3)2]
+ 8.5º 
trans-[Pt(4ET)Cl(NH3)2]
+ 15º trans-[Pt(7EE)Cl(NH3)2]
+ 10.5º 
trans-[Pt(6ET)Cl(NH3)2]
+ 19º trans-[Pt(4EE)Cl(NH3)2]
+ >32º 
trans-[Pt(5ET)Cl(NH3)2]
+ 4º trans-[Pt(6EE)Cl(NH3)2]
+ 13º 
cis-[Pt(2ET)Cl(NH3)2]
+ 21º trans-[Pt(5EE)Cl(NH3)2]
+ 13º 
cis-[Pt(6ET)Cl(NH3)2]
+ 19º cis-[Pt(3EE)Cl(NH3)2]
+ 19º 
cis-[Pt(5ET)Cl(NH3)2]
+ 21º cis-[Pt(6EE)Cl(NH3)2]
+ 13º 
trans-[Pt(Py)Cl(NH3)2]
+ 6.5º cis-[Pt(5EE)Cl(NH3)2]
+ 15º 
cis-[Pt(Py)Cl(NH3)2]
+ 6.5º transplatin 9º 
trans-[Pt(QUI)Cl(NH3)2]
+ 8.5º cisplatin 13º 
Table 2.1. Unwinding angles of steroidal pyridine and quinoline derivatives in pBR32240-41.  
Even though the initial results are promising, a few problems about the synthesis and 
anticancer activity of these compounds still need to be addressed. During the synthetic 
process, it was not possible to obtain some potential complexes of the library and others 
were produced only in low yields. This low amount of complex obtained was mainly 
due to inefficiency of the purification process required to remove impurities and 
secondary products (which involved multiple recrystalizations and the use of activated 
charcoal). Also, although initial cytotoxicity data showed that conjugation of 
testosterone introduced activity to previously inactive platinum(II) centres, no 
cytotoxicity data was obtained for corresponding estradiol derivatives, the possible 
dependence to the steroidal induced cellular effects was not studied and no information 
about response to resistance mechanism was provided. Cellular uptake experiments 
were needed to understand the delivery abilities of the used steroidal vectors and further 
studies of macromolecular interaction were needed to understand the difference in 
toxicity between cis and trans isomers. All of these problems will be addressed herein, 
together with a synthetic attempt to standardize the coupling of metallodrugs to steroids. 
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2.2 Synthesis and purification new monofunctional Pt(II) steroidal-
complexes 
Building on these previous studies we now present the synthesis of three new 
steroidal pyridine complexes (which had not previously been synthesised) and two 
interesting additional products. Also, we describe a simple and quick method to purify 
this kind of compounds, which allows us to increase the final yield. Importantly we are 
then able to differentiate between the cis and trans isomers through normal NMR 
techniques.  
2.2.1 Synthesis of new compounds 
Synthesis of trans-[Pt(1ET)Cl(NH3)2](NO3): 
 
When transplatin was stripped of one of its chloride ions and reacted with one 
equivalent of 1ET (added dropwise at -18ºC) trans-[Pt(1ET)Cl(NH3)2]
+
 was produced. 
Purification following the method outlined below (Section 2.2.2), afforded the 
compound in 49% yield. The white solid was analysed by mass spectrometry, showing 
the expected peak at 654 m/z ([Pt(1ET)Cl(NH3)2]
+
) and elemental analysis proved its 
purity. The 
1
H NMR spectrum (Fig. 2.5) shows the characteristic testosterone steroid, 
with an unmodified singlet at 5.7 ppm integrating for a proton that corresponds to H4. 
The two singlet peaks at 1.3 and 1.0 ppm (integration of three each) corresponding to 
the two methyl groups, Me19 and Me18 respectively. The absence of other peaks is 
further confirmation of the purity of the complex. The pyridine unit gives rise to four 
signals at 8.9, 8.0, 7.7 and 7.5 ppm (doublet of doublets, doublet of doublets of 
doublets, doublet and doublet of doublets of doublets), indicating H6’, H4’, H3’ and H5’ 
respectively, all with integration of one. Assignment was achieved by comparison with 
similar compounds. A peak corresponding to NH3 with an integration of six is observed 
at 4 ppm. This single peak confirms the trans nature of the complex (see Section 2.2.2). 
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Figure 2.5.  1H-NMR of trans-[Pt(1ET)Cl(NH3)2]
+ in deuterated methanol. 
Synthesis of cis-[Pt(1ET)Cl(NH3)2](NO3): 
 
 When the same reaction was done with cisplatin instead of transplatin, the result was 
a brown-black solid that was not the expected product. However, if the addition of the 
ligand (1ET) was performed under Argon bubbling, the desired cis version of previous 
complex was obtained. As for the trans isomer, the ESI-MS of the white powder showed 
a peak at 654 m/z (corresponds to [Pt(1ET)Cl(NH3)2]
+
) indicating the binding of the 
platinum centre to the ligand. The yield was half that of the trans version, probably as a 
result of the sensitivity of the synthesis and the need for the inert atmosphere. The 
1
H 
NMR spectrum (Fig. 2.6) shows four signals at 8.8, 7.9, 7.6 and 7.4 ppm (doublet of 
doublets, doublet of doublets of doublets, doublet and doublet of doublets of doublets), 
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indicating H6’, H4’, H3’ and H5’ (assignment under the known and distinctive coupling 
patterns on a pyridine ring). As expected, chemical shifts are different to those 
presented by trans complex. Also different are the methyl signals at 1.2 and 1.0 ppm 
corresponding to the two methyl groups, Me19 and Me18 respectively. The peak at 5.7 
ppm corresponding to H4 does not change shift, consistent with its remote location from 
the metal centre. Evidence of the cis form of the complex is provided by the two 
ammine signals observed at 4.5 and 4.1 ppm (integration of 3 protons each). This 
spectrum provides evidence for the formation of cis-[Pt(1ET)Cl(NH3)2]
+
. 
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Figure 2.6.  1H-NMR of cis-[Pt(1ET)Cl(NH3)2]
+ in deuterated methanol. 
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Synthesis of cis-[Pt(2EE)Cl(NH3)2](NO3):  
 
Reacting 2EE and cisplatin also gave a brown-black compound, but similarly, if the 
addition of the ligand was done under Argon bubbling, cis-[Pt(2EE)Cl(NH3)2]
+ 
was 
obtained. ESI-MS of the white powder reveal a peak at 638 m/z and elemental analysis 
(after purified as described in Chapter 2.2.2) indicated the expected stoichiometry. 
Again the yield was 1.5 fold lower than the trans version. The 
1
H NMR spectrum (Fig. 
2.7) shows four signals at 8.8, 8.7, 8.0 and 7.5 ppm (doublet, doublet of doublets, 
doublet of triplets and doublet of doublets), indicating H2’, H6’, H4’ and H5’ of the 
pyridine respectively, all with an integration of one. Assignment again used the known 
pyridine splitting patterns. The presence of a single methyl signal at 0.9 ppm, 
corresponding to Me18, gives a further indication of the purity of the compounds. 
Estradiol protons H1, H2 and H4 can be observed at 7.1, 6.6 and 6.5 ppm respectively 
(doublet, doublet of doublets and doublet). Evidence of the cis form of the complex is 
provided by the two ammine signals observed at 4.6 and 4.2 ppm (integration of 3 
protons each). This spectrum provides evidence for the formation of cis-
[Pt(2EE)Cl(NH3)2]
+
. 
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Figure 2.7.  1H-NMR of cis-[Pt(2EE)Cl(NH3)2]
+ in deuterated methanol. 
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Before purification a crude solution of the product in DMF was left in the fridge. 
After 24 hours, translucent crystals appeared. These crystals were explored by single 
crystal X-Ray Diffraction, and revealed two estradiol molecules attached through two 
triple bonds (Fig. 2.8). This is an expected side product (Glaser reaction)
47
 of the 
synthesis of the ligands, and was present as result of a poor purification of the ligand 
(2EE). However, further purification of the ligands was not necessary synthetically 
because the side product does not react with platinum and is very readily purified from 
the complexes. 
   
 
 
 
 
 
Figure 2.8. X-Ray diffraction crystal structure of the Glaser coupling product of 17α-ethynyl-estradiol. 
 66 
When a normal Glaser reaction
47
 was done with 17α-ethynylestradiol, the same 
compound was obtained in really good yield (70%), showing simplicity of preparation 
and purification. This type of compound could be interesting because similar bis-
estradiol compounds have been presented in the literature targeted at the ER in breast 
cancer
48
. Compounds with two molecules of bile acid have been used as well as gene 
transfer vehicles
49
. However, both those types of dimeric steroid compounds required 
long and difficult synthesis and purification. This new product can be synthesised and 
purified easily by a normal Glaser reaction in a single step from commercially available 
reagents.  
2.2.2 Purification of monofunctional Pt(II) steroidal-complexes 
Aside from these three new Pt complexes which co-workers in the group had been 
unable to prepare, a series of these compound types had been prepared
40-42
. However, 
two factors had been a problem; the first one is the purification, and the second one is 
the overall yield. The many steps of purification (such us recrystalizations and reaction 
with activated charcoal) make the final yield of the reaction go down to between 10-
30%. Especially dramatic is the case of cis-[Pt(2ET)Cl(NH3)2]
+
, (the most active of the 
testosterones) that showed a yield of just 12%
40, 42
.  
To address this problem, the use of HPLC separation techniques were explored, 
allowing us to discriminate between the single substituted and di-substituted complexes. 
First attempts of purification, under isocratic techniques and gradient techniques 
without the use of TFA (not used at first as steroidal compound show certain sensitivity 
to acidic mediums under high temperatures), were not successful. However, separation 
can be achieved using a water:methanol (0-100%) gradient during 40 minutes, with the 
use of TFA (0.05%) to sharpen the peaks. This could be applied to all these types of 
compounds and allowed us to standardise the purification into a simple and single step 
process. This has been a dramatic improvement compared to the previous purifications, 
which were different for each compound and involved different number of steps. 
Moreover the compounds were obtained in higher purity by this new method 
Following this procedure, the compounds can be achieved with yields improved 2 or 
3 fold times (from 12% to 44% for cis-[Pt(2ET)Cl(NH3)2]
+
) and with purities higher 
than 95% (assessed by HPLC, Fig. 2.9). Different methods are not needed for the 
different steroids, since both testosterone and estradiol can be purified following the 
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same procedure, nor for the isomer, or molecule linked to the steroid (pyridine, 
quinoline, aniline, etc.) 
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Figure 2.9.  Examples of purification of different complexes following the HPLC method described before. cis-
[Pt(6EE)Cl(NH3)2]
+ (top), trans-[Pt(3EE)Cl(NH3)2]
+ (middle) and trans-[Pt(7EE)Cl(NH3)2]
+ (bottom). 
After the purification with HPLC, all the residual solvents were removed. In these pure 
dried samples the ammino groups could be detected by 
1
H-NMR. Spectra of different 
isomers show that cis isomers have two different ammino peaks integrating each for 3 
protons, while in trans isomers there is only one peak integrating for 6 protons (Fig. 2.10). 
This is due to the different chemical enviroment of cis isomers against the identical one to 
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which the trans ones are exposed. In the spectra of the compounds previously prepared 
and purified by other techniques the ammines were frequently extremely broad and 
unresolved, perhaps due to binding to residual solvents. 
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                 cis-[Pt(2ET)Cl(NH3)2]
+
                                 trans-[Pt(2ET)Cl(NH3)2]
+ 
Figure 2.10.  1H-NMR differenciation between cis and trans isomers. 
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Figure 2.11.  A) HPLC chromatograph of cis-[Pt(2ET)Cl(NH3)2]
+ and the bisubstituted [Pt(2ET)2(NH3)2]
2+ 
“impurity” B)1H-NMR of bisubstituted [Pt(2ET)2(NH3)2]
2+ in deuterated methanol. C) 1H-NMR of 
[Pt(2ET)2(NH3)2]
2+ (middle), compared with cis-[Pt(2ET)Cl(NH3)2]
+ (top) and trans-[Pt(2ET)Cl(NH3)2]
+ (bottom) in 
deuterated methanol. 
The final advantage of this method is the possibility to isolate the disubstituted 
complexes. This usually represent between 5-10% of the final product. If the starting 
reaction is on a sufficiently large scale, enough compound can be obtained, and 
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characterization can be achieved (Fig. 2.11). An example of this is the disubstituted 
version of the 2ET [Pt(2ET)2(NH3)2]
2+
, obtained in the purification of the cis-
[Pt(2ET)Cl(NH3)2]
+
. Determining the geometry is complicated, since the two ammino 
groups of both cis and trans isomers present identical chemical environment. In the 
future, this kind of compound and also the Glaser coupling reaction product, could be 
interesting to be tested to see the effect of the metallic centre in disteroidal compounds. 
 
2.3 Toxicity of steroid derivatives 
As seen in Section 2.1.1 (Fig. 2.4) initial cytotoxicity data showed exciting activities 
for our testosterone linked monofunctional platinum(II) centres. No cytotoxicity data 
was obtained for estradiol derivatives and dependence to the steroidal induced cellular 
effects, response to resistance mechanism and cellular uptake were not studied. New 
information in these areas is presented in this section. 
2.3.1 Toxicity of Estradiol derivatives 
In order to check if the synergic effect observed for testosterone linked compounds is 
also present when the steroid used is estradiol, the activity of a series of pyridine and 
quinoline like estradiol linked triammine platinum(II) complexes has been tested. 
Different cell lines with different ER and AR status have been used (Table 2.2); SK-
OV-3, A2780, A2780cr (ovarian carcinoma), T-47D, MDA-MB-231 (breast carcinoma) 
and HBL-100
†
 (breast epithelium
†
). SK-OV-3 is in addition a cisplatin resistant cell 
line. The activity was measured after treatment for 72h with the studied complexes. The 
steroidal-Terpyridine derivatives [Pt(EET)Cl]
+
 and [Pt(ETT)Cl]
+
 (Fig. 2.2 D)
29, 50
 were 
tested as well as non-steroidal complexes and cisplatin (as controls). 
Cell line ERα ERβ AR 
HBL-100  - + - 
T-47 D + + + 
SK-OV-3 + + - 
MDA-MB-231 - + - 
A2780 - + - 
A2780cr - + - 
Table 2.2. Steroid receptor status among cell lines used. 
† Although recently doubt has been cast on the provenance and veracity of HBL-100 as a breast cancer cell line 
(Lacroix, M. (2008). Int. J. Cancer 122, 1–4.) the results that we obtained in this line are included for completeness 
and allow comparison with the many other previous studies in that cell line. 
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Figure 2.12.  IC50 values of estradiol-coupled and non-steroidal platinum(II) compounds.  
The non-steroidal complexes present low activity, with values over 100 µM, 
considered as non active. The estradiol linked complexes, as hoped, show higher 
activity than the non-steroidal analogues (Fig. 2.12). However, this activity is not 
remarkably high, and is generally lower than for the testosterone (androgenic) 
complexes (also very active). In general, most of the complexes show lower activity 
than cisplatin in every cell line. The only exceptions are trans-[Pt(5EE)Cl(NH3)2]
+
 and 
the steroidal-terpyridine derivatives (both [Pt(EET)Cl]
+
 and [Pt(ETT)Cl]
+
)
29, 50
. Trans-
[Pt(5EE)Cl(NH3)2]
+
 show similar activity to cisplatin only in HBL-100, but the steroidal 
terpyridine compounds present cisplatin-like growth inhibition abilities in SK-OV-3 and 
better in HBL-100, T-47D and MDA-MB-231 ( IC50 3 times lower than cisplatin for the 
last two). The non-steroidal [Pt(Tpy)Cl]
+
 derivative shows good activity by itself, as 
reported by Lowe
51
, but nevertheless, coupling to the steroid does introduce an 
improvement in the activity. 
It is interesting to see that the lower IC50 values for almost all the compounds, 
including cisplatin and the non-steroidal references, were obtained in HBL-100. This is 
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at first sight confusing since this cell line show ERα – status, while the other two are 
ERα +. However if we compare the values in each cell line to those of cisplatin in that 
cell line, we see that the higher ratios are present in T-47D, and that SK-OV-3 shows 
always higher or similar values than HBL-100 (except for trans-[Pt(5EE)Cl(NH3)2]
+
, 
where HBL-100 present the higher ratios). So the lower IC50 in HBL-100 could be 
merely an inherent higher sensitivity of this cell line to platinum drugs. In general we 
can say that when compared ratiometrically to cisplatin (Table 2.3), the compounds are 
more active in ERα + cell lines than in ERα – ones. 
 SK-OV-3 (ERα+) HBL-100 (ERα-) T-47D (ERα+) 
trans-[Pt(6EE)Cl(NH3)2]
+ 0.20 0.09 0.28 
cis-[Pt(6EE)Cl(NH3)2]
+ 0.26 0.26 0.42 
trans-[Pt(4EE)Cl(NH3)2]
+ 0.15 0.07 0.38 
trans-[Pt(5EE)Cl(NH3)2]
+ 0.32 0.86 0.68 
trans-[Pt(5EE)Cl(NH3)2]
+ 0.14 0.07 0.36 
trans-[Pt(1EE)Cl(NH3)2]
+ 0.15 0.15 0.40 
[Pt(EET)Cl]+ 0,31 1.45 3.06 
[Pt(Tpy)Cl]+ 0.23 0.37 0.46 
Table2. 3. Cisplatin/Complexes IC50 ratio in the different cell lines. 
2.3.2 Effect of added estradiol to non-steroidal complexes 
In 2000, Lippard
27
 showed that co-administration of estradiol and/or progesterone, 
with platinum complexes increased their toxicity by 2 or 4 fold in hormone dependent 
cell lines (ER+ or PR+). It was suggested that these hormones increase the production 
of HMG proteins, possibly upon binding to its receptors. One of the questions that we 
have with our compounds is if the improved activity is coming from the steroid domain 
linkage, or is just as a result of this hormonal effect. To study this possibility we 
explored the effect of co-administering the non steroidal controls trans-
[Pt(QUI)Cl(NH3)2]
+
 and [Pt(Tpy)Cl]
+
 with 10
-7
 M of 17α-ethynylestradiol (as used by 
Lippard). 
 SK-OV-3 HBL-100 T-47D 
trans-[Pt(QUI)Cl(NH3)2] 243.3 ± 7.1 98 ± 9.7 75 ± 4.6 
trans-[Pt(QUI)Cl(NH3)2]* 125 10 53.7 
trans-[Pt(4EE)Cl(NH3)2] 74.52 ± 2.14 73.33 ± 3.51 74.23 ± 7.4 
trans-[Pt(6EE)Cl(NH3)2] 56.58  55.45  99.68  
trans-[Pt(4ET)Cl(NH3)2]
&  49.9 ± 1.8 24 ± 1.2 51.4 ± 1.9 
trans-[Pt(6ET)Cl(NH3)2]
&  45.4 ± 3.5 26.3 ± 2.8 38.6 ± 2.4 
[Pt(Tpy)Cl]+ 22.46 ± 2.27 13.02 ± 1.65 60.96 ± 2.12 
[Pt(Tpy)Cl]+* 13 10 30 
[Pt(EET)Cl]+ 18.59 ± 2.18 3.35 ± 0.35 9.25 ± 0.59 
Table 2.4. Effect of the addition of estradiol to non-steroidal complexes in their IC50 values (µM). *= addition of 
estradiol; &= data from Martin Huxley40. 
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Table 2.4 shows the results of this experiment, and comparison with the steroid 
coupled complexes. Both treated complexes, as expected, show more or less a 2 fold 
increase of the activity in SK-OV-3 and T-47D (considered ER+). However, in HBL-
100, where no action was expected (considered ER-) the improvement is much bigger 
for trans-[Pt(QUI)Cl(NH3)2]
+
, almost 10 times, but only 1.3 times for [Pt(Tpy)Cl]
+
. In 
general, this increase in the growth inhibition abilities is not strong enough to reach the 
activities of the steroidal linked derivatives; the only exceptions are found for trans-
[Pt(QUI)Cl(NH3)2]
+
 in HBL-100 (addition of estradiol produced an unexpectedly high 
effect), and [Pt(Tpy)Cl]
+
 in SK-OV-3 (due to small differences between initial 
cytotoxicities of the complexes). We could say that the increased anticancer activity 
observed for covalently coupled steroidal platinum(II) complexes is not solely due to 
the possible steroidal effects produced by the ligand in hormone dependent cell lines. 
2.3.3 Activity of free ligands 
Steroids are a family of compounds found naturally in all sort of organisms and 
posses a spectrum of biological activity. Recently a series of natural steroidal alkaloids 
with a structure similar to our quinoline derivatives has been isolated from marine 
sponges. These compounds show anti-angiogenic capacities, showing anti-proliferative 
activity against HUVEC cells (Human umbilical vein endothelial cells)
52
 (Fig. 2.13). 
Figure 2.13.  Structures of cortistatins obtained from the marine sponge Corticium Simplex 
It is noteworthy that our platinum complexes formed with quinolines and 
isoquinolines steroidal derivatives showed good activity in cancer cell lines, being some 
of the best of the series (especially complexes of 6EE and 6ET). Moreover a platinum 
complex of the 5EE derivative showed similar activity to cisplatin in HBL-100. For this 
reason it was important investigate the possibility that the activity could come from the 
ligand instead of from the synergy between the components. Four free ligands were 
tested in the same cell lines to check their activity. 2ET, 4ET, 5EE and 6ET were 
 73 
chosen to cover the different steroids (estradiol and testosterone) and structures 
(pyridine and quinoline in different positions). 
 SK-OV-3 HBL-100 T-47D 
2ET >200 >170 >200 
trans-[Pt(2ET)Cl(NH3)2]
+& 39.1 ± 1.7 27.3 ± 1.9 62.8 ± 7.8 
cis-[Pt(2ET)Cl(NH3)2]
+& 15.7 ± 0.4 7.4 ± 0.9 15.9 ± 0.5 
4ET 21.1  48.6 
trans-[Pt(4EE)Cl(NH3)2]
+ 74.52 ± 2.14 73.33 ± 3.51 74.23 ± 7.4 
trans-[Pt(4ET)Cl(NH3)2]
+&  49.9 ± 1.8 24 ± 1.2 51.4 ± 1.9 
5EE 35 9 40 
trans-[Pt(5EE)Cl(NH3)2]
+ 34.53 ± 2.6 5.63 ± 0.72 41.39 ± 1.59 
trans-[Pt(5ET)Cl(NH3)2]
+& 70.7± 2.7 28 ± 1.8 51.4 ± 1.9 
cis-[Pt(5ET)Cl(NH3)2]
+& 26.3 ± 0.3 27.7 ± 1 32.8 ± 0.7 
6ET 30.6  38.7 
trans-[Pt(6EE)Cl(NH3)2]
+ 56.58 55.45 99.68 
cis-[Pt(6EE)Cl(NH3)2]
+ 43.5 ± 0.4 18.7 ± 0.5 67.1 ± 4.3 
trans-[Pt(6ET)Cl(NH3)2]
+&  45.4 ± 3.5 26.3 ± 2.8 38.6 ± 2.4 
cis-[Pt(6ET)Cl(NH3)2]
+& 16.4 ± 0.7 12.4 ± 1.4 14.4 ± 1 
Table 2.5. Activity of free ligands and comparison with complexes formed with these ligands. &= data from Martin 
Huxley40. 
Results are shown in Table 2.5 together with the data for some of their Pt complexes. 
As we observe, 2ET is not active at all, with IC50 normally over 200 µM. This indicates 
that the activity of its platinum(II) complexes must come from the platinum conjugate. 
In contrast, 4ET, 5EE and 6ET ligands show a similar activity to the platinum 
complexes (in most cases better). The only cell line in which the free estradiol ligand 
shows a lower cytotoxicity is in HBL-100 (5EE), which maybe due to its sensitivity to 
platinum and ERα – status. We cannot consider that the activity of the (quinoline based) 
complexes came from the introduction of the metal centre. For this reason experiments 
undertaken after this point used only the pyridine derivatives, since we cannot prove 
that our aim of enhancing and locating the activity of a metal centre is achieved with the 
quinoline and isoquinoline derivatives.  
2.3.4 Toxicity of Testosterone derivatives 
Testosterone can be metabolized to estradiol by aromatases. Moreover, AR has 
proven to have an important regulatory role of ERα (ER = estrogen receptor) in breast 
cancer
53
. Both T-47D and SK-OV-3 are ERα and ERβ positives, so it was interesting to 
observe the cytotoxicity capacities in other (ER-) tumour cells. Breast cell line MDA-
MB-231 (AR-, ERα- and ERβ +) and ovarian cell line A2780 (AR-, ERα- and ERβ +) 
were chosen. In order to see how well our compounds are able to overcome resistance 
mechanisms, the cisplatin resistant strain of A2780 was selected as well. Major 
resistance mechanisms found in A2780cisR are reduced uptake of platinum(II) drugs 
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and elevated levels of the tri-peptide glutathione whose cysteine residue detoxifies 
platinum(II) drugs via rapid binding
54
. cis-[Pt(2ET)Cl(NH3)2]
+
, being the most potent 
complex with no inherent ligand activity, was chosen for further studies, alongside its 
trans isomer and the non-steroidal analogous complexes (Table. 2.6). The steroidal-
complexes again show better activity than the non-steroidal analogues, but, 
interestingly, trans-[Pt(2ET)Cl(NH3)2]
+
 shows the same cisplatin-like levels of activity 
as its cis isomer in the MDA-MB-231 cell line. Even more interesting both isomers 
show certain selectivity: apparently, the trans derivative is more efficient when the are 
not present in the cell, while the cis isomer shows better activities in the presence of 
ERα receptors. This could indicate different interactions with the receptors, or different 
effects upon binding to them.  
 For A2780, cis-[Pt(2ET)Cl(NH3)2]
+
 is again more active than the trans isomer 
but no dramatically more so its the non-steroidal analogue. However, the platinum 
resistance mechanisms do not affect the steroidal complex to the same extent as the non-
steroidal. Indeed the activity of cis-[Pt(2ET)Cl(NH3)2]
+
 remains at a potent level. This 
could suggest that steroidal complexes, as expected, are transported better into the cell. 
Table 2.6. IC50 values (μM) of cis and trans-[Pt(2ET)Cl(NH3)2]
+ and their non-steroidal controls.  
 MDA-MB-231 SK-OV-3 T-47D A2780 A2780cisR Rx
[a] 
trans-[Pt(Py)Cl(NH3)2]
+ 334 ± 54  98 ± 6 181 ± 11 72 ± 7 157 ± 2 2.2 ± 0.2 
cis-[Pt(Py)Cl(NH3)2]
+ 186 ± 14 115 ± 5 197 ± 17 25.0 ± 1.2 105 ± 3 4.2 ± 0.2 
trans-[Pt(2ET)Cl(NH3)2]
+ 27.3 ± 4.7 39.1 ± 2& 63 ± 8& 35.3 ± 4.2 88 ± 2 2.5 ± 0.3 
cis-[Pt(2ET)Cl(NH3)2]
+ 29.2 ± 8.1 15.7 ± 0.5& 15.9 ± 0.5& 17.4 ± 3.1 33.3 ± 4.3 1.9 ± 0.4 
Cisplatin 31.3 ± 4.7 6.0 ± 1.3 32.0 ± 4.8 3.0 ± 0.5 12.8 ± 1.4 4.3 ± 0.8 
[a]Rx is increase in IC50 observed for a compound when tested in the cisplatin-resistant A2780cisR compared to 
A2780. &= data from Martin Huxley. 
2.3.5 Cellular uptake  
In order to explore the uptake, MDA-MB-231, T-47D and SK-OV-3 cells were treated 
with platinum drugs and uptake determined using Induced Coupled Plasmon Mass 
Spectrometry (ICP-MS). A short time of exposure (3h) and a single concentration for all 
compounds (30 µM)
55
 was chosen in order to determine speed and efficiency of all, 
under the same conditions. The short time period negates any issues related to the 
different effects of the compounds on cell division or death. Again cis-
[Pt(2ET)Cl(NH3)2]
+
, as the most interesting compound, and its trans isomer was chosen, 
and non-steroidal analogues and cisplatin were used as controls. Whole cell, cytoplasm 
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and nucleic fractions were obtained from the same experiment to observe distribution 
through the cell. In Figure 2.14 we can see the results. Surprisingly, linkage of a 
testosterone lowers the delivery in whole cells through all three cell lines (at least at this 
time point). There is a co-relation between cellular uptake and cytotoxicity for the non-
steroidal complexes, but not for the testosterone derivatives (Appendix B). However, 
when the cytoplasm and nuclear fractions are studied we notice that similar levels of 
platinum are observed for both steroidal and non-steroidal complexes, suggesting that a 
lot of the non-steroidal complexes get stuck into the membrane, while all, or almost all 
of the steroidal ones cross into the cytoplasm. So it appears that addition of a lipophilic 
biomolecule does help the cationic complexes to cross through the cellular membrane, 
as expected. Distribution inside the cell is also different: almost all of the steroidal 
complexes are in the cytoplasm at this time point, while distribution in the non-steroidal 
complexes is similar between cytoplasm and nuclei. This may be because of slower 
transport of steroidal complexes to the nuclei or for a possible interaction with 
cytoplasmatic proteins. A more effective delivery across the cellular membrane is 
visible then in steroidal complexes, however, nuclear or cytoplasm delivery seems not 
to be related to cytotoxic values through the cell lines studied.   
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Figure 2.14. pmols of Pt in T-47D, SK-OV-3 and MDA-MB-231 after 3 hours of treatment with 30 µM of  cis and 
trans-[Pt(2ET)Cl(NH3)2]
+, cis and trans-[Pt(Py)Cl(NH3)2]
+ and cisplatin. 
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2.4 Interaction with macromolecules 
It is known that the presence of the bulky steroid has a dramatic effect on the 
structure of DNA: previous experiments (Section 2.1.1) showed that when these 
complexes interact with ct-DNA they bend it and unwind the double helix. The 
observed bending and unwinding are much bigger for steroidal complexes than for the 
non-steroidal analogues. Due to the co-relation between DNA mode of binding and 
anticancer activity (Section 1.2) it is possible that these differences in DNA distortions 
are the origin of the steroidal complexes’ toxicity. A few questions are still left to be 
addressed about the interaction of our complexes with macromolecules. Previous 
experiments (Section 2.1.1) were not able to explain the difference in activity between 
cis and trans isomers and they did not provide information about how the presence of 
the metallic unit affected the interaction with proteins that usually bind steroids. Finally, 
since steroids can interact with DNA and have importance in cellular response toward 
platinum complexes, an important question is how the presence of free oestrogen and 
androgenic molecules affects the interaction of the non-steroidal complexes with DNA 
(although previously (Section 2.3.2) we showed that the simultaneous action of steroids 
and non-steroidal platinum(II) complexes is not the origin of the additional 
cytotoxicity).  
Herein we will explore further the behaviour of conjugates of testosterone and 
otherwise inactive platinum(II) complexes in aqueous solution, with nucleobases, DNA 
and proteins using a variety of techniques, such as ESI-MS, NMR, gel electrophoresis 
and CD. 
2.4.1 Effect of free steroid in DNA unwinding 
Gel electrophoresis of negative-supercoiled and open-circle plasmid DNA can be 
used to assess unwinding of the DNA helix caused by platinum complexes
56-57
. Plasmid 
DNA produces two bands on agarose gels, a band of negatively-supercoiled DNA (SC) 
and another of open-circle DNA (OC). Upon binding of the complexes a retardation of 
the negatively-supercoiled band and an acceleration of the open-circle band are 
observed. These changes in migration speed would be consistent with bending/kinking 
of the DNA helix by the Pt centre leading to positive supercoiling of the plasmid which 
causes uncoiling of the negatively-supercoiled band and positive supercoiling of the 
open-circle band. Given enough complex binding to DNA these two bands co-migrate. 
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Using that point, unwinding angles can be quantified by applying the formula 
18r(c),
58
 where, =unwinding angle, ζ=
(base:complex bound) where supercoiled and relaxed DNA co-migrate. Plasmid 
pBR322 was chosen, and using cisplatin, known to unwind the DNA by 13º
56, ζ was 
determined to be -0.059. Complexes were incubated in different concentrations 
(between 30:1 to 2:1 base:complex ratio) with the plasmid for 24h, in the presence or 
absece of steroids (estradiol and testosterone; ratio steroid:complex 1:1). Mixing 
complexes with pBR322 resulted in changes to the migration of the plasmid bands, 
indicating all bind to DNA (as expected), and unwinding angles were calculated (Table 
2.7).  
Table 2.7. Unwinding angles of non-steroidal complex with and without ethisterone(EE) and 17α-ethynyl-estradiol 
(ET) in pBR322. 
 Unwinding Angle Addition of EE Addition of ET 
trans-[Pt(Py)Cl(NH3)2]
+ 6.5º 6.5º 6.5º 
trans-[Pt(QUI)Cl(NH3)2]
+ 8.5º 8.5º 8.5º 
cis-[Pt(Py)Cl(NH3)2]
+ 6.5º 6.5º 6.5º 
EE 0º 0º 0º 
ET 0º 0º 0º 
Addition of the steroid did not cause any effect on the close circular plasmid 
pBR322, and no additional effect was observed when the steroids were added to the 
non-steroidal complexes (Table 2.7). This explain that the dramatic DNA unwinding 
abilities previously observed for the steroid conjugated platinum(II) complexes (Table 
2.1) are probably the result of the conjugation of the steroid to the platinum moiety, 
instead of combination of the effects produced by the non-conjugated units. 
2.4.2 Studies with mononucleotides models 
 No significant differences are detected in the DNA distortions produced by cis 
and trans isomers that could explain the lower anticancer activity of the trans 
complexes. In order to further study how the different isomers bind to DNA, the 
interactions with model nucleobases such as 9-ethylguanine (9EG) and guanosine 
5’monophosphate were studied (Fig 2.15). NMR and ESI-MS were used to investigate 
the interaction.  
 78 
NH
N
N
N NH2
O
9-ethylguanine
NH
N
N
O
NH2
N
O
OHOH
OP-O
O
O-
5'-GMP
2
3
4
5
10
1
6
7
8
9 14
13
12
11
15
16
17
OH
18
19
O
N
3'
4'
5'
6'
2'
21
20
8
8
1'
2'3'4'
5'
Pt
N
Pt
2
3
4
5
6
9CH2
9Me
 
Figure 2.15. The structure of a steroidal, a non-steroidal platinum(II) complex, 5’-GMP and 9EG. 
ESI-MS studies: 
An initial study by a colleague had shown that adducts with bound nucleobases could 
be detected by ESI-MS. In addition a deprotonated hydrolytic product was also 
observed
40
.  
Those studies were performed in TAE buffer, a system without the presence of Cl
-
 
anions that can affect the hydrolysis of the complexes and lately their DNA binding. 
However, since some Cl
-
, around 4mM
59
, is present inside the cell, here we chose to 
study how presence of Cl
-
 affects DNA binding. Cis and trans-[Pt(2ET)Cl(NH3)2]
+
 and 
cis and trans-[Pt(Py)Cl(NH3)2]
+
 were treated with 5’-GMP for 72 h, in presence of 
chloride in sodium cacodylate buffer (pH 6.8). Sodium cacodylate is an arsenic derived 
buffer used for DNA interaction studies that have a small amount of Cl
-
 ions (around 
one fith of the concentration of the buffer for pH used). ESI mass spectra confirm that 
mono-functional adducts are formed for all the complexes. No deprotonated hydrolysis 
products are observed for cis isomers, while it is the main peak for trans isomers.  
Table 2.8.  ESI-MS peaks found for the reaction of the studied complexes and mononucleotides 5’-GMP and 9-EG. 
The same experiment was repeated with 9-EG to observe possible effect of the 
phosphate and sugar ring and showed similar results to 5’-GMP (Table 2.8). 
 
 + 5’ GMP in TAE (Martin Huxley)
40
 + 5’ GMP in sodium cacodylate + 9-EG in sodium cacodylate 
 [Pt(NH3)2(L)(5’-GMP)]
+
  [Pt(NH3)2(L)(OH2)]
+
-(H
+
) [Pt(NH3)2(L)(5’-GMP]
+
  [Pt(NH3)2(L)(OH2)]
+
-(H
+
) [Pt(NH3)2(L)(9-EG]
+
  [Pt(NH3)2(L)(OH2)]
+
-(H
+
) 
trans-[Pt(2ET)Cl(NH3)2]
+ + + + + + + 
cis-[Pt(2ET)Cl(NH3)2]
+ + + + - + - 
trans-[Pt(Py)Cl(NH3)2]
+ + + + + + + 
cis-[Pt(Py)Cl(NH3)2]
+ + + + - + - 
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NMR studies:  
To understand these MS results better, the same compounds were also investigated 
by NMR, adding 5’-GMP in presence of sodium cacodylate buffer. Fig. 2.16 shows 
representative spectra for cis and trans-[Pt(2ET)Cl(NH3)2]
+
 with GMP at 0 and 24h.   
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Figure 2.16. 1H NMR spectra for cis-[Pt(2ET)Cl(NH3)2]
+ (bottom) and trans-[Pt(2ET)Cl(NH3)2]
+ (top) with 5’-GMP 
in 1mM sodium cacodylate buffer in D2O (pH 6.8) and 1:1 nucleotide:complex ratio. 
Changes to resonances of 5’-GMP and those of pyridine protons are clearly observed 
in both sets of spectra.  The dramatic shift of the gH8 proton of 5’-GMP in Figure 2.16 
(both complexes) is strongly indicative of platinum binding to the N
7
 of the guanine 
ring
60
 and the reaction is complete after 24 hours (as no unbound gH8 is visible 
anymore). The binding to the trans-[Pt(2ET)Cl(NH3)2]
+
 results in shifting of the gH1
’
, 
gH3
’
 and gH4
’
 to lower field and splitting of the resonance ascribed to gH5
’
 indicating 
the furanose ring is affected (Table 2.9) (gH2’ was not detected as result of their similar 
chemical shift to water). For cis-[Pt(2ET)Cl(NH3)2]
+
 the sugar ring protons show no 
effect for gH3’ and gH4’ and only minor effects on gH1’ (upfield 0.03ppm) and gH5’ 
(same chemical shift but broad). The shifts of the aromatic proton resonances of the 
pyridine ring support 5’-GMP binding with complexes, with all signals of trans-
[Pt(2ET)Cl(NH3)2]
+
 moving between 0.09 and 0.06 downfield. cis-[Pt(2ET)Cl(NH3)2]
+
, 
meanwhile, shows a similar effect for H2’ (0.05ppm) and H5’ (0.03ppm), but H4’ moves 
0.04ppm upfield, and more dramatically H6’ moves downfield by 0.23ppm (probably 
because of proximity of GMP). Finally, to our surprise, upfield shifts are clearly 
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observed for H4 (a proton with a really stable chemical shift compared with other 
steroidal or aromatic protons of the ligands) and Me18 and Me19 of the testosterone 
skeleton for cis-[Pt(2ET)Cl(NH3)2]
+
 but not trans-[Pt(2ET)Cl(NH3)2]
+
. The 3-position 
of ethynyltestosterone on pyridine and the cis geometry around the platinum(II) centre 
appear to bring the steroidal skeleton close to 5’-GMP. The non-steroidal complexes 
behave in a similar way and their NMR spectra can be seen in Figs 2.17 and 2.18.  
Table 2.9. Chemical shifts of more important protons of studied complexes in presence of 5’-GMP, 9-EG, alone and 
hydrolytic products. 
 H4 Me18 Me19 H2’ H4’ H5’ H6’ pyH2/6 pyH3/5 pyH4 gH8 gH1’ gH3’ gH4’ gH5’ 9H8 9CH2 9Me 
GMP           8.18 5.92 4.47 4.30 3.97    
9EG                7.75 3.99 1.32 
2ET-cis 5.79 0.9 1.21 8.79 8 7.5 8.65            
2ET-cis 
hydrolysis 
5.79 0.9 1.21 8.79 8 7.5 8.65            
2ET-cis GMP 5.59 0.85 1.05 8.85 7.96 7.53 8.88    9.01 5.89 4.47 4.30 4broad    
2ET-cis 9EG 5.69 0.88 1.15 8.73 7.98 7.5 8.71         8.22 3.98 1.25 
2ET-trans 5.79 0.94 1.23 8.94 8.01 7.53 8.77            
2ET-trans 
hydrolysis 
5.79 0.94 1.23 8.86 7.94 7.44 8.71            
2ET-trans GMP 5.79 0.94 1.24 9.02 8.07 7.6 8.88    8.97 6.05 4.51 4.36 4.00/4.06    
2ET-trans 9EG 5.79 0.94 1.23 9 8.09 7.6 8.84         8.30 4.10 1.38 
Py-cis        8.7 7.53 7.99         
Py-cis hydrolysis        8.7 7.53 7.99         
Py-cis GMP        8.76 7.41 7.89 8.98 5.96 4.47 4.34 4/4.02    
Py-cis 9EG        8.67 7.49 7.99      8.20 3.99 1.26 
Py-trans        8.82 7.54 8         
Py-trans 
hydrolysis 
       8.76 7.46 7.92         
Py-trans GMP        8.9 7.62 8.05 8.96 6.07 4.51 4.37 4/4.06    
Py-trans 9EG        8.89 7.61 8.06      8.30 4.11 1.39 
Cis and trans-[Pt(Py)Cl(NH3)2]
+
 bind to N
7
 of 5’-GMP as shown by downfield shift 
of gH8. For trans-[Pt(Py)Cl(NH3)2]
+
 (Fig. 2.17) downfield shifts between 0.06 and 0.08 
ppm are observed for all the pyridine proton resonances (almost exactly as observed for 
trans-[Pt(2ET)Cl(NH3)2]
+
). Furanose ring protons gH1’, gH3’, gH4’ and gH5’ (showing 
split of the signal) move downfield as well (similar to the shifts produced by trans-
[Pt(2ET)Cl(NH3)2]
+
). The similar chemical shifts displacements observed in the 
nucleotide sugar ring and the complexes pyridine upon binding to 5’-GMP of trans 
isomers could indicate that the interaction responsible of the modification of the 
furanose ring does not depend of the presence of the steroid.  
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Figure 2.17. 1H NMR spectra for trans-[Pt(Py)Cl(NH3)2]
+ with 5’-GMP in 1mM sodium cacodylate buffer in D2O 
(pH 6.8) and 1:1 nucleotide:complex ratio. &, this set of peaks will be addressed below in this section. 
 81 
This is partially reinforced by the fact that, for cis-[Pt(Py)Cl(NH3)2]
+
, the furanose 
gH3’ and gH5’ show a similar effect to cis-[Pt(2ET)Cl(NH3)2]
+
 (no effect), although the 
other two protons (gH1’ and gH4’) show downfield shifts of around 0.05 ppm, like the 
trans compounds (Fig. 2.18). Cis-[Pt(Py)Cl(NH3)2]
+
 pyridine protons pyH4 and pyH3/5 
move upfield (around 0.1ppm), meanwhile pyH2/6 is downfield shifted around the same 
amount. This is not observed for trans complexes or for the cis steroidal derivative. 
However, a similar upfield effect can be observed in the steroidal skeleton of cis-
[Pt(2ET)Cl(NH3)2]
+
 and can be indicative that the cis symmetry induces the pyridine (or 
the steroid in case of our testosterone coupled complex) to be closer to the 5’-GMP 
(probably to the nucleobase due to the lack of modification of the furanose ring 
protons).  
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Figure 2.18. 1H NMR spectra for cis-[Pt(Py)Cl(NH3)2]
+ with 5’-GMP in 1mM sodium cacodylate buffer in D2O (pH 
6.8) and 1:1 nucleotide:complex ratio.  
To further prove the former hypothesis while excluding any interference of the 
phosphate and furanose group, the complexes were also mixed with 9-EG and the 
reaction followed by 
1
H NMR (Figs. 2.19 to 2.22). Mixing with 9-EG resulted in the 
downfield shift of the 9H8
’
 resonance from 7.75 ppm to 8.20 ppm (cis isomers, Figs. 
2.20 and 2.21) and 8.30 ppm (trans isomers, Figs. 2.19 and 2.22); indicating again 
platinum binding directly via N
7
. Differences in the spectra of the cis and trans 
complexes indicate the binding arrangements are very different, as found when using 
5’-GMP. The spectra of trans isomers (both trans-[Pt(2ET)Cl(NH3)2]
+
 (Fig. 2.22) and 
trans-[Pt(Py)Cl(NH3)2]
+
 (Fig. 2.19)) and 9-EG, show the same downfield shift of 
pyridine resonances in similar values observed for 5’-GMP (around 0.1 ppm) and the 
downfield alterations for the methyl and methylene groups of the 9-EG. However, cis 
isomers (both cis-[Pt(2ET)Cl(NH3)2]
+
 (Fig. 2.21) and cis-[Pt(Py)Cl(NH3)2]
+
 (Fig. 2.20)) 
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show upfield alterations for 9Me methyl group and no modifications for the methylene 
group 9CH2. This confirms that the interaction of the studied complexes with the sugar 
ring probably occurs through the pyridine ring (for both cis and trans complexes) and is 
more related with the spatial position of that ring in the complex than with the presence 
or not of steroid. Also, both cis-[Pt(Py)Cl(NH3)2]
+
 and cis-[Pt(2ET)Cl(NH3)2]
+
 show 
upfield shifts for their pyridine resonances (cis-[Pt(Py)Cl(NH3)2]
+
) or steroid skeleton 
(cis-[Pt(2ET)Cl(NH3)2]
+
) when bound to 9EG. This behaviour in absence of the 
phosphate and furanose ring tells us that these displacements of the chemical shifts of 
the steroidal skeleton for cis-[Pt(2ET)Cl(NH3)2]
+
 can be caused by a possible stack with 
the nucleobase of the mononucleotide.  
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Figure 2.19. 1H NMR spectra for trans-[Pt(Py)Cl(NH3)2]
+ and 9-EG in 1mM sodium cacodylate buffer in D2O (pH 
6.8) and 1:1 nucleotide:complex ratio. &, this set of peaks will be addressed below in this section. 
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Figure 2.20. 1H NMR spectra for cis-[Pt(Py)Cl(NH3)2]
+ with 9-EG in 1mM sodium cacodylate buffer in D2O (pH 6.8) 
and 1:1 nucleotide:complex ratio. 
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Figure 2.21. 1H NMR spectra for cis-[Pt(2ET)Cl(NH3)2]
+ with 9-EG in 1mM sodium cacodylate buffer in D2O (pH 
6.8) and 1:1 nucleotide:complex ratio. 
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Figure 2.22. 1H NMR spectra trans-[Pt(2ET)Cl(NH3)2]
+ (bottom left) with 9-EG in 1mM sodium cacodylate buffer in 
D2O (pH 6.8) and 1:1 nucleotide:complex ratio. &, this set of peaks will be address below in this section. 
-2 0 2 4 6 8 10 12 14 16 18 20 22
-0,2
0,0
0,2
0,4
0,6
0,8
1,0
1,2
 trans-[Pt(Py)Cl(NH3)2]
 cis-[Pt(Py)Cl(NH3)2]
 trans-[Pt(2ET)Cl(NH3)2]
 cis-[Pt(2ET)Cl(NH3)2]
P
ro
p
o
rt
io
n
 o
f 
c
o
m
p
o
u
n
d
 b
o
n
d
 t
o
 G
M
P
Time (h)
-2 0 2 4 6 8 10 12 14 16 18 20 22
-0,1
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
1,1
 trans-[Pt(Py)Cl(NH3)2] hydrolysis
 trans-[Pt(2ET)Cl(NH3)2] hydrolysis
 trans-[Pt(Py)Cl(NH3)2] +GMP
 trans-[Pt(2ET)Cl(NH3)2] +GMPP
ro
p
o
rt
io
n
 o
f 
c
o
m
p
o
u
n
d
 r
e
a
c
te
d
Time(h)
 
 
 
Figure 2.23.  A) Rate of appearance of 5’-GMP adducts (left) and comparison of hydrolysis and 5’-GMP appearance 
for trans isomers (right). B) 1H NMR spectra of trans-[Pt(2ET)Cl(NH3)2]
+ (lower), trans-[Pt(2ET)Cl(NH3)2]
+ in 
sodium cacodilate after 5 hours (second), trans-[Pt(2ET)Cl(NH3)2]
+ in sodium cacodilate with 5’-GMP after 5 hours 
(third), and trans-[Pt(2ET)Cl(NH3)2]
+ in sodium cacodilate with 5’-GMP after 24 hours (upper) 
7.407.607.808.008.208.408.608.809.009.20
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 85 
When the reaction between the complexes and 5’-GMP is followed in time, we see 
that interaction between cis-[Pt(2ET)Cl(NH3)2]
+
 and 5’-GMP is substantially complete 
in 3 hours, whilst the reaction between trans-[Pt(2ET)Cl(NH3)2]
+
 and 5’-GMP requires 
around 18 hours. Similar results are observed for the non-steroidal analogues. However, 
binding is a bit slower, indicating that the steroid may have some effect on the kinetics 
(graph Fig. 2.23).  It is interesting to note that during this experiment only a single set of 
new resonances is detected for the cis isomers, while two new products are seen for the 
trans ones (Fig. 2.23, and peaks marked as 
&
 previously in this section). 
Because ESI shows hydrolysis for the trans isomers and not for cis isomers, the same 
experiment was repeated without mononucleotide (just in buffer), to detect if this 
second set of signals is hydrolysis. The NMR of the cis compounds (Figs. 2.25 and 
2.27) are not modified, while the trans ones (Figs. 2.24 and 2.26) show a different set of 
signals that coincide with previous ones. Thus confirming then that cis isomers do not 
show hydrolysis while the trans complexes do. The lack of hydrolysis products for the 
cis geometry complexes might suggest that this geometry hinders substitution reactions. 
Moreover, NH3 and pyridine ligands, in cis and trans-[Pt(2ET)Cl(NH3)2]
+
, respectively 
have very similar ability to labilise the chloride ligand trans to them and the noticeably 
shorter reaction time of cis-[Pt(2ET)Cl(NH3)2]
+
 compared to trans-[Pt(2ET)Cl(NH3)2]
+
 
with 5’-GMP is unlikely to arise from that effect. The fact that the kinetics of the 
hydrolysis in trans complexes is almost identical to the kinetics of binding to 5’-GMP 
(Fig. 2.23), can be taken as trans and cis isomers have different mechanism of binding 
to DNA, with the trans first undergoing hydrolysis and the cis reacting  directly with the 
nucleobase. 
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Figure 2.24. 1H NMR spectra for trans-[Pt(Py)Cl(NH3)2]
+ hydrolysis in 1mM sodium cacodylate buffer in D2O (pH 
6.8) and 1:1 nucleotide:complex ratio. 
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Figure 2.25. 1H NMR spectra for cis-[Pt(Py)Cl(NH3)2]
+ hydrolysis in 1mM sodium cacodylate buffer in D2O (pH 6.8) 
and 1:1 nucleotide:complex ratio. 
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Figure 2.26. 1H NMR spectra trans-[Pt(2ET)Cl(NH3)2]
+ hydrolysis in 1mM sodium cacodylate buffer in D2O (pH 
6.8) and 1:1 nucleotide:complex ratio. 
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Figure 2.27. 1H NMR spectra for cis-[Pt(2ET)Cl(NH3)2]
+ hydrolysis in 1mM sodium cacodylate buffer in D2O (pH 
6.8) and 1:1 nucleotide:complex ratio. 
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In summary, all the compounds bind to nucleobases, but the manner of the reaction 
and effects on the sugar ring seems to be more related to the geometric isomer than to 
the presence or absence of the steroid. The speed of the binding is also principally 
dependent on the isomer, although the steroid does have some effect, enhancing the rate 
of reaction. The cis conformation brings the steroidal ligand and nucleobase closer 
together as expected and demonstrated by the steroidal skeleton alterations created by 
the mononucleotides. The retention of these modifications without the presence of sugar 
ring seems to indicate a possible interaction with the guanine rings. The ability to bind 
to nucleobases is a good predictor that these complexes will bind to DNA and this was 
explored next. 
2.4.3 Studies with DNA  
Circular Dichroism: 
CD measures the difference of absorption in left and right circularly polarised light, 
and when performed using macromolecules can be used to report changes in the 
conformation of the macromolecule itself, and to prove information on its interaction with 
small molecules, particularly by confering induced CD (ICD) signals in the spectroscopy 
of the small molecule
61
. When a titration of ct-DNA with our complexes was recorded by 
CD, the first thing observed was that the B-DNA conformation is retained with non-
steroidal complexes. B-DNA is marked by a characteristic positive CD band centred at 
275 nm, and a negative band at 250 nm, with the zero being around 260 nm (Fig. 2.28).  
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Figure 2.28. ct-DNA CD titration with cis-[Pt(Py)Cl(NH3)2]
+ (right) and trans-[Pt(Py)Cl(NH3)2]
+ (left). (Michael 
Browning)41. 
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When ct-DNA is titrated with the steroidal complexes dramatic alterations in the 200-
300 nm region compared with non-steroidal compounds are observed. These 
modifications are different for cis and trans geometries, showing again the possibility of 
different DNA interacting modes (Fig. 2.29). However, the testosterone molecule 
coupled to the metallic centres make the complexes chiral, therefore they have their own 
CD spectrum. For that reason the titration spectra would be a combination of ct-DNA 
and the complexes CD absorbance, making impossible to obtain any DNA 
conformational information.  
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Figure 2.29. ct-DNA CD titration with cis and trans-[Pt(2ET)Cl(NH3)2]
+. 
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Figure 2.30. CD titration with cis and trans-[Pt(2ET)Cl(NH3)2]
+. 
When the CD spectra of both cis and trans-[Pt(2ET)Cl(NH3)2]
+
 are measured under 
the same conditions and concentrations of the different titration points Fig.2.30 is 
produced. As expected, both complexes show similar CD absorbance, due to the fact 
that the chirality is introduced by the ethisterone molecule, common to both of them. 
Subtracting this set of spectra from the initial ct-DNA tritation, information about DNA 
conformation modifications could perhaps be obtained. Fig. 2.31 shows the corrected 
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DNA titration, where DNA binding modes for both complexes can still be observed. 
However, major modifications of the ct-DNA spectrum are observed where cis and 
trans-[Pt(2ET)Cl(NH3)2]
+
 present CD absorbance bands, so no conformational 
information is available. 
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Figure 2.31. Corrected ct-DNA CD titration with cis and trans-[Pt(2ET)Cl(NH3)2]
+. 
The induced CD (ICD) signals produced in the titration (subtracting from the original 
spectrum all the chiral components) are different for cis and trans-[Pt(2ET)Cl(NH3)2]
+
 
(Fig. 2.32). It is noticeable as well the fact that both ICD show similar mirror image 
patterns with different intensities (the cis isomer shows higher intensity than the trans). 
This fact could indicate a possible difference in the steroid orientation towards the 
DNA, induced upon binding of cis or trans isomers (as steroid position in the complex 
is different). Higher ICD intensities could indicate as well that the cis geometry bring 
the testosterone closer to the DNA, as suggested in 2.4.1. These differences in the DNA 
binding mode between cis and trans isomers (presented here and in section 2.4.1) could 
be the reason of the difference in activity observed between the two geometries 
(togheter with the substantial differences in rates of binding and hydrolysis). 
200 220 240 260 280 300 320 340
-2
0
2
4
C
D
 (
m
d
e
g
)
nm
 ICD trans-[Pt(2ET)Cl(NH3)2]
 ICD cis-[Pt(2ET)Cl(NH3)2]
 cis-[Pt(2ET)Cl(NH3)2]
 trans-[Pt(2ET)Cl(NH3)2]
 
Figure 2.32. ICD  of ct-DNA CD titration with cis and trans-[Pt(2ET)Cl(NH3)2]
+. 
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2.4.4 Studies with proteins 
Steroids are biomolecules with an important role in the organism, showing different 
actions around the body
62-64
. Most of them are due to their interaction with proteins, 
controlling their transport around the body
65
, metabolism
66
 or activity
67
 (through their 
own nuclear receptors). One of the most important groups of proteins in steroids 
regulation are the AKRs (aldo-Keto reductases), a family of cytosolic NADPH 
dependent proteins that reduce aldehydes and ketones to their correspondent primary 
and secondary alcohols. There are 13 human subfamilies of them, with different 
substrates and function
68
. Of particular interest to us is the subfamily of AKR1C that 
catalyze the reduction of ketosteroids to hydroxysteroids in both 3 (3β-HSD and 3α-
HSD action) and 17 positions (17α-HSD)69 (Fig. 2.33), and which are able to regulate 
the occupancy of steroid receptors in determinated tissues
69
. This is done upon the direct 
regulation of the amount of steroids available in the cell, transforming them into 
products with lower receptor affinities (sometimes even 5 orders of magnitude lower
70
), 
that can lead to the final elimination of the steroids. They are also known to be 
important in the role of androgens in prostate cancer
71
. Four different forms of this 
subfamily have been detected, with different targets and tissue distribution (Table 2.10). 
3β-HSD 
3α-HSD 
17α-HSD 
 
Figure 2.33. Possible tranformations catalyzed by AKRs in estradiol and testosterone. 
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 Activity Receptor regulated 
AKR1C1 20α-HSD, 3β-HSD, 3α-
HSD 
PR, ERβ 
AKR 1C2 3α-HSD AR 
AKR1C3 17α-HSD, 3α-HSD AR, ERα 
AKR1C4 3α-HSD Hepatic clearance of 
steroids 
Table 2.10. Activities of AKRs and Receptors regulated.  
In modifying the structure of steroids (adding the Pt complexes) there is a risk of the 
modified molecules loosing their capacity to interact with their natural receptors. It is 
known that steroidal complexes can interact with Human serum albumin
29
, and with 
their receptors with different efficiencies
23-28
. However, what has not been studied is 
how such compounds might interact with AKRs regulatory proteins that can transform 
them inside the cell, or even help with excretion. Indeed potential metabolism of 
steroidal metal complexes has not been considered previously. For that reason it is of 
interest to see how our complexes interact with this kind of proteins. Herein, two 
different kinds of experiments are investigated (AKRs provided by Dr. Chris Bunce 
group, School of Biosciences, University of Birmingham); first we check by HPLC 
whether our complex can be reduced by these proteins. Second, we undertake enzymatic 
studies in order to determinate their abilities as inhibitor and substrate for AKRs. 
HPLC experiments:  
Our first experiment was to measure the disappearance of complex and appearance 
of metabolite in a reaction at room temperature. This would tell us if the complex were 
metabolized, if so into how many products (and maybe which products) and how 
rapidly. The different species were detected with the same HPLC method used to purify 
the complexes (Water:Methanol (0-100%) gradient for 40 minutes, with the use of TFA; 
retention time around 30 minutes). The experiment was undertaken for cis-
[Pt(2ET)Cl(NH3)2]
+
 since it was the most active complex, and for the four AKR1Cs. 
Recombinant enzyme was treated with cis-[Pt(2ET)Cl(NH3)2]
+
 and NADPH. The final 
volume was taken to 2 ml with KH2PO4 Buffer. The order of addition was Buffer, 
enzyme, substrate and NADPH. Samples were taken and injected into HPLC every hour 
for 24 hours and followed at 254 nm. As controls, the same experiment was repeated 
with AKR1C3 for ethisterone and 9,10-phenanthrenequinone.  
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At time 0 h two main peaks appear in the chromatograph; NADPH (around 9.7 min) 
and cis-[Pt(2ET)Cl(NH3)2]
+
 (30.1 min). For all four AKRs after a few hours these peaks 
start to decrease in magnitude and two new peaks appear both running around 2 minutes 
faster in the chromatograph (7.5 and 28.6 min) (Fig. 2.34 and 2.35). When the two 
peaks around 30 minutes (28.6 and 30.1 min) were collected and analysed by ESI-MS, 
the second one (at 30.1 min) corresponds to the expected starting material (our 
complex). The one at 28.6 min. shows a similar mass, rather than the expected reduced 
species; this can be due to reoxidation of the compound once separated (although 
trifuoroacetic acid can act as an oxidant in presence of metals
72
, or maybe occurs as a 
result of too strong ESI-MS ionization). However, the different retention time marks the 
increased polarity of the product, suggestive of a reduction.  
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Figure 2.34.  HPLC chromatographs of cis-[Pt(2ET)Cl(NH3)2]
+ with AKR1C3  at t = 0 (top) and t = 1 h (bottom). 
This indicated that the complex was a possible substrate for all of the AKR1Cs 
studied. When appearance of metabolite and disappearance of substrate (our complex) 
were plotted against time (Fig. 2.36) we could see that the four enzymes produced the 
main metabolite at almost the same rate (AKR1C3 a bit slower). 50% of the 
transformation (metabolite produced) is complete in around 13 hours, except for 
AKR1C3 where only 45% of the substrate transformation is reached even at 22 hours. 
This is interesting since AKR1C3 regulates the access of steroids to AR and ERα. 
However, if we observe the rate of disappearance of starting material, this is somewhat 
different from what we would expect. As expected, for most of the AKR1Cs a 
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“stationary phase” is reached between 11 and 13 hours. However, this only occurs for 
AKR1C2 (responsible of regulation of AR) when 50% of the starting material has 
disappeared. Meanwhile, for both AKR1C1 and 3 the “stationary phase” is reached 
when between 40 and 30% of starting material is remaining, indicating possible 
presence of secondary products. For AKR1C4 this is not observed, probably due to 
technical errors.  
 
Figure 2.35.  HPLC chromatographs of cis-[Pt(2ET)Cl(NH3)2]
+ with AKR1C4 at t = 0 (top) and t = 1 h (bottom). 
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Figure 2.36. Rate of appearance of AKR1C metabolic product (left) and disappearance of cis-[Pt(2ET)Cl(NH3)2]
+ 
(right). 
Two controls were used, to check the effect of the presence of the metallic centre; a 
good substrate phenanthrenequinone, and ethisterone (as a simple androgen, to see the 
direct effect of the metallic centre). Even at room temperature, both 
phenanthrenequinone and ethisterone proved to be much better substrates, disappearing 
totally in 1 h. Remarkably, the change in the retention time showed by the metabolized 
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ethisterone (travel 1.7 min. faster) is similar to the one observed when cis-
[Pt(2ET)Cl(NH3)2]
+
 is used (travel 1.5 min faster), confirming the transformation of our 
complex and indicating that an analogous product is obtained (Fig. 2.37). This 
experiment proves that the introduction of the metallic centre causes a major decrease in 
the rate at which normal steroidal metabolic proteins modify the complex. While these 
initial results are informative they were conducted at room temperature.  
 
 
Figure 2.37.  HPLC chromatographs of ethisterone with AKR1C3 at t = 0 (top) and t = 1 h (bottom). 
Enzymatic experiments: 
In order to understand more about the interaction of cis-[Pt(2ET)Cl(NH3)2]
+
 with 
these proteins further experiments were conducted under physiological conditions. Our 
compound is toxic, making difficult to understand fully the interaction with proteins 
using data from cellular assays. For that reason an in vitro experiment using similar 
conditions to the physiologically found was considered our best option. This would give 
an idea about how they interact under similar conditions to the ones found in the cell, 
and would be closer to reality than the HPLC experiments. The four AKR1Cs used 
previously, were treated with different concentrations of cis-[Pt(2ET)Cl(NH3)2]
+
 (from 
40 µM to 0.313 µM), and the rate of disappearance of NADPH noted (UV absorbance 
at 340 nm). Reactions were done at 35ºC in phosphate buffer. In the first attempt, no 
turnover was observed over a 5 minutes time for any of the enzymes, indicating that the 
compound was a poor substrate for them. In order to improve activity, we repeated the 
experiment using four times the concentration of enzymes. This time turnover was 
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observed (Fig. 2.38), but it was quite slow, confirming that the compound was a poor 
substrate for the enzymes. However, Km values (Table 2.11; Michaelis-Menten 
constant, obtained from the Michaelis-Menten kinetic equation v0=(vmax[S])/(Km+[S])  
defined as the concentration of substrate [S] at which the v0 is half of vmax and is 
indicative of the affinity of the active centre of the enzyme for the substrate) indicate 
that the presence of the metallic centres do not affect their affinity towards the AKR1Cs 
enzymes, showing rate constant values in the range of naturally occurring strong 
androgens (5α-dihydrotestosterone)73. However, the transformation rate of cis-
[Pt(2ET)Cl(NH3)2]
+
 per unit of enzyme (kcat; Table 2.11; catalytic rate constant, defined 
as the amount of substrate [S] transformed per unit of enzyme and time; kcat=(vmax/[E]0)) 
was between 20 and 30 times lower than for 9.10-phenanthrenequinone and 4 times 
lower than for 5α-dihydrotestosterone73. These results indicate that even if it is possible 
for the complexes to be turned over by AKR1Cs in the cells, this process is quite slow. 
For that reason it is quite unlikely that the cytotoxicity of our complexes is significantly 
directed by the action of AKR1Cs inside the cells. It is, however, interesting to note that 
the enzymes showing best activity are AKR1C2 and AKR1C3, enzymes responsible of 
the control of access to AR by androgens. 
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Figure 2.38. Rate of comsumption of NADPH (nmol/min) compared with concentration of cis-[Pt(2ET)Cl(NH3)2]
+ 
for AKR1Cs. 
 cis-[Pt(2ET)Cl(NH3)2] 9,10-phenanthrenequinone 
 Km ( μM) kcat (min-1) Km ( μM) kcat (min-1) 
AKR1C1 1.12 ± 0.60 1.46 ± 0.16 2.48 ± 0.54 21.0 ± 1.59 
AKR1C2 0.83 ± 0.22 1.60 ± 0.09 2.37 ± 0.46 38.1 ± 2.58 
AKR1C3 0.62 ± 0.18 1.65 ± 0.08 1.59 ± 0.28 18.8 ± 1.46 
AKR1C4 - - 2.44 ± 0.54 18.9 ± 1.47 
Table 2.11.  Km (μM) and Kcat of cis-[Pt(2ET)Cl(NH3)2]
+ with AKR1Cs, calculated using the “Enzymics” program 
(Softzymics, Princetown, NJ, USA). 
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If a compound is a poor substrate, but still can be metabolized by the protein (as seen 
by HPLC) it could still be effective as an AKR inhibitor. To study this possibility an 
experiment was performed in which a good substrate (9,10-phenanthrenequinone) was 
provided in different concentrations (from 20 to 0.313 μM) and turnover in a time 
period of 5 minutes measured in the presence of different concentrations of our 
compound (from 0 to 0.1 mM). The experiment was repeated for the four AKR1Cs, and 
results can be seen in Figure 2.39. Immediately we can see that all four enzymes are 
inhibited (through an uncompetitive inhibitory mode) by our steroidal platinum 
complex. However this inhibition is mild and we need to go to high concentrations of 
our compound to see dramatic effect in the activity (around 100 µM). They present high 
Ki (Table 2.12), needing high concentrations to stop the activity by 50% compared with 
other inhibitors
108
. It is interesting to note that the highest inhibition is in AKR1C4 
(estimated 50% of activity inhibition at around 30 µM) which is present in the liver and 
is responsible of hepatic clearance.  
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Figure 2.39. Rate of consumption of NADPH (nmol/min) compared with concentration of PQ for AKR1Cs under 
different concentrations of cis-[Pt(2ET)Cl(NH3)2]
+ (0 (blue), 4 (brown), 20 (green) and 100 μM (red)).  
 Ki 
AKR1C1 174 ± 66.7 
AKR1C2 207 ± 78.5 
AKR1C3 84.8 ± 19.3 
AKR1C4 17.2 ± 3.8 
Table 2.12.  Ki inhibitory constants (μM) of the compound, calculated using the “Enzymics” program (Softzymics, 
Princetown, NJ, USA). 
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The experiment was repeated, pretreating the enzymes for 24 hour with our complex. 
After that time, 9,10-phenanthrenequinone and NADPH were added, and the turnover 
measured. The results are presented in Figure 2.40. We can observe that the inhibition 
increased after 24 hours pre-treatment with cis-[Pt(2ET)Cl(NH3)2]
+
, with the Ki 
decreasing around an order of magnitude (Table 2.13), except for AKR1C4 that seems 
to suffer degradation under the conditions used (as the drop of activity without complex 
suggest, maybe as result of a covalent binding of the complex with the enzyme). The 
mode of this inhibition is unchanged for AKR1C2 and 3 (Uncompetitive), while change 
for AKR1C1 (competitive), suggesting that the complex inhibit through binding to the 
active site. It is interesting to note that inhibition almost stops the activity of AKR1C3 
at 0.1 mM concentration, this being the most strongly inhibited with an estimated 50% 
of activity inhibition at around 5 µM. Due to the affinity towards the enzyme showed by 
cis-[Pt(2ET)Cl(NH3)2]
+
, this effect is probably more related to the occupation of the 
enzymatic active centre during the pre-treatment by complex than to covalent 
modifications of the protein. 
7
6
5
4
3
2
1
0
-1
V
el
o
ci
ty
20x10
-3
151050
Substrate
AKR1C1
25
20
15
10
5
0
-5
V
el
o
ci
ty
20x10
-3
151050
Substrate
AKR1C3 (uncomp)
14
12
10
8
6
4
2
0
V
el
o
ci
ty
20x10
-3
151050
Substrate
AKR1C2 Kii plot
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
V
el
o
ci
ty
20x10
-3
151050
Substrate
AKR1C4
[PQ] mM [PQ] mM
[PQ] mM [PQ] mM
n
m
o
l/
m
in
n
m
o
l/
m
in
n
m
o
l/
m
in
n
m
o
l/
m
in
V
el
o
ci
ty
V
el
o
ci
ty
V
el
o
ci
ty
V
el
o
ci
ty
V
el
o
ci
ty
V
el
o
ci
ty
V
el
o
ci
ty
V
el
o
ci
ty
n
m
o
l/
m
in
n
m
o
l/
m
in
n
m
o
l/
m
in
n
m
o
l/
m
in
 
Figure 2.40.  Rate of consumption of NADPH (nmol/min) compared with concentration of PQ for AKR1Cs under 
different concentrations of cis-[Pt(2ET)Cl(NH3)2]
+ after 24 hours pre-treatment (0 (blue), 4 (brown), 20 (green) and 
100 μM (red)). 
 Ki 
AKR1C1 on 13 ± 5.3 
AKR1C2 on 52.7 ± 13.5 
AKR1C3 on 2.9 ± 0.7 
AKR1C4 on - 
Table 2.13.  Ki inhibitory constants (μM) after pre-treatment with the compound for 24 hours, calculated using the 
“Enzymics” program (Softzymics, Princetown, NJ, USA). 
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The different experiments undertaken demonstrate that our compound has the ability 
to be a substrate for AKR1C enzymes (reaction that can be followed by HPLC, but not 
for AKRC4), but it is neither a good substrate nor a good inhibitor. Conjugation of the 
platinum centre to the steroidal molecule, does maintain the affinity of the enzyme 
active centre towards the complex, but affects heavily the transformation rate (action of 
the enzyme) of the substrate (steroidal moiety). This indicates that our compound can be 
metabolised by proteins inside the cell, but the slow rate of transformation make us 
think that cis-[Pt(2ET)Cl(NH3)2]
+
 does not act as an AKR-activated prodrug.  
 
2.5 Synthesis of additional new steroidal compounds  
As we have seen before, steroids can be used to target breast cancer (sections 2.1, 2.2 
and 2.3), and possibly prostate cancer. The syntheses of these complexes normally 
follow two main steps; one in which the organic ligand is created, and a second one in 
which the metal centre is attached. These ligands are created specifically for each 
compound following sometimes difficult synthetic routes. Our intention is to create a 
simple method to attach different molecules to steroids using the same simple procedure 
used for our monofunctional complexes (section 2.1), developing schemes for the 
standardization of the attachment to steroids.  
Following previous work made in our laboratory
16,29,40-42
, we knew that all the 
designs should contain two elements: a steroidal domain and a linker that allows 
attachment to the platinum(II). This linker would present a simple reactive centre that 
would allow us to attach different chelators, or metallic binding domains to the steroid 
(Fig. 2.42). We chose to explore a benzaldehyde as linker. To attach this moiety to the 
steroid, Sonogashira coupling
75
 was chosen as a synthetic route (Fig. 2.41), due to the 
commercial availability of inexpensive bromo-aromatic derivatives and 17α-
ethynyltestosterone and estradiol.  
A Sonogashira coupling is a palladium catalysed reaction between an acetylinic 
group and a halo-aromatic. A copper(I) salt (often CuI) is used to reduce Pd(II) to 
catalytically active Pd(0) in situ. As a result, the reaction requires inert conditions as 
copper(I) salts can catalyse homo-coupling of the acetylinic groups in a Glaser 
coupling
47
. Removal of the acetylinic proton is conducted in basic medium. The 
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proposed catalytic cycle for the Sonogashira reaction is presented in Figure 2.41 and in 
addition to the product, a protonated base is the major byproduct of the reaction. The 
catalytic cycle involves reduction of Pd(II) to Pd(0) by Cu(I), insertion of the catalyst 
into an aromatic-bromo bond and the formation of a palladium-carbon bond after the 
deprotonation of acetylsteroid by a base. The protonated base precipitates out from 
solution and a 1,2-insertion reaction at the Pd centre completes the reaction to form the 
desired product. 
 
Figure 2.41. Sonogashira coupling Reactive cicles 
 
Figure 2.42.  Scheme of intended synthesis  
Following attachment of the benzaldehyde, picolinamine and thiosemicarbazones 
complexes were synthesised. Both are active units in the absence of the steroid
76-78
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would be good examples for the attachment of other molecules. Also, we present herein 
the synthesis of new Ru (III) complexes of the previously synthesised EET and ETT 
ligands
29, 50
.  
2.5.1 Synthesis of multiple chelators 
Synthesis of steroidal linker to chelators (ETBza) 
 
The Sonogashira cross-coupling reaction between ethisterone and 4-
bromobenzaldehyde afforded the product 17α-benzaldehyde-4-ylethynyl-testosterone as 
a yellow solid in good yield (73%). The product was insoluble in water, but soluble in 
most common organic solvents. Purification of the crude product involved a flash silica 
column using ethanol:dicloromethane (3%) as eluent. 
The product was analysed by mass spectroscopy giving peaks consistent with the 
proposed structure (m/z 417.4 [H(ETBza)]
+
). In the 
1
H NMR spectrum (Fig. 2.43) both 
steroidal skeleton (from 0-6 ppm) and benzaldehyde (from 7-11 ppm) are present in a 
1:1 ratio and the loss of the acetylene resonance ca. 2.55 ppm indicates a reaction at that 
centre. The α,β-unsaturated carbonyl proton of the A ring of the testosterone and the 
methyl resonances appear at 5.92, 1.38 and 1.14 ppm respectively, hardly shifted when 
compared to ethisterone (as would be expected due to the distance form the aromatic 
ring). The aromatic protons of the benzaldehyde moiety appear as two doublets at 7.98 
and 7.75 ppm. The increase in the gap between these resonances compared to the free 4-
brombenzaldehyde is due to the attachment to the testosterone. Finally, the α-carbonyl 
proton of the benzaldehyde can be assigned at 10.17 ppm. In the next steps, this proton 
will be an important marker indicating whether the condensations have worked or not. 
This structure is the starting point for the next ligands: thiosemicarbazone (ETTsc) and 
picolinamine (ETPcl). 
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Figure 2.43.  1H-NMR of ETBza in deuterated chloroform. 
Synthesis of steroidal thiosemicarbazone (ETTsc) 
 
The steroidal benzaldehyde linker was condensed with a thiosemicarbazide, giving a 
thiosemicarbazone, affording ETTsc in good yield (72%) (Fig. 2.44). After synthesis, 
the product was purified on a flash silica column using the same conditions as for 
ETBza. The product showed insolubility in water, again, and a reduced solubility in 
organic solvents compared with ETBza. 
 
 
 
Figure 2.44. Synthetic procedure for ETTsc. 
The product was analysed by elemental analysis and mass spectrometry, showing the 
expected result with the desired structure. The 
1
H NMR spectrum (Fig. 2.45 shows the 
disappearance of the α-carbonilic proton from ETBza, and the appearance of the iminic 
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proton of the thiosemicarbazone at 8.17 ppm as result of the condensation. The labile 
protons of the NH of the thiosemicarbazone are visible as well at 10.58, 7.92, 7.58 ppm. 
Finally a small opening in the gap between aromatic protons is seen as result of the 
condensation, the two doublets being found at 7.78 and 7.44 ppm. The α,β-unsaturated 
carbonyl proton and methyl resonances appear with little shifting compared to ETBza 
(as would be expected due to the distance from the aromatic ring again). 
 
Figure 2.45.  1H-NMR of ETTsc in deuterated acetone. 
Synthesis of steroidal picolinamine (ETPcl) 
 
ETPcl was synthesised through the condensation of the ethisterone coupled 
benzaldehyde (ETBza) and a 2-picolinamine, followed by an in situ reduction (Fig. 
2.46), as described by Yajima et al
79 
for non-steroidal analogues. The crude product was 
soluble in similar range of solvents to ETBza, containing a mixture of ETPcl with 
ETBza (as shown by ESI-MS). Numerous purification attempts of the crude product 
were unsuccessful.  
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Figure 2.46. Synthetic procedure for ETPcl.  
In the 
1
H NMR (Fig. 2.47) as a result of the similar chemical shift of the products it 
is impossible to fully assign the peaks. However, the α-carbonilic proton is still visible 
due to the absence of signals in this area, confirming the presence of the starting 
material. Since the aldehyde ligand ETBza will have low reactivity to palladium and 
platinum salts, we proceeded without further purification. 
 
Figure 2.47.  1H-NMR of ETPcl in deuterated chloroform. 
Steroidal thiosemicarbazones complexes 
A set of neutral Pt(II) and Pd(II) compounds have been prepared, using the ETTsc 
and ETPcl bidentate ligands. All these complexes show low solubility, being soluble 
only in DMF and DMSO. Attempts to increase solubility by ligand exchange of one or 
two chlorides co-ligands with different monoanionic or neutral substituents failed. 
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Synthesis of [Pt(ETTsc)Cl2]. 
 
 The desired product was formed relatively easily by reaction of potassium 
tetrachloroplatinate with ETTsc in the minimum amount of ethanol. Unfortunately the 
low solubility of the resulting yellow-orange solid, (only soluble in DMF and DMSO), 
prevented a further purification. The mass spectrum shows a peak at m/z=756 whose 
isotopic distribution pattern matches that of [Pt(ETTsc)Cl2H]
+
. The 
1
H NMR spectrum 
(Fig. 2.48) shows the benzene ring system, shifted to low field, as result of the Pt(II) 
coordination. 
 
Figure 2.48.  1H-NMR of [Pt(ETTsc)Cl2] in deuterated DMSO. 
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Synthesis of [Pd(ETTsc)Cl2].  
 
With a similar procedure from the previous complex, but using potassium 
tetrachloropalladate instead of the platinum salt, a bright orange solid was obtained. 
Mass spectrometry analysis shows a main peak at 666 m/z, corresponding with the 
expected complex [Pd(ETTsc)Cl2], but shows as well a secondary peak at 1084 m/z, 
that correspond to [Pd(ETTsc)2]. The 
1
H NMR (Fig. 2.49) shows a main product, 
probably the expected [Pd(ETTsc)Cl2], and impurity of 20-30%, probably 
[Pd(ETTsc)2]. 
 
Figure 2.49.  1H-NMR of [Pd(ETTsc)Cl2] in deuterated DMSO. * bisubstituted complex 
Experiments using the more labile palladium (II) salt bis-benzonitrile palladium (II) 
dichloride, gave a different result. The mass spectrum shows a major peak 
corresponding to [Pd(ETTsc)2] and a really minor [Pd(ETTsc)Cl2]. 
1
H NMR (Fig. 2.50) 
show and almost clear set of signals, corresponding to the minor product from the other 
synthesis. Small resonances are visible at shifts previously assigned to [Pd(ETTsc)Cl2]. 
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0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
7.207.407.607.808.008.208.40
 
Figure 2.50. 1H-NMR of [Pd(ETTsc)2] in deuterated DMSO.  
The low solubility of both compounds, only soluble in DMF and DMSO, has this far 
made imposible to purify any of them. 
Steroidal picolinammine complexes 
Synthesis of [Pd(ETPcl)Cl2].  
 
This palladium complex has been synthesised from ETPcl, reacting with potassium 
tetrachloropalladate in the minimum amount of methanol. A yellow solid was obtained, 
only soluble in DMSO and DMF. Analysis in mass spectrometry gives a peak of 
m/z=685 ([Pd(ETPcl)Cl2]H
+
). The 
1
H NMR (Fig. 2.51) show a clear set of signals for 
the benzene ring at 7.56 and 7.34 ppm. Four pyridinic protons appear at 8.65, 7.97, 7.51 
and 7.43 ppm. The α,β-unsaturated carbonyl proton and methyl resonances appear with 
little shifting again, as result of the long distance from the Pd(II) nucleus. On the other 
hand around 4 ppm, in the region where the resonance for the methylene protons should 
appear, a complex set of signals is observed. Integration of this region did not allow a 
definitive assignment of the signals without further NMR experiments. 
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Figure 2.51.  1H-NMR of [Pd(ETPcl)Cl2] in deuterated DMSO. 
The synthesis of Pt(II) analogue using different salts, such as potassium 
tetrachloroplatinate and bis(benzonitrile) platinum(II) dichloride, was unsuccessful. 
2.1.2 Synthesis of new steroidal terpyridine complexes 
[Ru(EET)Cl3] 
 
 
Using two steroidal terpyridine ligands previously designed in our group 
29, 50
 we 
now prepared some Ru(III) chloro derivatives. [Ru(tpy)Cl3] compound is reported to be 
active against cancer cell lines and this presents an interesting unit for conjugation
80-81
. 
Synthesis of the metal complex was straightforward and under normal procedures used 
for non-steroidal complexes, the compounds were obtained. Reacting EET with 
Ru(III)Cl3 led to the desired compound. Purification was simple: since the complex is 
neutral and soluble only in DMSO or DMF, only continuous washes with different 
solvents were needed to remove the impurities. Mass spectrometry and elemental 
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analysis confirm the 1:1 stechiometry. Impurities removed by washing include the bis-
ligand Ru(II) complex (previously synthesised by Phil Barker)
50
, that can be isolated by 
washes of the crude product with ethanol. 
As this is a neutral and paramagnetic complex, characterization was more difficult 
than for previous complexes, however ESI-MS show a major peak corresponding to the 
[Ru(EET)Cl2]
+
. Finally paramagnetic 
1
H-NMR (Fig. 2.52) shows 5 paramagnetic 
signals at 7.12, -3.25, -8.05, -9 and -35.4 ppm, corresponding to the five protons close to 
the Ru(III) centre, H3’’, H4’, H5’, H3’ and H6’ respectively (assigned by comparison with 
non-steroidal complexes
82
). Most of these signals are not visible under normal NMR 
conditions. However, protons belonging to the steroidal skeleton appear both under 
paramagnetic and normal conditions, as a result of the distance to the metallic centre. 
Protons H1, H2 and H4 can be detected at the normal 7 to 6.3 ppm (6.95, 6.46, 6.38 ppm) 
and the methyl group at 1.11 ppm. The NMR confirms the removal of impurities after 
the washes.  
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Figure 2.52. Paramagnetic 1H-NMR of [Ru(III)(EET)Cl3] in deuterated DMSO. 
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[Ru(ETT)Cl3] 
 
The synthesis with ETT was analogous. ESI-MS show this time the lost of two 
chlorides, and elemental analysis confirms the stechiometry. Again 
1
H-NMR (Fig. 2.53) 
show the 5 paramagnetic signals at 6.94, -3.33, -8.11, -9.09 and -35.38 ppm, 
corresponding to the five terpyridine protons close to the Ru(III) centre (with similar 
assignments to the estradiol complex). These signals are not visible under normal 
conditions, unlike the steroidal skeleton protons that being far away from the metallic 
centre does not suffer quenching. H4 can be seen at 5.58 ppm integrating for a proton 
and the absence of impurities in the methyl groups (integrating for three protons each at 
1.08 and 1.02 ppm) show the purity obtained after the multiple washes. 
3’
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Figure 2.53. Paramagnetic 1H-NMR of [Ru(III)(EET)Cl3] in deuterated DMSO. 
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Although these compounds were prepared in order to test their biological activities, 
their low solubility prevented this, since a high percentage of DMSO in the medium is 
needed for even low concentration solutions. 
 
2.6 Conclusions 
Three different points have been presented in this chapter: the description of new 
procedures to synthesise and purify steroidal compounds, the interaction of these 
compounds with cells and the interactions with macrobiomolecules.  
First three new pyridine derivates of both estradiol and testosterone linked complexes 
have been synthesised, and a HPLC procedure optimized for the purification of these 
and similar compounds. This purification allows us to remove secondary products such 
as disubstituted Pt molecules or Glaser coupling products, and improves the overall 
yields as a result of the simplification of the procedures. In addition, removal of the 
solvents from the complexes allows us to visualize the amino groups from the platinum 
moiety allowing differentiation between cis and trans isomers through standard 
1
H-
NMR. 
The interesting cytotoxicity presented by some metallo-steroid compounds was 
previously known. For these active compounds we studied their cellular behaviour. As 
previously seen with testosterone derivatives, toxicity was observed for the estradiol-
linked complexes; this showed that functionalisation with an steroid could confer 
activity to inactive metallic moieties. The possibility that this activity came from a 
simple hormonal effect forced by the steroid was ruled out: addition of estradiol to the 
non-steroidal complexes increased the activity (as expected) but did not reach the 
toxicity of covalently coupled steroidal drug complexes. The steroidal quinoline ligands 
appear to have some inherent activity, further studies to probe the effects therefore 
focused on pyridine derivatives (whose ligands have no activity). Since estradiol 
derivatives show lower toxicity than the testosterone analogues, we focused on the 
testosterone conjugates. Studies with the cis and trans-[Pt(2ET)Cl(NH3)2]
+
 complexes 
showed that certain level of specificity towards AR can be achieved. However, this 
specificity seems to be opposite for cis or trans isomers, with the cis complex more 
active in AR+ cells and the trans (surprisingly) showing a 2-fold better activity towards 
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AR- cells. Testosterone derivatives give better activity in cisplatin resistant cell lines 
than their non-steroidal complexes. Finally, the importance of uptake has been studied 
using an ICP-MS, showing that although lower uptake is observed for steroidal 
complexes, better delivery across of the cellular membrane is achieved through linkage 
of a testosterone. However nuclear or cytoplasmic delivery seems not to be related with 
cytotoxic values, contrary to previous literature
83
 and there seems to be some added 
steroidal effects that increase the complexes activity. In summary, the conferred activity 
seems to be not just about delivery but about modulation of the biomolecular binding. 
It was observed previously in our group that the presence of an ethynyl-testosterone 
moiety on a bound aromatic ligand results in complexes substantially altering the 
structure of DNA
40-41, 46
. Non-steroidal complexes generally produce a much smaller 
degree of unwinding
40-41, 46
 (Section 2.1). This large degree of unwinding cannot simply 
be obtained by a combination of steroid free metallic centre and steroids. In order to 
understand this better, the interaction of these agents with mononucleotides was studied. 
It was found that steroidal platinum(II) complexes are, in certain aspects, similar to 
those without steroids. All of them bind to the guanine N
7
 forming only a monoadduct. 
This interaction, and its mechanisms, appears to be more related to the particular 
geometrical isomer than to the presence or not of testosterone. We showed that under 
low concentrations of Cl
-
 ions cis isomers do not suffer hydrolysis and bind in a direct 
way to the Guanine, and trans isomers suffer hydrolysis and bind to Guanine through an 
aqua intermediate. Cis isomers react more quickly than their trans analogues. Only two 
small differences between steroidal and non steroidal complexes appear in their 
interaction with mononucleotides; steroid compounds are slightly quicker to react than 
the non steroidal ones, and steroidal cis isomers seem to force an interaction between 
the base and the steroid skeleton.  
When interaction with DNA was further studied CD experiments showed that B-
DNA conformation is retained when ct-DNA is treated with cis and trans-
[Pt(Py)Cl(NH3)2]
+
,  but no DNA conformation information could be obtained for 
testosterone coupled metallic centres, due to the chirality of the steroid. However, the 
mirror image induced CD signal observed for cis and trans-[Pt(2ET)Cl(NH3)2]
+
 isomers 
suggest that it is possible that the geometric isomers force a different orientation of the 
steroid when bound to the DNA. This could be related with the fact that the cis isomers 
interact differently with mononucleotides bringing the steroid skeleton close to the base 
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(maybe through a possible intercalation of the A ring). Together with the fact that cis 
complexes have a different mechanism of binding to nucleobases (being quicker and not 
suffering hydrolysis), could explain why they are more biologically active than the 
complexes with trans geometries. 
We observed as well that the presence of the metallic moiety is a drawback for 
interaction with proteins. Our compounds can be a substrate of AKR1Cs enzymes, but 
are poorly turned over; with a transformation rate 4 times lower than normal substrates. 
Enzyme inhibition is also observed, although only at high concentrations. That leads us 
to believe that the target of our complexes is DNA, that the compounds are not 
significantly metabolized inside the cell, and that the reactive molecule is thus the 
administered complex. 
Finally we reported the synthesis of a reactive intermediate product that had potential 
to allow easy binding of multitude of metallodrugs to steroids using straightforward 
chemistry. This intermediate consists in a benzaldehyde linked to a steroid through a 
normal Sonogashira reaction. The presence of the aldehyde makes possible the 
connection of different molecules through easy procedures. Picolinamine and 
thiosemicarbazone derivatives were synthesised as examples, and Pd and Pt complexed 
with these ligands. This shows the flexibility of this steroidal benzaldehyde as linking 
moiety. In addition different metals have been introduced and Ru(III) complexes have 
been created with previously synthesised steroidal tpy ligands. Unfortunately all these 
types of compounds were neutral and presented very low solubility that made them 
unsuited for further biological studies. This is an important finding: That a charged 
(cationic) metal complex is essential to the molecular design of these steroidal metallo-
drugs. 
 
2.7 Experimental 
Synthesis: All solvents and chemicals were purchased from Sigma-Aldrich. All 
Sonogashira reaction reagents were fully dried before use and solvents degassed and 
followed the original protocol with the exception of using THF as a solvent. 
1
H NMR 
spectra were recorded on Brucker AC300 or DRX500 spectrometers. ESI mass spectra 
were recorded on a Micromass LCT Time of flight mass spectrometer. Microanalyses 
were performed on a CE Instruments EA1110 elemental analyser. UV/VIS was 
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performed in a Varian Cary 5000 UV/VIS spectrophotometer. HPLC was performed in a 
Dionex HPLC system with a semi-prep column fitted.  
 
trans-[Pt(1ET)Cl(NH3)2](NO3): A solution of AgNO3 (26.1 mg, 0.125 mmol) in 
DMF (1 ml) was added to a solution of transplatin (40.2 mg, 0.13 mmol) in DMF (2 
ml). The mixture was stirred at room temperature with light exclusion for 18 hours. The 
mixture was cooled to -18ºC using a NaCl-ice bath, and 1ET (48.8 mg, 0.13 mmol) in 
DMF (2 ml) was added dropwise over 10 minutes. The reaction was then stirred for 3 
hours at -18ºC and a further 1 hour at room temperature. The suspension was then 
filtered through celite to remove any AgCl precipitate, and the filtrate concentrated 
under reduced pressure. MeOH (10 ml) was added causing precipitation of un-reacted 
platinum materials, which were removed through filtration. The filtrate was 
concentrated under reduced pressure and Et2O (50 ml) was added to precipitate a white 
solid. This crude solid was collected by filtration, washed with Et2O, dried under 
vacuum and purified using semi-prep HPLC (as described in Chapter 2.2.2), resulting in 
a white solid (47.8 mg, 49%). 
1
H-NMR (300 MHz, CD3OD): δ 8.84 (dd, 1H, J = 5.2, 
1.5 Hz, H6’), 7.94 (ddd, 1H, J = 7.7, 8.1, 1.5 Hz, H4’), 7.7 (d, 1H, J = 8.1 Hz, H3’), 7.46 
(dd, 1H, J = 5.9, 7.7 Hz, H5’), 5.67 (s, 1H, H4), 4.02 (b, 6H, NH3) 2.60-1.40 (m, 18H, 
steroid), 1.26 (s, 3H, Me19), 1.15-1.03 (m, 2H, steroid), 0.98 (s, 3H, Me18). IR: υ 3445m, 
2945m (C-H str), 2722m (C-H str), 2222m (C≡C str) 1667m (C=O str). Mass spectrum 
(ESI, +ve): m/z = 654 [Pt(1ET)Cl(NH3)2]
+. UV/Vis: λmax (MeOH) 238nm (ε= 15100 
dm
3
mol
-1
cm
-1) and 291 nm (ε= 5010 dm3mol-1cm-1). Elemental analysis: calculated for 
C26H37ClN4O5Pt.2H2O; C, 38.4; H, 4.9; N, 8.6.  Found C, 37.9; H, 4.9; N, 9.1. 
 
cis-[Pt(1ET)Cl(NH3)2](NO3): A solution of AgNO3 (26.1 mg, 0.125 mmol) in DMF 
(1 ml) was added to a solution of cisplatin (40.2 mg, 0.13 mmol) in DMF (2 ml). The 
mixture was stirred at room temperature with light exclusion for 18 hours. The mixture 
was placed under argon atmosphere, cooled to -18ºC using a NaCl-ice bath, and 1ET 
(57.4 mg, 0.15 mmol) in DMF (2 ml) was added dropwise over 10 minutes. The 
reaction was then stirred for 3 hours at -18ºC and a further 1 hour at room temperature. 
The suspension was then filtered through celite to remove any AgCl precipitate, washed 
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with MeOH (10 ml) and the colourless filtrate concentrated under reduced pressure. The 
green solution was concentrated under reduced pressure; dissolved in the minimum 
amount of MeOH (1ml) and precipitated with Et2O (100 ml).The light green solid was 
collected by filtration, washed with Et2O and dried under vacuum. The crude product 
was purified using semi-prep HPLC (as described in Chapter 2.2.2), resulting in a green 
powder (25.1 mg, 26%). 
1
H-NMR (300 MHz, CD3OD): δ 8.78 (dd, 1H, J= 5.5, 1.5 Hz, 
H6’), 7.9 (ddd, 1H, J= 7.7, 7.4, 1.5 Hz, H4’), 7.62 (d, 1H, J= 7.4 Hz, H3’), 7.44 (dd, 1H, 
J= 7.7, 5.5 Hz, H5’), 5.68 (s, 1H, H4), 4.5(b, 3H, NH3) 4.1 (b, 3H, NH3) 2.60-1.40 (m, 
18H, steroid), 1.25 (s, 3H, Me19), 1.15-1.03 (m, 2H, steroid), 0.99 (s, 3H, Me18). IR: υ 
3278m, 2945m (C-H str), 2861m (C-H str), 2222m (C≡C str) 1667m (C=O str). Mass 
spectrum (ESI, +ve): m/z = 654 [Pt(1ET)Cl(NH3)2]
+. UV/Vis: λmax (MeOH) 237nm (ε= 
16900 dm
3
mol
-1
cm
-1) and 291 nm (ε= 5500 dm3mol-1cm-1). 
 
cis-[Pt(2EE)Cl(NH3)2](NO3): A solution of AgNO3 (26.1 mg, 0.125 mmol) in DMF 
(1 ml) was added to a solution of cisplatin (40.9 mg, 0.14 mmol) in DMF (2 ml). The 
mixture was stirred at room temperature with light exclusion for 18 hours. The mixture 
was placed under argon atmosphere, cooled to -18ºC using a NaCl-ice bath, and 2EE 
(56.8 mg, 0.15 mmol) in DMF (2 ml) was added dropwise over 10 minutes. The ratio of 
platinum group:2EE used was 1:1.1. The reaction was then stirred for 3 hours at -18ºC 
and a further 1 hour at room temperature under argon atmosphere. The suspension was 
then filtered through celite to remove any AgCl precipitate, washed with MeOH (10 ml) 
and the colourless filtrate concentrated under reduced pressure. The concentrated 
solution was cooled to -4ºC and left for 3 days. Transparent crystals were grown (Glaser 
coupling). The crude product was purified using semi-prep HPLC (as described in 
Chapter 2.2.2), resulting in a brown solid (28.4 mg, 30%). 
1
H-NMR (300 MHz, 
CD3OD): δ 8.79 (d, 1H, J= 1.8 Hz, H2’), 8.66 (dd, 1H, J = 5.6, 1.5 Hz, H6’), 7.99 (dt, 1H, 
J = 8.1, 1.5, 1.8 Hz, H4’), 7.46 (dd, 1H, J = 5.6, 8.1 Hz, H5’),7.07 (d, 1H, J= 8.1 Hz, H1), 
6.51 (d, 1H, J= 8.1 Hz, H2) 6.45 (s, 1H, H4), 4.58(b, 3H, NH3) 4.19 (b, 3H, NH3) 2.60-
1.05 (m, 15H, steroid), 0.91 (s, 3H, Me18). IR: υ 3278m, 2917m (C-H str), 2861m (C-H 
str), 2222m (C≡C str) 1667m (C=O str). Mass spectrum (ESI, +ve): m/z = 638 
[Pt(2EE)Cl(NH3)2]
+.  UV/Vis: λmax (MeOH) 238nm (ε= 15100 dm
3
mol
-1
cm
-1
) and 291 
nm (ε= 5010 dm3mol-1cm-1). 
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Di-17-α-Ethynyl-Estradiol: 17α-Ethynyl-estradiol (500 mg, 1.69 mmol) was 
dissolved in 30 ml of dry THF, 0.1 equivalent of CuI (32.3 mg, 0.17 mmol), 0.2 
equivalents of bis-(triphenylphospine)dichloropalladium(II) (238.7 mg, 0.34 mmol) and 
0.5 ml of dry triethylammine were added. The mixture was left to react in the darkness 
overnight. Then, the brown solution was filtered and taken to dryness in vacuo. The 
solid was dissolved in the minimum amount of THF and precipitated with hexane, 
giving a brown crude powder 0.348 g, 70% yield.  
1
H-NMR (300 MHz, CD3OD): δ 7.04 
(d, 2H, J = 8.5 Hz, H1), 6.51 (dd, 2H, J = 8.5, 2.6 Hz, H2), 6.42 (d, 2H, J = 2.6 Hz H4), 
2.75-1.20 (m, 30H, steroid), 0.82 (s, 6H, Me19). Mass spectrum (ESI, +ve): m/z = 589 
[(EE)2-H
+
]
+
. 
 
[Pt(2ET)2(NH3)2](NO3)2: To a solution of cis-diamminedichloroplatinum(II) (0.300 
g, 1 mmol) in DMF (3 ml) was added silver nitrate (0.161 g, 0.95 mmol) in DMF (1 ml) 
and this mixture was stirred overnight in the absence of light.  The silver chloride 
precipitate was removed by filtration leaving a pale yellow filtrate.  To the filtrate was 
added 17α-pyridin-3-ylethynyl-testosterone (0.390 g, 1 mmol) and the solution stirred 
overnight.  The slow addition of diethylether (200 ml) to the solution yielded a white 
precipitate which was filtered off.  The crude product was purified using the HPLC 
procedure explained in the section 2.1.3 using a preparative column. Two products were 
obtained and collected. The first one (retention time 33.6 min; white powder) 
corresponded to cis-[Pt(1ET)Cl(NH3)2](NO3); 0.318 g, 45% yield. The second peak 
(retention time 36.7 min; white powder) corresponded to [Pt(2ET)2(NH3)2](NO3)2; 
0.045 g, 4% yield.  
1
H-NMR (300 MHz, CD3OD): δ 8.93 (s, 2H, H2’), 8.74 (d, 2H, J = 
5.9 Hz, H6’), 8.02 (d, 2H, J = 8.5 Hz, H4’), 7.51 (t, 2H, J= 5.9, 8.5 Hz, H5’), 5.68 (s, 2H, 
H4), 2.55-1.40 (m, 38H, steroid), 1.24 (s, 6H, Me19), 0.93 (s, 6H, Me18). Mass 
spectrum (ESI, +ve): m/z = 504 [Pt(NH3)2(ET-3Py)2]
2+
.  
 
17α (4-ethynylbenzaldehyde) testosterone (ETBza): A Schlenk flask was charged 
with ethistherone (2 g, 6.4 mmol), bis (triphenylphospine)dichloropalladium (II) (0.180 
g, 0.256 mmol, 4 mol%) and copper iodide (0.094 g, 0.512 mmol, 8 mol%). THF (50 
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ml), potassium carbonate (1.325g, 9.6 mmol, 150 mol%) and 4-bromobenzaldehyde (1.2 
g, 6.4 mmol) were added resulting in a deep red coloured suspension. The reaction was 
stirred at 40 ºC for 72 hours under nitrogen atmosphere with light exclusion. The 
resulting dark brown suspension was filtered and the filtrate reduced in vacuo to a crude 
solid. The final product was purified by column chromatography (silica gel 60, DCM-
EtOH 3%, Rx= 0.33) giving a lightly yellow solid. 1.95g, 73% yield. 
1
H-NMR (300 
MHz, CDCl3): δ 10.17 (s, 1H, H5’), 7.98 (d, 2H, J = 8.3 Hz, H2’), 7.75 (d, 2H, J = 8.3 
Hz, H3’), 5.92 (s, 1H, H4), 2.50-1.30 (m, 18H, steroid), 1.38 (s, 3H, Me19), 1.22-1.19 (m, 
2H, steroid), 1.14 (s, 3H, Me18). Mass spectrum (ESI, +ve): m/z 417.4. 
 
17α (4-ethynylbenzylthiosemicarbazone) testosterone (ETTsc): A round bottom 
flask was charged with a suspension of thiosemicarbazide (0.49 g, 5.38 mmol) in water 
with 8% of acetic acid, and the temperature was raised to 40ºC till total solution. Then, 
ETBza (2.2 g, 5.38 mmol) was added with the minimum amount of ethanol to get a 
solution. The temperature was raised till reflux, and left during 24h. After that the 
reaction was stopped and the solvent removed under vacuum to a crude solid. The final 
product was purified by column chromatography (silica gel 60, DCM-EtOH 3%, Rf= 
0.26) giving a slightly yellow solid. 1.9g, 72% yield. 
1
H-NMR (300 MHz, D
6
-Acetone): 
δ 10.55 (b, 1H, H7’), 8,18 (s, 1H, H5’), 7.93 (b, 1H, H9’’), 7.79 (d, 2H, J = 8.3 Hz, H2’), 
7.58 (b, 1H, H9’), 7.45 (d, 2H, J = 8.3 Hz, H3’), 5.65 (s, 1H, H4), 2.50-1.30 (m, 18H, 
steroid), 1.24 (s, 3H, Me19), 1.15-0.98 (m, 2H, steroid), 0.97 (s, 3H, Me18). Mass 
spectrum (ESI, +ve): m/z 490.3 [H(ETTsc)]
+
. Elemental analysis: calculated for 
C29H35N3O2S-1.5(H2O); C, 67.4; H, 7.4; N, 8.1.  Found C, 67.4; H, 7.1; N, 8.6. 
 
17α ((4-ethynylbenzyl)-pyridin-2-ylmethyl-amine) testosterone (ETPcl): A 
solution of ETBza (1g, 2.4 mmol) in MeOH is added to a MeOH solution of 2-
picolinammine (0.26g, 2.4 mmol). Then 0.8 eq of NaBH4 (0.073 g, 1.92 mmol) were 
added slowly and the reaction left stirring at room temperature for 4h. After that the 
reaction is quenched using 6M HCl, driven to almost dryness and 50 ml of water added. 
This solution is washed three times with chloroform (50 ml). This chloroform is rotated 
and the crude mixture with ETBza is obtained as a yellow solid (1.1g). All the attempts 
to purify the product finish in failure. Mass spectrum (ESI, +ve): m/z 509 [H(ETPcl)]
+
. 
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[Pd(ETTsc)Cl2]: ETTsc (75 mg, 0.153 mmol) was solved in the minimum amount of 
Ethanol, after that potassium tetrachloropalladate (50mg, 0.153 mmol) was added. The 
reaction was heated till reflux and left during 24 hours. After that an orange solid was 
filtered, and washed with ethanol (10 ml) and ether (10 ml), three times each. The 
impure final product was obtained as a bright orange solid. 72.52 mg, 71% yield. 
1
H-
NMR (300 MHz, D
6
-DMSO): δ 8.24 (s, 1H, H5’), 8.06 (d, 2H, J = 8.7 Hz, H2’), 7.40 (d, 
2H, J = 8.7 Hz, H3’), 5.63 (s, 1H, H4), 2.50-1.30 (m, 18H, steroid), 1.17 (s, 3H, Me19), 
1.15-0.98 (m, 2H, steroid), 0.83 (s, 3H, Me18). Mass spectrum (ESI, +ve): m/z 666 
[H(Pd(ETTsc)Cl2)]
+
. 
 
[Pt(ETTsc)Cl2]:  ETTsc (58.5 mg, 0.12 mmol) was solved in the minimum amount 
of ethanol, after that potassium tetrachloroplatinate (50mg, 0.12 mmol) was added. The 
reaction was heated to 70ºC for 72 hours. After that an orange solid was filtered, and 
washed with ethanol (10 ml) and ether (10 ml), three times each. The impure final 
product was obtained as a pale orange solid. 50.65 mg, 56% yield. 
1
H-NMR (300 MHz, 
D
6
-DMSO): δ 8,33 (s, 1H, H5’), 7.88 (d, 2H, J = 8.9 Hz, H2’), 7.46 (d, 2H, J = 8.9 Hz, 
H3’), 5.62 (s, 1H, H4), 2.50-1.30 (m, 18H, steroid), 1.16 (s, 3H, Me19), 1.15-0.98 (m, 2H, 
steroid), 0.83 (s, 3H, Me18). Mass spectrum (ESI, +ve): m z 756 [H(Pd(ETTsc)Cl2)]
+
. 
 
[Pd(ETPcl)Cl2]: Assuming 50% purity for the crude ETPcl, 1 equivalent of this 
crude was solved in the minimum amount of methanol (141.4 mg, 0.153 mmol). Then 1 
equivalent of potassium tetrachloropalladate was added (50 mg, 0.153 mmol). The 
reaction was left stirring during 24 hours at room temperature, precipitating a yellow 
solid. The solid was filtered, and washed three times with water (5 ml), acetone (5 ml), 
ethanol (5 ml) and ether (5 ml), obtaining the pure expected compound. 47.3 mg, 45% 
yield. 
1
H-NMR (300 MHz, D
6
-DMSO): δ 8,65 (d, 1H, J= 6.2 Hz, H6’’), 7.97 (ddd, 1H, 
J= 7.9, 1.5 Hz, H4’’), 7.59 (d, 2H, J= 8.5 Hz, H2’), 7.52 (d, 1H, J= 7.9 Hz, H3’’), 7.43 (t, 
1H, J= 6.2 Hz, H5’’) 7.33 (d, 2H, J= 8.5 Hz, H3’), 7.01 (bs, 1H, H6’), 5.62 (s, 1H, H4), 
4.28-3.93 (bm, 4H, Met5’, Met7’) 2.50-1.30 (m, 18H, steroid), 1.16 (s, 3H, Me19), 1.15-
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0.98 (m, 2H, steroid), 0.82 (s, 3H, Me18). Mass spectrum (ESI, +ve): m/z 685 
[H(Pd(ETPcl)Cl2)]
+
. 
 
[Ru(EET)Cl3]: 15.8 mg (0.076 mmol) of RuCl3 and 40 mg (0.076 mmol) of EET 
(synthesised as previously described in Phil Barker’s Thesis50) were dissolved in 10 ml of 
ethanol, and the reaction was allowed to reflux overnight. Reaction changed from a really 
dark brown solution to a dark red suspension, showing an abundant precipitate. This was 
collected by filtration and washed with abundant ethanol and ether, obtained a bright red 
solution (di-substituted ruthenium complex, previously synthesised in Phil Barker’s 
Thesis
50
) and a red brick solid corresponding to the target compound (29.2 mg, yield 52 
%). 
1
H-NMR (400 MHz, DMSO): δ 7.06 (b, 2H, H3’’), 6.95 (d, 1H, J= 8.4 Hz, H1), 6.46 
(ddd, 1H, J= 8.4, 2.4 Hz, H2), 6.38 (d, 1H, J= 2.4 Hz, H4), 4.69 (t, 1H, J= 12 Hz, steroid), 
2.63 (d, 1H, J= 5.4 Hz, steroid), 2.2-1.15 (m, 13H, steroid), 1.11 (s, 3H, Me18), -3.25 (b, 
2H, H4’), -8.05 (b, 2H, H5’), -9.03 (b, 2H, H3’), -35.4 (b, 2H, H6’). Mass spectrum (ESI, 
+ve): m/z 738 [Ru(EET)Cl2]+(K). Elemental analysis: calculated for C35H33Cl3N3O2Ru-
(H2O); C, 55.8; H, 4.7; N, 5.6. Found C, 55.1; H, 4.5; N, 5.5. 
 
[Ru(ETT)Cl3]: 15.3 mg (0.073 mmol) of RuCl3 and 40 mg (0.073 mmol) of ET-Terpy 
(synthesised as previously described in Phil Barker’s Thesis50) were dissolved in 10 ml of 
ethanol, and the reaction set to reflux overnight. Reaction changed from a really dark 
brown solution to a dark red suspension, showing a big amount of precipitate. This was 
collected by filtration and washed with abundant ethanol and ether, obtained a bright red 
solution ([Ru(ETT)2]
2+, previously synthesised in Phil Barker’s Thesis50) and a red brick 
solid corresponding to our compound (23.5mg, yield 43 %).  
1
H-NMR (400 MHz, d6-
DMSO): δ 6.94 (b, 2H, H3’’), 5.58 (s, 1H, H4), 4.64 (bm, 1H, steroid), 4.27 (t, 1H, J= 13.8, 
11.5, steroid), 2.35-0.6 (m, 18H, steroid), 1.08 (s, 3H, Me19), 1.02 (s, 3H, Me18), -3.33 (b, 
2H, H4’), -8.11 (b, 2H, H5’), -9.09 (b, 2H, H3’), -35.38 (b, 2H, H6’). Mass spectrum (ESI, 
+ve): m/z 758 [Ru(ETT)Cl(DMSO)]+ and 680 [Ru(ETT)Cl]+. Elemental analysis: 
calculated for C36H37Cl3N3O2Ru-1.5(H2O); C, 55.5; H, 5.1; N, 5.4. Found C, 55.1; H, 5.0; 
N, 5.2. 
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Biological Testing: Tissue culture flasks, 96 well plates, RPMI 1640, DMEM, L-
glutamine, trypsin-EDTA, HEPES, sodium pyruvate and FBS were obtained from 
Sigma, UK.  Thiazolyl blue tetrazolium bromide (MTT) and DMSO were from 
Avocado, UK.  Cells were grown in RPMI 1640 (T-47D, SK-OV-3) or DMEM (MDA-
MB-231, A2780/cr) in 10 % FBS supplemented with 1% L-glutamine, 1% HEPES 
buffer and 1% sodium pyruvate. The MTT assay
84
 was carried out using 96-well plates.  
Cells were harvested in logarithmic growth, 4,000 (A2780/cr), 10,000 (SK-OV-3, 
MDA-MB-231) or 25,000 cells (T-47D) were seeded per well and left overnight to 
attach.  The cells were treated, in quadruplicate with 6 difference concentrations of 
complex dissolved in fresh media; the range of concentrations used is dependent on the 
complex.  The cells were incubated for 72 hours and 20 μl of thaizolyl blue tetrazolium 
bromide (5mg / ml, 0.2 μm filtered) added.  The cells were further incubated for 2 
hours.  The media was carefully removed by aspiration and 200 μl of DMSO added to 
dissolve the purple crystals.  Absorbance was measured using a 96-well plate reader 
(Biorad) set at 570 nm.  Each cell line was investigated beforehand to determine the 
correct cell numbers to initially seed and the required amount of time exposed to 
thiazolyl blue tetrazolium bromide to ensure sensitivity and accuracy. 
 
Cellular Uptake: Two million cells were seeded in a 60mm diameter Petri dishes 
and left overnight to attach. Next day cells were treated with 30µM of the different 
compounds for 3 hours. After that time, the medium was removed and cells washed 
three times with PBS to remove all the platinum complexes not taken up but cells. Cells 
were collected and two aliquots of one million cells were taken, one of them to see 
whole cell uptake and the other for Cytoplasm and Nuclei fraction extraction 
(Nuclear/Cytoplasm extraction kit. BioVision). Two ml of ultrapure concentrated Nitric 
Acid (Traceselect Ultra, Aldrich) was added to the samples, and digested overnight at 
90ºC. Samples were then taken to dryness at 120ºC, resuspended in a 2% solution of 
Nitric acid and filtered. The amount of Platinum was measured in a Agilent 7500CX 
ICP-MS (analysis was done with Pt sample cone in He and No-gas mode. Plasma 
settings: Ar.flow: 15 L/min; Neb gas: 0.8 L/min; RF power 1550W; T of spray 
chamber: 15 º C). 
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ESI-MS Nucleotide binding studies: 5’-GMP and 9-ethylguanine were stored at 
4°C in a dessicator; they were dissolved freshly in 1mM sodium cacodylate buffer (pH 
6.8) before each experiment. Fresh solution of complexes in 1mM sodium cacodylate 
buffer (pH 6.8) were used and mixed with nucleotides in a 1:1 ratio. The stock solutions 
of base and complex were both 2 mM. All the solutions were incubated for three days at 
37°C in the dark.  ESI-MS spectra were taken on a Micromass LCT Time of flight mass 
spectrometer. 
1
H-NMR Nucleotide binding studies: 5’-GMP and 9-ethylguanine were stored at 
4°C in a dessicator; they were dissolved freshly in 1mM sodium cacodylate buffer in 
D2O (pH 6.8) before each experiment. Fresh solution of complexes in 1mM sodium 
cacodylate buffer in D2O (pH 6.8) were used and mixed with nucleotides in a 1:1 ratio. 
The stock solutions of base and complex were both 2 mM. For hydrolysis assays no 
nucleotide was added, and complex was diluted to 1mM using 1mM sodium cacodylate 
buffer in D2O (ph 6.8). H
1
-NMR was measured at 0 h, 24 h and 72 h (96 h and 120 h for 
9-ethylguanine) in a Bruker MX400 MHz with a BBI 5 mm inverse 
1
H broadband 
probe. Between measurements the samples were kept in an incubator at 37ºC in the 
dark. For kinetic determination samples were prepared as described before and 
measured in a a Bruker MX400 MHz with a BBI 5 mm inverse 
1
H broadband probe, at 
0 h, 30 min, 1 h and every hour for 24 h at 37ºC. For NOE experiments the samples 
were prepared as described and measured in a a Bruker DRX500 MHz with a TBI 5 mm 
inverse Z gradient probe. 
 
Gel electrophoresis unwinding assay: Plasmid pBR322 remained frozen until 
required for use. It is mixed with varying amounts of complex and steroids (1:1) and 
incubated for 24 hours. The total solution of 20 μl consists of 1 μl (stock = 1 μg / μl ) 
pBR322, between 1.7 and 17 μl of complex:steroid (stock = 60 μM) and the remainder 
with ultra-pure water. After an incubation period of 24 h at 37 °C, 10 μl was removed 
and added to 3 μl of loading buffer and 10 μl loaded onto an agarose gel. The loading 
buffer consisted of 30 % glycerol, 0.05% bromophenol blue and 0.025 % cyanol xylene 
in ultra-pure water. 1% agarose gels were used and run using a HE99X Maxi 
(Amersham Biosciences, UK) submarine gel kit. The gel was loaded with 8 μl of DNA / 
loading buffer solution and ran using 1x TAE for 250 minutes at 5 V cm 
-1
. The gel was 
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stained after electrophoresis in TAE buffer containing ethidium bromide (0.5 mg ml
-1
) 
for 10 minutes. The gel was visualized using an UVIdoc Platinum system (UViDoc, 
Cambridge, UK) at 312 nm. For gels of non-steroidal complexes with ethysterone a 
ratio 1:1 was used between the complex and the steroid. 
 
Circular Dichroism: All CD spectra were recorded on a Jasco J-810 
spectropolarimeter operated with the following parameters: sensitivity, 100 mdeg; start 
wavelength, 350 nm; end wavelength, 200 nm; data pitch, 0.5 nm; scanning mode, 
continuous; scanning speed, 200 nm per min; response, 0.1 seconds; bandwidth, 1.0; 
accumulation, 12. Stock solutions of ct-DNA (500 μM) and complex (500 μM) were 
mixed in varying proportions, and made up to 1 ml with ultrapure water with 20 mM 
NaCl and 0.89 mM Sodium Cacodylate pH 6.8, to achieved DNA:complex ratios of 
100:1, 60:1, 40:1, 25:1, 15:1, 10:1, and 5:1.  The solutions were incubated at 37 °C for 2 
days.  
 
HPLC enzymatic substrate assay: All measurements were performed in a Dionex 
HPLC system with an analytical column and an autosampler fitted operated with the 
following parameters: injection volume, 75 µl; Solvent A, water 0.05% TFA; Solvent B, 
methanol 0.05% TFA; method: 0-100% B gradient (0-40 min), 100% B (40-50 min), 
100% A (50-60 min). AKR1Cs enzymes remained frozen until required for use. 20 µl 
(1.5 mg/ml) of recombinant enzyme was treated with 20 µl of cis-
[Pt(2ET)Cl(NH3)2](NO3) (5 mM, ethanol) and 100 µl of NADPH (3 mM, Sigma). The 
final volume was taken to 2 ml with KH2PO4 Buffer (50 mM; pH 6.5). The order of 
addition was Buffer, enzyme, substrate and NADPH. Injections were done every hour 
for 24 hours. The same experiment was repeated with AKR1C3 for ethisterone and 
9,10-phenantrenequinone (4 mM, acetonitrile, Sigma). 
 
Enzymatic substrate assay: All the UV measurements were done in a Varian Cary 
5000 UV/VIS spectrophotometer with a Varian 6x6 Multicell Block Beltier and a 
Varian Cary Temperature Controller attached operated with the following parameters: 
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sensitivity, 1 nm; wavelength, 340 nm; response, 0.1 seconds; temperature, 35ºC; cicle, 
0.5 min; end time, 5 min. And data analysed using the Visual Enzymics program 
(Softzymics, Princetown, NJ, USA). AKR1Cs enzymes remained frozen until required 
for use. 10 or 40 µl (1.5 mg/ml) of recombinant enzyme was treated with 20 µl of cis-
[Pt(2ET)Cl(NH3)2](NO3) (Stock solution: 5mM, ethanol; final concentrations: 40, 20, 
10, 5, 2.5, 1.25, 0.625 and 0.3125 µM) and 50 µl of NADPH (3 mM, Sigma). The final 
volume was taken to 1 ml with KH2PO4 Buffer (50m M; pH 6.5) preheated to 35 ºC. 
The order of addition was Buffer, enzyme, substrate and NADPH. Reaction was placed 
in a quartz cuvette and measured at 340nm in a prewarmed spectrophotometer. 
 
Enzymatic inhibition assay: All the UV measurements were done in a Varian Cary 
5000 UV/VIS spectrophotometer with a Varian 6x6 Multicell Block Beltier and a 
Varian Cary Temperature Controller attached operated with the following parameters: 
sensitivity, 1 nm; wavelength, 340 nm; response, 0.1 seconds; temperature, 35ºC; cicle, 
0.5 min; end time, 5 min. And data analysed using the Visual Enzymics program 
(Softzymics, Princetown, NJ, USA). AKR1Cs enzymes remained frozen until required 
for use. 10 µl (1.5 mg/ml) of recombinant enzyme was treated with 20 µl of 9,10-
phenantrenequinone (Stock solution: 4 mM, acetonitrile, Sigma; final concentrations: 
20, 10, 5, 2.5, 1.25, 0.625 and 0.3125 µM), 20 µl of cis-[Pt(2ET)Cl(NH3)2](NO3)  
(Stock solution: 5mM, ethanol; final concentrations:100, 20, 4 and 0 µM) and 50 µl of 
NADPH (3mM, Sigma). The final volume was taken to 1 ml with KH2PO4 Buffer 
(50mM; pH6.5) preheated to 35 ºC. The order of addition was Buffer, enzyme, substrate 
and NADPH. Reaction was placed in a quartz cuvette and measured at 340nm in a 
prewarmed spectrophotometer. The same experiment was repeated pretreating the 
enzymes with the different concentrations of cis-[Pt(2ET)Cl(NH3)2](NO3)  at 35ºC for 
24h. 
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Chapter 3: Steroidal non-covalent metallodrugs 
 
3.1 Introduction 
As explained previously (Section 2.1) sex hormones such as estrogens and testoterone 
are interesting as delivery vectors because of their importance in reproductive system 
cancers
1-6
. For that reason active cytotoxic metallo-drugs have been attached to natural or 
synthetic oestrogens, aiming to target the estradiol receptor (ER; Fig. 3.1 A to D)
7-16
. In 
the previous chapter (Chapter 2) it was demonstrated that the same strategy can be used to 
target the androgen receptor (AR). Using a series of testosterone-derived 
mononufunctional complexes previously synthesised in our group (Fig. 3.1 E)
17-20
, it was 
shown that linkage of the testosterone confered cytotoxic activity to otherwise non toxic 
compounds. It improved the effectiveness of the uptake of the complexes in cells
20
 and 
the compounds caused big distortions when bound to DNA
21
. 
 
Figure 3.1.  Recent examples of steroids coordinated to platinum drugs. 
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  All of the previous steroid-drug bioconjugates have focused on DNA “alkylating” 
agents that form a direct covalent or coordinative bond to the bases (like cisplatin). As 
explained in Chapter 1.1 small molecules can interact with DNA without binding 
covalently
21-23
. Non-covalent DNA-binding metallo-drugs (Fig. 3.2) have in general been 
less extensively studied than cisplatin analogues, but show a broad spectrum of direct 
activities
24-25
. They represent an interesting alternative to the covalent coordinative DNA-
binders, because having a different mode of action they perhaps can circumvent some 
problems, such as cross-resistance or side effects. For these reasons the conjugation of 
non-covalent metallo-drug units to steroids was of interest. Synthetic techniques and 
approaches that allow very easy access to such conjugates are described below, as well as 
how the presence of the steroid affect the toxicity and behaviour of such drugs in their 
interaction with both whole cells and macromolecules.  
 
Figure 3.2. Metallodrugs that bind in the major groove (A) or intercalate between DNA bases (B); non-covalent 
DNA Three Way Junction binding (C, taken from Olesky et al2) and Phospate binding (D, TriplatinNC, taken from 
Komeda et al3).  
 
D 
C 
B 
A 
N
N
N
N
H2
N
N
H2
2+
Pt
 131 
3.2 Design and synthesis of complexes 
3.2.1 Design of complexes 
There are five commonly accepted kinds of non-covalent DNA binding interactions: 
minor groove binders, major groove binders, intercalators, phosphate binders and junction 
binders
21-23
 (see Chapter 1 for more details). Normally the molecules binding in these 
ways are quite big, so the attachment of a steroidal moiety that would make them even 
bigger can present some challenging syntheses. Furthermore, the bulkiness of these 
“DNA Binding Domains” could make the final construct too big to target the steroid 
receptors effectively. The type of non-covalent binder that tends to be smaller, 
comparable sometimes to covalent binding molecules, are the intercalators. For that 
reason we decided to focus on these. From the multiple variety of metallo-intercalators
26-
29
, we chose a Pt(II) metallic centre bound to a terpyridine molecule. This unit has been 
broadly studied; its DNA binding abilities has been known for a long time (a crystal 
structure with a short oligomer was published in the late 1970s
30
), a broad spectrum of 
modified monomers and dimers have been synthesised and showing some of them 
citotoxicity properties
31-33
. Covalent DNA binders comprising Pt(II) terpyridines linked to 
steroids have been synthesised previously in our group
16, 34
, so this will give us the 
opportunity to compare the two modes of DNA binding. 
Our previous examples of attaching covalent binding terpyridine complexes to steroids, 
took much effort, and many steps. However, as Ma et al.
35
 previously described, platinum 
terpyridines can be easily coordinated to triple bonds. This procedure allows us to 
synthesise the new complexes in a much easier way than the covalent binders. A single 
step would conjugate commercially available 17α-ethynyl-steroids, and 
terpyridineplatinum(II)chloride, under normal coupling conditions (Fig. 3.3). This is 
probably the easier way to attach a steroid to a metallodrug, since is a one pot synthesis of 
a commercially available steroid and a well established metallodrug, without need for 
prior synthesis of steroidal ligands. Similar strategies can potentially be used for different 
metals such as gold
36
.  
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Figure 3.3. Synthetic pathway for steroidal and non-steroidal terpyridine intercalators. 
Following the same procedure, non-steroidal controls could also be easily synthesised 
to compare the effect of the steroid on the activity of the complexes. Previously 
synthesised covalent binding terpyridines steroids could be used as starting material as 
well (Fig. 3.4); this would show us how the binding mode of the platinum terpy affects 
the activity of the compounds, and how important the intercalation of the terpyridine is 
compared with intercalation of smaller aromatic rings.  
 
Figure 3.4. Synthetic pathway for steroidal phenyl intercalators. 
 133 
3.2.2 Synthesis of complexes 
Following the general routes proposed above, we synthesised a series of compounds 
that satisfied our designs. Starting from commercially available steroids or 
benzylacetylene and from the chloride salt of [Pt(tpy)Cl]
+
 (obtained easily following the 
procedure reported by Buchner et al.
37
) we can obtain our intercalators in a single step 
using a CuI catalyst. Use of an inert atmosphere (Ar or N2), was necesary to minimize 
Glaser
38
 coupling (connection of two triple bonds) that occurs when oxygen is present.  
Once the complexes have been synthesised, purification is easily achieved through a 
semipreparative HPLC [40 minutes gradient of water:acetonitrile (0-100%) in presence 
of 0.05% of TFA] and TFA used in the HPLC replaces the chloride counter ion. 
Following this procedure the complexes can be obtained in good yields, around 50-70%, 
and compared with overall yields of previous steroidal complexes their synthesis is 
extremely effective. Previously reported steroidal terpyridine covalent binders
16, 34
 were 
used as starting material for the steroidal phenyl intercalators (Fig. 3.4). However, while 
HPLC purification can be achieved following the same protocol and yields are similar, 
the starting material synthesis means that this complex is obtained in low overall yield. 
All the complexes are partially soluble in methanol or acetonitrile, but extremely 
soluble in mixtures of water and acetonitrile.  
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All five complexes are fluorescent when excited in the MLCT region in 
dichloromethane and other aprotic solvents. However, this fluorescence is not visible 
Figure 3.5. UV/Vis and 
emission spectra 
(normalized) of the five 
complexes synthesised. 
Excitation in the MLCT 
region.  
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when the complexes are placed in protic solvents (such as water), because the excited 
state is quenched by O-H vibrations
39-40
 (Fig. 3.5).  
 (EE-Pt-Terpy)TFA 
 
 
Using 17α-ethynyl-estradiol we obtained the first of our steroidal intercalator 
complexes, EE-Pt-Terpy. Analysis by ESI-MS shows the expected +1 cation at 723 m/z. 
1
H-NMR in mixtures of deuterated water:acetonitrile (Fig. 3.6) show both steroid and 
terpyridine units in a 1:1 ratio. The steroid protons 1, 2 and 4 can be clearly detected 
between 7.1 and 6.4 ppm, integrating for one proton each. The methyl group of the 
estradiol is clearly detected as well at 0.94 ppm, integrating for 3 protons. For the 
terpyridine there is a doublet at around 9.3 ppm (H6’, 2 protons, JHH = 5.5 Hz); a doublet 
of doublets at 7.78 ppm (H5’, 2 protons, JHH = 5.5 and 7.7 Hz) and a multiplet centered 
around 8.4 ppm integrating for 7 protons. This multiplet corresponds to protons H4’, H3’, 
H3’’ and H4’’. The expected JHH couplings for the terpyridine protons (around 5 Hz for 
H6’, 5 and 8 Hz for H5’, 8 and 8 Hz for H4’ and 8 Hz for H3’)
33
 and the subtle JPtH 
observed for H6’ further prove our assignment, which is consistent with these of ET-Pt-
Terpy and Ph-Pt-Terpy (see below), whose assignation was confirmed by 2D-COSY. 
 135 
12345678910
6.66.87.07.27.47.67.88.08.28.48.68.89.09.2
H4
H1 H2
H6’ H5’
H3’, H4’, H3’’, H4’’
Me18
 
Figure 3.6. 1H-NMR of EE-Pt-Terpy in a mixture of deuterated water:acetonitrile (1:1). 
 The UV/VIS absorption spectrum was measured in dichloromethane and shows a 
terpyridine ligand-based band between 300-350 nm and the steroid band, showing the 
maximum at around 242 nm. The Pt(tpy) region corresponding to the MLCT transitions 
can be detected between 400-500 nm. The complex can be excited in this MLCT region 
(around 425 nm), to obtain a fluorescence with a maximum of emission at 540 nm (Fig. 
3.7). 
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Figure 3.7. UV/Vis and emission spectra (normalized) of EE-Pt-Terpy (25 μM) in dichloromethane. λexc=425nm.  
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(ET-Pt-Terpy)TFA 
 
 
The androgenic version of the previous complex can be synthesised easily if 17α-
ethynyl-testosterone (ethisterone) is used. Again analysis by ESI-MS shows the 
expected +1 cation at 739 m/z, showing that the complex is formed. To prove further 
this 
1
H-NMR in mixtures of deuterated water:acetonitrile was performed, showing again 
steroidal and terpyridine based peaks (Fig. 3.8). The testosterone proton 4 can be 
detected clearly with an integration of one at 5.7 ppm. Methyl groups of the 
testosterone, are observed at 1.27 and 0.98 ppm (indicating that only one compound is 
present). In the terpyridine region, protons integration shows a 1:1 ratio with the 
testosterone moiety. These terpyridine protons have been assigned through the use of 
information provided by the observed terpyridine JHH couplings (as explained for EE-Pt-
Terpy)
33
 and the presence of JPtH couplings, with the help of 2D 
1
H-NMR (Fig. 3.9). 
Three peaks and a multiplet can be detected from seven expected peaks, integrating for 
two (two double doublets and a doublet) and five protons (a multiplet), adding between 
them the expected 11 protons of the terpyridine molecule. Using the JHH couplings these 
peaks can be assigned as H6’ (d, 9.25 ppm, JHH = 5.5 Hz), H4’ (dd, 8.4 ppm, JHH =7.6 and 
8.0 Hz) and H5’ (dd, 7.78 ppm, JHH = 5.5 and 7.6 Hz), indicating that the multiplet 
correspond to H3’, H3’’ and H4’’ protons. This is consistent with the observed satellites 
produced by the JPtH coupling in the proton assigned as H6’ and the information obtained 
from the 2D-COSY NMR of the molecule (Fig. 8). In this spectrum the resonance signal 
assigned as H5’ is shown to be related to the signal assigned as H6’ and H4’, showing that 
these peaks represent correlative protons.  
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Figure 3.8. 1H-NMR of ET-Pt-Terpy in a mixture of deuterated water:acetonitrile (1:1). 
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Figure 3.9. 2D-COSY 1H-NMR of ET-Pt-Terpy (aromatic region) in a mixture of deuterated water:acetonitrile 
(1:1). 
 138 
The UV/VIS spectrum in dichlorometane shows similar pattern that the estradiol 
complex, with the terpyridine-based region between 300-350 nm, and the steroidal with 
a maximum at 248 nm. However this testosterone band is more intense showing an 
absortion of almost twice the intensity of the oestrogenic compound. The MLCT area 
can be detected between 400-500 nm and is the place were the complex can be excited 
(around 425 nm), to obtain a fluorescence with a maximum of emission at 540 nm (Fig. 
3.10). 
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Figure 3.10. UV/Vis and emission spectra (normalized) of ET-Pt-Terpy (25 μM) in dichloromethane. λexc=425 nm. 
(Ph-Pt-Terpy)TFA 
 
Following the same procedure that the steroidal versions, with the use of the 
commercially available benzylacetylene, Ph-Pt-Terpy can be obtained. Analysis by ESI-
MS shows the expected +1 cation at 529 m/z. Again 
1
H-NMR (deuterated 
water:acetonitrile) allow us to confirm the data from ESI-MS showing that we obtained 
the desired compound (Fig. 3.12). A benzyl molecule is seen, in the aromatic region. 
Five protons can be clearly detected, with the correct integration, showing two doublets 
integrating for two protons (H1 and H2) and a doublet doublet for one (H3), between 7.2 
and 7.3 ppm. The terpyridine signals maintain a 1:1 ratio with the phenyl group and can 
be assigned using a similar reasoning to the one used for EE and ET-Pt-Terpy. H6’ (d, 
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8.7 ppm, JHH = 5. 4 Hz), H4’ (dd, 8.15 ppm, JHH = 7. 7, 7.8 Hz, visible JPtH coupling), H3’ 
(d, 8.09 ppm, JHH = 7.7 Hz) and H5’ (dd, 7.59 ppm, JHH = 5.5 and 7.6 Hz) can be 
assigned following the standard patterns of the JHH couplings presented by the 
terpyridine molecule
33
. H3’’ and H4’’ then, can be assigned as the multiplet visible at 8.2 
ppm. 2D-COSY 
1
H-NMR (Fig. 3.11) confirms the assignment showing close relation 
between the signals assigned to H5’-H6’, H5’-H4’ and H4’-H3’ and weak interactions 
between H6’-H4’ and H5’-H3’. 
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.
 
 Figure 3.11. 2D-COSY 1H-NMR of Ph-Pt-Terpy in a mixture of deuterated water:acetonitrile (1:1). 
UV/VIS shows the same tpy-based band and a maximum at 248 nm with intensity 
between the two previous complexes. The MLCT region can be detected between 400-
500 nm, being broader than the steroidal compounds. If this transition is excited (around 
480 nm), fluorescence emission is obtained with a maximum at 650 nm. However, for 
this complex the area of excitation is bigger than for the steroidal ones, showing the 
same emission when excited all the way through the MLCT region (Fig. 3.13). 
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Figure 3.12. 1H-NMR of Ph-Pt-Terpy in a mixture of deuterated water:acetonitrile (1:1). 
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Figure 3.13. UV/Vis and emission spectra (normalized) of Ph-Pt-Terpy (25 μM) in dichloromethane. λexc=480 nm.. 
(EE-Terpy-Pt-Ph)TFA 
 
EE-Terpy-Pt-Ph is created through the coupling of benzylacetylene and EETPt
16, 34
. 
The increased complexity of the molecule make the 
1
H-NMR (mixtures of deuterated 
water:acetonitrile) more complicated than usual (Fig. 3.14).  The addition of the benzyl 
unit, adds (theoretically) 3 new peaks to the aromatic region, making it more crowded. 
As observed in Figure 3.15, the coupling of this phenyl acetylene group produces a 
broadening of the signals close to the metallic centre (maybe due to a possible different 
stacking between the molecules to the one presented by previously explained 
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complexes). This makes it impossible to assign the peaks by following the terpyridine 
JHH coupling pattern. A possible assignment of these terpyridines proton signals can be 
done using the EETPt
16, 34
 parent complex as a guide. Using this as a template, H6’ (8.11 
ppm), H4’ (7.95 ppm, seen as a broad triplet), H3’ (7.67 ppm, seen as a broad doublet), 
and H3’’ (7.56 ppm) can be assigned. H5’ resonance is found to be close to the ones 
belonging to the phenyl group. This combination of signals (H5’ and phenyl protons) 
produces a multiplet integrating for 5 protons at 7.21 ppm and a broad peak at 6.85 ppm 
integrating for 2 protons. Again, using EETPt as a template, H5’ can be assigned in the 
multiplet (because chemical shift difference with other protons is similar to the one 
observed in EETPt) togheter with two signals from the phenyl ring probably H2’’’ and 
H3’’’ (by comparison with Ph-Pt-Terpy), allowing to assign H1’’’ as the broad signal at 
6.85 ppm. Since the steroid is far away from the platinum centre, it is not affected by 
broadening problems. That makes assignment easier; protons H1, H2 and H4 are assigned 
to the doublets at 7.14 and 6.60 ppm and to the singlet at 6.56 ppm respectively, 
showing integration for a proton each. The methyl group appears at 0.89 ppm as a single 
peak giving an initial confirmation about purity of the complex. Analysis by ESI-MS 
shows the expected +1 cation at 823 m/z.  
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Figure 3.14. 1H-NMR of EE-Terpy-Pt-Ph in a mixture of deuterated water:acetonitrile (1:1). 
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The UV/VIS was measured in dichloromethane and shows terpyridine-based (300-
350 nm), benzyl (200-220 nm) and estradiol (250-300 nm) bands. A MLCT signal can 
be detected between 400-500 nm. This MLTC band is broader when the phenyl is 
attached. When excited in the MLCT (maximum around 480 nm), fluorescence is 
obtained with a maximum of emission at 600 nm (Fig. 3.15).  
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Figure 3.15. UV/Vis and emission spectra (normalized) of EE-Terpy-Pt-Ph (25 μM) in dichloromethane. λexc=480 
nm. 
 (ET-Terpy-Pt-Ph)TFA 
 
The androgenic phenyl intercalator can be easily synthesised when benzylacetylene 
and ETTPt
34
 are used. ESI-MS shows the expected +1 cation at 839 m/z, without 
signals corresponding to complex breakdown. 
1
H-NMR in mixtures of deuterated 
water:acetonitrile show similar behaviour to these of the oestrogen derivative, showing 
the broadening of peaks close to platinum (preventing the assignment through the 
expected terpyridine JHH couplings; maybe due to a possible stacking between the 
molecules) and the form of multiplets with the signal of the phenyl ring (Fig. 3.16). 
Again, using ETTPt as a template, H6’, H4’, H3’, and H3’’ terpyridine proton resonances 
can be assigned as the peaks observed at 8.13, 7.99, 7.69 and 7.55 ppm respectively. H5’ 
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(assigned following the similar chemical shift difference with other terpyridine protons 
compared with ETTPt
34
) is found forming a broad multiplet at 7.25 ppm with protons 
H2’’’ and H3’’’ of the phenyl ring (assigned by comparison with Ph-Pt-Terpy). Proton 
H1’’’ of the same ring can be detected as a broad signal at 6.84 ppm. Finally testosterone 
signals again do not suffer the broadening seen for the aromatic peaks, showing a 1:1 
ratio steroid:metallo-moiety. H4 is detected at 5.73 ppm and the methyl groups (1.21 and 
0.90 ppm) give us a first idea about the purity of the complex.  
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Figure 3.16. 1H-NMR of ET-Terpy-Pt-Ph in a mixture of deuterated water:acetonitrile (1:1). 
The UV/VIS (dichloromethane) shows similar bands to the oestrogenic compound. 
However, the maximum this time is present at 248 nm, in the region of testosterone, not 
in the phenyl. The MLCT area can be detected between 400-500 nm, and again is 
broader that for steroidal terpyridine intercalators. Exciting in the MLCT (maximum 
around 480 nm) again leads to a broad fluorescence, with a maximum of emission at 
600 nm (Fig. 3.17). 
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Figure 3.17. UV/Vis and emission spectra (normalized) of Et-Terpy-Pt-Ph (25 μM) in dichloromethane. λexc=480 nm. 
 
3.3 Biological activity 
3.3.1 Cytotoxic activity 
To study their potential anti-cancer properties, EE, ET and Ph-Pt-Terpy were subject to 
in vitro testing in three cancer cell lines, ovarian line SK-OV-3 (AR-, ERα+, ERβ+), and 
breast lines T-47D (AR+, ERα+, ERβ+) and MDA-MB-231 (AR-, ERα-, ERβ+). The 
results are shown in Figure 3.18. The complexes are more active than cisplatin for the 
breast cancer cell lines (between 3 and 10 fold) and less active in the ovarian cell line. The 
non-steroidal compound is, as expected, quite active (as previously reported
35
, similar 
activity has been observed for complexes with smaller ligands compared with the 
phenylacetylene
33
), but surprisingly it is even more active than the steroidal derivatives. 
This is different from examples of covalent binders discussed in the previous chapter, 
where there was always an increase in the activity of the complexes when a steroidal unit 
was bound
17, 19
. Especially dramatic is the case with T-47D cells, where the non-steroidal 
complex is 6 times more active than the testosterone derivative and 7 time more than the 
estradiol. For the other cell lines, however, the difference is smaller. 
 In order to measure the possible influence of the phenyl moiety on the toxicity, the 
activity of EE-Pt-Terpy and ET-Terpy-Pt-Ph (the second kind of steroidal complexes) 
was measured in the same cell lines (Fig. 3.18). The results show a drastic difference in 
the activity between the steroidal compounds with intercalative phenyl and terpyridine 
molecules. This effect is specially pronounced for estradiol complexes, where a 6 fold 
reduction can be observed in the T-47D cell line. If activity comes from intercalating 
 145 
the platinum (II) terpyridine unit, the difficulty of access to this when the steroid is 
directly linked to it could explain the drop in the activity. 
Figure 3.18. Toxicity of steroidal and non-steroidal platinum(II) compounds (IC50 μM) in breast and ovarian cell 
lines. 
There seems not to be a big dependence on the status of receptors in the activity. This is 
particularly true for the testosterone derivatives, where activity for MDA-MB-231 (AR-) 
and T-47D (AR+) is almost the same. However, for the estradiol derivatives some effect 
is noticed in breast cancer cell lines (though not that expected). The oestrogenic 
complexes show better activity (2.5 fold) for MDA-MB-231 (ERα-, ERβ+) than for T-
47D (ERα+, ERβ+), although the ER status might have been expected to favour the 
former. The fact that the non-steroidal complex shows the opposite trend (IC50 is lower in 
T-47D than in MDA-MB-231) removes the possibility that the difference of the activity 
comes from a better response from any of the cell lines to the mode of action of the 
complexes. So this difference of activity may come from the interaction of the oestrogenic 
complexes with the receptors.   
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Figure 3.19. Toxicity of EE and ET-Pt-Terpy (IC50 μM) in ovarian cell lines. Effect of cisplatin resistance. 
As highlighted previously, non-covalent DNA binders can be useful for overcoming 
cisplatin resistance, as their mode of action is different. Ovarian cell line A2780 (AR-, 
ERα- and ERβ +) and its cisplatin resistant strain A2780cr were chosen to study this 
possibility (Fig. 3.19). Major resistance mechanisms found in A2780cisR are reduced 
uptake of platinum(II) drugs and elevated levels of the tri-peptide glutathione whose 
cysteine residue detoxifies platinum(II) drugs via rapid binding
41
. The stability of this 
kind of terpyridine complex (without leaving groups) makes it possible for us to exclude 
glutathione coordination as a factor. As observed in previous experiments in ovarian cell 
line, the complexes show a similar activity to cisplatin. However, a better response to the 
resistant cell line is observed, with a 2 fold increase in the capacity to overcome platinum 
resistance mechanisms. These results confirm that by using a non-covalent drug we can 
achieve different activity to cisplatin-like molecules (as seen with breast and cisplatin 
resistant cell lines).  
3.3.2 Cellular uptake 
In order to explore how the presence of the steroid affects cellular uptake, MDA-MB-
231, T-47D and SK-OV-3 cells were treated with platinum drugs and uptake determined 
using ICP-MS. A single concentration for all compounds (30 µM)
42
 was chosen in order 
to determinate speed and efficiency, under the same conditions. Short time of exposure (3 
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h) was used because it has been previously shown that platinum terpyridine-like 
compounds can enter in the cell very quickly, sometimes entering in large quantities in 
times as short as five minutes
43
. Both testosterone and estradiol complexes were tested 
and non-steroidal analogues and cisplatin were used as controls. EE and ET-Terpy-Pt-Ph 
were not used due to their low toxicity. Whole cell, cytoplasm and nuclear fractions were 
obtained from the same experiment to observe distribution through the cell. In Figure 3.20 
we can see the results. As expected, the delivery is very quick, with a large amount of 
compound entering the cell after only 3 hours. If compared with cisplatin, the difference 
is at least of an order of magnitude in each fraction (also observed when compared with 
the steroidal DNA-covalent-binding complexes from previous chapter; Section 2.3.5). It 
is noticeable that linking to the steroids can lower the delivery in MDA-MB-231 and SK-
OV-3 cell lines (2 or 3 fold). There is no noticeable co-relation between platinum uptake 
and cytotoxicity across the different cell lines: there is not a larger uptake in cells with 
lower IC50 (Appendix B).  
ET-Pt-Terpy EE-Pt-Terpy Ph-Pt-Terpy CDDP 
0
100
200
300
400
500
600
700
p
m
o
l/
1
0
6
c
e
ll
MDA-MB-231
 whole cell
 cytoplasm
 nuclei
ET-Pt-Terpy EE-Pt-Terpy Ph-Pt-Terpy CDDP 
0
100
200
300
400
500
p
m
o
l/
1
0
6
c
e
ll
T-47D
 whole cell
 cytoplasm
 nuclei
 
ET-Pt-Terpy EE-Pt-Terpy Ph-Pt-Terpy CDDP 
0
100
200
300
400
500
600
700
800
p
m
o
l/
1
0
6
c
e
ll
SK-OV-3
 whole cell
 cytoplasm
 nuclei
 
In previous chapter it was shown that for covalent DNA-binders, even though non-
steroidal complexes were taken up more, the steroidal ones were more effective at 
Figure 3.20. pmols of Pt in 
T-47D, SK-OV-3 and 
MDA-MB-231 after 3hours 
of treatment with 30µM of 
EE, ET and Ph-Pt-Terpy 
and cisplatin.  
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crossing the membrane and arriving in the cytoplasm (Section 2.3.5)
16, 19
. When steroids 
are coupled to non-covalent DNA-binders, this effect is only evident for estradiol 
derivatives in ERα+ cell lines (Table 3.1), where between 80-100% of the compound 
taken up crosses the membrane. When an ERα- cell line is studied, this percentage drops 
to 25%. The non-steroidal analogues show between 30-80% in the different cell lines and 
there is a clear co-relation between the cytotoxicity and percentage of complex that cross 
the membrane. The testosterone compound is the least effective at crossing the membrane 
(around 20%). However, the uptake of the testosterone compound is increased for AR+ T-
47D cell line (in whole cell), compared with the non-steroidal control. So in this case 
(unlike in the toxicity assay) a dependence on the receptor status can be traced.  
 ET-Pt-Tpy EE-Pt-Tpy Ph-Pt-Tpy 
MDA-MB-
231 
T-47D SK-OV-3 MDA-MB-
231 
T-47D SK-OV-3 MDA-MB-
231 
T-47D SK-OV-3 
% across the 
membrane 
33 17 26 26 85 95 51 87 35 
% cytoplasm 23 13 20 17 62 69 25 38 18 
% nuclei 9 4 6 9 23 26 25 49 17 
Table 3.1. % of compound found crossing the membrane (related to compound taken up by whole cell) and in nuclear 
or cytoplasm fractions after 3 h. 
When intracellular fractions are investigated, we observed that the non-steroidal 
complex shows a 1:1 ratio between cytoplasm and nuclei (nuclear transport doesn’t 
depend on cytoplasmic proteins), while the steroidal complexes show a 3:1 ratio. These 
data are consistent with the presence of steroid affecting the interaction with 
macromolecules in the cytoplasm and that influencing the cellular distribution of the 
complexes (as seen previously in Section 2.3.5). The non-steroidal complex is always 
delivered to the nucleus in larger amounts and this may be the reason why complexes 
with an attached steroid show lower activity. To study how this might affect the toxicity, 
studies of the interaction with nucleic acids are needed. 
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3.4 DNA interaction 
3.4.1 Stability of complexes 
 
 
 
Figure 3.21. UV/Vis of EE-Pt-Terpy (left) and ET-Pt-Terpy (right) (50 μM) during 72h in water (top), RPMI 1640 
(middle) and DMEM medium (bottom).  
In order to see how the presence of the steroid affects the interaction with DNA, 
different techniques have been used. By exploring possible interactions with 
nucleobases we confirm that coordinative binding did not take place. First, stability in 
water and media of the complexes alone was measured over a 72 h period
44
 by UV/VIS 
(Fig. 3.21). The complexes are very stable in water and only small changes appear in 
DMEM medium, probably as result of interaction with proteins present in the medium 
(Foetal Bovine Serum is added to the medium and serum albumin in known to bind to 
steroids
16
). This indicates that the reactive species are the provided complexes and not 
degradation products. The compounds were then incubated with 5’GMP for 72 h44 and 
measured with ESI-MS. No adducts were observed, only the initial complex, suggesting 
that the hypothetical interaction with DNA would indeed be in a non-covalent non-
coordinative mode.  
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Once it was determined that no covalent interaction was detected with nucleobases, 
and that the compounds were stable under experimental conditions, studies of the 
interaction with polymeric DNA were performed. Gel electrophoresis was 
uninformative: being an intercalator, no retardation was observed (Fig. 3.22)
45
. 
However, other techniques proved more successful. 
EE-Pt-Terpy:                                                       ET-Pt-Terpy: 
      
 
EE-Terpy-Pt-Ph:                                          ET-Terpy-Pt-Ph: 
     
 
Ph-Pt-Terpy: 
 
 
Figure 3.22. Gel electrophoresis of the complexes with circular plasmid pBR322 after 1 hour incubation. Lanes 
indicate (left to right in bp:complex ratio): plasmid, 15:1, 10:1, 8:1, 6:1, 5:1, 4:1, 3:1, 2:1 and plasmid (EE and ET-Pt-
Terpy);  plasmid, 40:1, 30:1, 20:1, 15:1, 10:1, 8:1, 6:1, 5:1, 4:1, 3:1, 2:1 and plasmid (EE and ET-Terpy-Pt-Ph and 
Ph-Pt-Terpy). The small bands observed in some of the lanes correspond to different supercoiling states of the 
plasmid and they can be observed as well for the plasmid control lanes. Possible DNA cleavage abilities where tested 
in presence of H2O2 with negative results. 
3.4.2 Ethidium bromide displacement 
In order to see if our compounds interact with DNA, a simple Ethidium Bromide (EB) 
displacement assay was performed. This assay is based in the fact that, when bound to 
DNA, EB show an increase in its fluorescent capacities
46
. So, molecules of DNA are 
loaded with EB measuring the fluorescence, and then, we titrate this EB loaded DNA with 
an expected DNA binding compound. If the intensity of the fluorescence signal observed 
decrease as result of the titration, this can be interpreted as a signal that EB is being 
displaced from DNA by our compound. The effectiveness of this displacement is co-
related to the binding affinity of the compound to DNA
46
.  
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Figure 3.23. Displacement of ethidium bromide (15 μM) from ct-DNA (12 μM) by the synthesized Pt complexes. 
Mixing ratios EB/complex are shown in the caption. λexc=480nm. Decreasing ratios of emission (bottom right). 
(Normalized to the maximum of emission of EB-DNA) 
We expected our compounds to be able to displace EB from DNA, since they were 
designed to be intercalators. All of them displace EB (Fig. 3.23), however not all with the 
same efficiency. The non-steroidal control compound has a greater ability to displace EB 
compared to the steroidal derivatives, indicating a decrease in DNA binding affinity upon 
conjugation. Between the steroidal complexes, we observed that terpyridine intercalators 
show higher binding affinities, than the phenyl intercalators, with estradiol derivatives 
being better binders than testosterone derivatives (Fig. 3.23). These data show 
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correspondence with the cytotoxicity data previously presented, indicating that maybe the 
presence of steroid decrease the ability of the complexes to intercalate into DNA, and this 
brings the lose of biological activity.  
3.4.3 Hoechst displacement 
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Figure 3.24. Displacement of Hoechst 33258 (1.5 μM) from ct-DNA (12 μM) by synthesized complexes. Mixing 
ratios EB/complex are shown in the caption. λexc=350nm. Decreasing ratios of emission (bottom right). (Normalized 
to the maximum of emission Hoechst-DNA)  
A similar experiment was performed with Hoechst 33258
47-49
, a minor groove binder. 
The results are a little different. All the complexes again seem to be able to displace the 
pre-loaded molecule (Fig. 3.24). But, contrary to previous experiment, all show the same 
 153 
efficiency in removing Hoechst from DNA up to a 15:1 ratio (Hoechst:complex). After 
that all of them show different behaviour. The estradiol terpyridine intercalator is the most 
effective at displacing Hoechst, followed by the testosterone phenyl intercalator. The 
other three remaining complexes rebind Hoechst at high concentrations. This could be 
binding of Hoechst to the DNA after structural changes forced by the complexes, or result 
of an interaction between the complexes and Hoechst 33258. The EB results, being 
displacement of an intercalator, may be more pertinent. 
3.4.4 Circular and linear Dichroism 
In order to detect possible DNA structural changes, circular and linear dichroism (CD 
and LD) were performed with the complexes and ct-DNA
50
. CD measures the difference 
of absorption of left and right circularly polarised light, and when performed on 
macromolecules can be used to report changes in the conformation of the macromolecule 
itself, and to prove interaction with small molecules, especially if an induced CD (ICD) 
signal is observed in the small molecule spectroscopy
50
. When a titration of ct-DNA with 
our complexes was investigated by CD, the first thing observed was that the B-DNA 
conformation (evidenced by a characteristic positive CD band centred at 275 nm, and a 
negative band at 240 nm, with the zero being around 260 nm) is retained with all the 
complexes, except ET-Terpy-Pt-Ph (Table 3.2). For EE-Terpy-Pt-Ph, EE, ET and Ph-Pt-
Terpy distortions to the DNA structure are quite small and an ICD signal was observed in 
all the complexes spectroscopy around 300 nm. The observation of such ICD signals for 
these complexes confirms the binding to DNA consistent with the findings from EB 
displacement.  
When ct-DNA is titrated with ET-Terpy-Pt-Ph, changes in the B-DNA conformation 
are bigger compared with the other complexes (Fig. 3.25), although only when the CD 
absorbance of the complex is subtracted (Fig. 3.25 C). Free ET-Terpy-Pt-Ph presents a 
surprising CD absorbance spectrum: very high compared with the other steroidal 
complexes (Fig. 3.25 A). An explanation for this difference in CD absorbance might be 
different solution behaviours due to the stacking of the planar aromatic units present in the 
molecule. In this case, on interaction with DNA the CD absorbance would be lost; 
explaining why small modifications are observed in the ct-DNA titration (Fig. 3.25 B) 
and why the ICD is a mirror image of the original CD absorbance spectrum of the free 
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complex (Fig. 3.25 D). However, this is only a hypothesis and no information on the B-
DNA conformation can be obtained.  
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Figure 3.25.  CD absorbance of the complexes at equivalent concentration to the 5-1 (DNA(bp):complex) titration 
point (A); ct-DNA titration with ET-Terpy-Pt-Ph (B); ct-DNA titration with ET-Terpy-Pt-Ph after subtraction of the 
CD absorbance of the free complex (C); CD absorbance spectrum and ICD signal at the 5-1 DNA(bp):complex point 
(D). 
Modification of the DNA structure was further studied using flow linear dichroism 
(LD)
51
.
 
In this experiment long polymeric ct-DNA is orientated by viscous drag in a 
couvette cell and the extent of orientation may be assessed by the difference in absorption 
of light linearly polarised parallel and perpendicular to the orientation direction. B-DNA 
produces a characteristic negative band between 220 nm and 300 nm (arising from π - π* 
transitions) as the base pairs are orientated at almost 90° to the orientation axis. The 
magnitude of this LD signal is dependent on the degree to which DNA is orientated, being 
reduced by effects such as DNA-bending, and increased by intercalation of aromatic rings 
between the bases of the DNA (“stiffening”). 
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Table 3.2.  CD and LD spectra of titration of ct-DNA(300 μM in 20 mM NaCl and 0.89 mM Sodium Cacodylate 
pH 6.8) with EE-Pt-Terpy, ET-Pt-Terpy, Ph-Pt-Terpy (third), EE-Terpy-Pt-Ph  and ET-Terpy-Pt-Ph. Corrected 
substracting CD absorbance of the complexes. 
When the complexes are titrated into oriented ct-DNA we observed different effects 
(Table 3.2). The first thing observed, as in previous CD experiment, is the appearance of 
induced LD (ILD) signals around 300 and 400nm, (the second of which is weaker). This 
again confirms that the binding to DNA is happening. The second thing observed is that 
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for all the terpyridine intercalators (steroidal and non-steroidal; although EE-Pt-Terpy 
appear to be mantained) the signal at 260nm is increased consistent with the “stiffening” 
characteristic of intercalation. This “stiffening” is quite visible for the non-steroidal 
complex, less so for the steroidal ones, maybe as result of the presence of the bulky 
steroid, that make the DNA loose some orientation to accommodate the big molecule (as 
seen previously for alkylating examples). Nevertheless an overall intercalation is detected 
(Fig. 3.26). When the steroidal complexes with phenyl moieties are studied, another effect 
is observed. These compounds do not show any signal of intercalation into the DNA. 
Rather, big loses of orientation are observed, especially for the testosterone complex, 
indicating that the complexes somehow bend the DNA double helix (Fig. 3.26). This 
implies that terpyridines and phenyl complexes interact with DNA in different ways. This 
difference in interaction could be responsible for the lower biological activity of the 
phenyl derivatives. 
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Figure 3.26.  Effect in the orientation of ct-DNA when complexes were added. 
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3.4.5 DNA Fluorescence tritation 
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Figure 3.27. Titration of the complexes (25 μM) with ct-DNA, in 50 mM NaCl and 1mM sodium cacodylate buffer 
(pH 6.8). Mixing ratios DNA (bp)/complexes are shown in the caption. λexc=450 (EE and ET-Pt-Ph) or 480nm (Ph-
Pt-Ph, EE and ET-Terpy-Pt-Ph). The graphs were normalized to the emission of the complexes (25 μM) in DCM. 
In order to probe further this difference of DNA interaction between the terpyridine and 
phenyl terminated complexes, another experiment was undertaken. As explained before, 
the complexes are fluorescent in aprotic solvents, but in protic solvents this fluorescence 
is quenched. Our hypothesis was that if the platinum(II) terpyridine unit bound in an 
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intercalative way between the bases of DNA, the complex would be again in a 
hydrophobic environment and its fluorescence would be unquenched. Thus, terpyridine 
intercalators would show a fluorescence response on interaction with DNA, while if the 
phenyl ring is intercalated or a complete intercalation of the terpyridine is avoided they 
would not. All the complexes were titrated against ct-DNA and the fluorescence recorded 
(Fig. 3.27). As predicted, for EE, ET-Pt-Terpy and Ph-Pt-Terpy complexes fluorescence 
is observed, being visible starting at a 1:1 ratio (DNA (bp):complex). However, for EE 
and ET-Terpy-Pt-Ph (where the phenyl group and the position of the steroid can make the 
intercalation of the terpyridine difficult) this fluorescence is not observed (Fig. 3.27), 
indicating that the interaction with DNA does not occur through intercalation of the 
platinum(II) terpyridine moiety (or that this intercalation is only partial and the complex 
remains exposed to the solvent). 
When the fluorescence is plotted against the ratio DNA (bp):complex we see that all the 
terpyridine intercalators (EE, ET and Ph-Pt-Terpy) present similar rates in the increase of 
their fluorescence (Fig. 3.28). However, it is noticeable that the non-steroidal complex 
arrives at a possible saturation point before the other two. This could imply more effective 
intercalation by the smaller non-steroidal complex. 
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Figure 3.28. Fluorescence response of the complexes at their maximum of emission (540 nm for EE-Pt-Terpy and 
ET-Pt-Terpy and 625 nm for Ph-Pt-Terpy) observed on addition of DNA (bp): normalized to maximun of 
fluorescence observed upon addition of DNA at 20:1 (A); related to maximun of fluorescence of the complexes at 25 
μM in dichloromethane (B). 
The fact that only DNA bound complex would produce a fluorescence response was 
used to attempt to follow cellular uptake and localisation. Adherent ovarian cell line 
SK-OV-3 (AR-, ERα+, ERβ+), and breast lines T-47D (AR+, ERα+, ERβ+) and MDA-
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MB-231 (AR-, ERα-, ERβ+) were treated with the complexes. Similar conditions to the 
ICPMS uptake experiment (15 µM for 3 hours) were used, knowing that in this time the 
complexes are internalized and arrive in different quantities to the nuclei. Treated cells 
were then visualized under a confocal microscope, exciting the cells with an Argon laser 
(λex=488 nm; Ph-Pt-Terpy, EE and ET-Terpy-Pt-Ph) or a Blue Diode laser (λex=405 nm; 
EE and ET-Pt-Terpy). Unfortunately, no fluorescence response was obtained. 
3.4.6 Interaction with proteins 
Figure 3.29.  Induced CD spectrum for various mixtures of chiral components. DNA+complex , HSA+complex 
and HSA+complex+DNA. The order of the component denotes the order of mixing. 
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The previous steroidal terpyridine (covalent binding) complexes interacted with 
proteins as well as with DNA
16, 34
. This interaction varied depending of the order of 
addition of the macromolecules. To ascertain if these new complexes also had the same 
ability to bind proteins, interaction with Human Serum Albumin (used as a model of 
protein interaction), DNA, and both in concert, were measured through CD and 
Fluorescence (not shown). Observed ICD signals (Fig. 3.29), indicate that all the steroidal 
complexes have the ability to interact with HSA, while the non-steroidal analogue does 
not. As expected all the complexes (steroidal and non-steroidal) interact with DNA. When 
both of the macromolecules are added to the complexes, the results are independent of the 
order of addition of the macromolecules, with no significative differences between ICDs. 
This indicates that each macromolecule interacts with a different unit of the complexes 
(intercalator with DNA, and steroid with HSA). This is reinforced by fluorescence 
experiments (not shown) that show that fluorescence is only observed when DNA (not 
HSA) is added.  
 
3.5 Conclusions 
Steroidal intercalators have been synthesised in a simple way that allows good yields 
and flexibility of starting materials. The same procedures could potentially be used for 
different steroids and different metals allowing the rapid formation of a library of 
compounds. Controls without a steroid and with a different intercalative moiety have been 
prepared and allowed us to determine the importance of both of the components in the 
activity of the complexes. The complexes were tested against breast and ovarian cell lines. 
These tests showed that coupling of steroids has a negative effect on the biological 
activity of the intercalative terpyridines. The attachment of steroids did not seem to 
increase the uptake into the cells either (however, compared to covalent binders, 
intercalators show much better abilities to enter into the cell). When the amount of 
complex that arrives to the nuclei is compared we see that greater amounts of the non-
steroid complexes is localised there, while the steroidal complexes are concentrated in the 
cytoplasm. However, this effect does not seem big enough difference to explain the loss 
of activity. 
The stability of the complexes and their ability to bind to DNA were also studied. The 
compounds proved to be stable in the reaction conditions over 72 h, excluding the 
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possibility of a covalent interaction with DNA. Ethidium bromide displacement 
experiments showed the same order in possible DNA affinity as in toxicity potency, a 
circumstantial indication that the DNA binding affinity is co-related to toxicity. This, 
together with the fact that the presence of steroid does not produce major distortions in the 
DNA double helix (as seen for covalent binders) can explain why in this system steroid 
conjugation does not enhance activity. Indeed when the conjugation locks the ability of 
the terpyridine to intercalate, the affinity drops even more, and the intercalation is 
replaced by a mode that includes bending of the double helix. This seems to reinforce the 
hypothesis that the active factor is the intercalation of the terpyridine. Finally, steroidal 
complexes showed the ability to interact with proteins, probably through the steroidal 
moiety. This can explain the difference in distribution inside the cells of the complexes 
(more in cytoplasm when the steroid is conjugated).  
As a result of all of this we could say that coupling of a steroidal moiety to a 
intercalative unit, unlike in the case of covalent binders, appears to be a drawback in the 
potency and activity of the complex (at least within the confines of the molecular design 
explored herein). This is mainly a result of the impediments that the steroidal molecule 
has to intercalation, but may also be because of the possible interactions inside the cell 
that distract the complex from its DNA target. 
 
3.6 Experimental 
Synthesis: All solvents and chemicals were purchased from Sigma-Aldrich. 
[Pt(terpyridine)Cl] and EE and [ET(terpyridine)Cl] were synthesised following previous 
procedures
16, 34, 37
. 
1
H NMR spectra were recorded on Brucker AC300 or DRX500 
spectrometers. ESI mass spectra were recorded on a Micromass LCT time-of-flight 
mass spectrometer. Microanalyses were performed on a CE Instruments EA1110 
elemental analyser. UV/VIS was performed in a Varian Cary 5000 UV/VIS 
spectrophotometer. HPLC was performed in a Dionex HPLC system with a semi-prep 
column fitted. Fluorescence spectra were recorded using a Shimadzu RF-5301 PC 
Fluorescence Spectrophotometer (resolution = 0.4nm; Speed medium; Excitation split = 
5; Emmision split = 1.5) 
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(EE-Pt-Terpy)TFA: The chloride salt of Pt(terpyridine)Cl (50 mg, 0.1 mmol) was 
dissolved in 50 ml of dry DMF. To that, 1.1 equivalent of 17α-ethynylestradiol (32.6 mg, 
0.11 mmol), 8% w/w of CuI (1.68 mg, 8 µmol) and a couple of drops of dry triethylamine 
were added. The reaction was left overnight under Argon atmosphere and at room 
temperature. Then 10 ml of dry methanol was added, and the reaction left for another 24 h 
in the same conditions. After that the solution was filtered and the solvent removed under 
vacuum, yielding a dark solid containing the chloride salt of the wanted product. This 
solid was purified by HPLC using a 40 minutes gradient of water/acetonitrile (0-100% 
acetonitrile) with TFA (0.05%), during which the Chloride salt was exchanged to the TFA 
salt. After removing the solvent we obtained a bright orange solid (54.8 mg, yield 65.6%). 
1
H-NMR (300 MHz, CD3OD): δ 9.26 (d, 2H, J = 5.5 Hz, H6’), 8,43 (m, 7H, 
H4’,H3’,H3’’,H4’’), 7.78 (dd, 2H, J = 5.5, 7.7 Hz, H5’), 7.06 (d, 1H, J = 8.8 Hz, H1), 6.49 (d, 
1H, J= 8.8, H2), 6.45 (s, 1H, H4), 2.9-1.2 (m, 18H, steroid), 0.94 (s, 3H, Me18). UV / 
Visible (Dichloromethane): 242nm (ε = 14600 mol-1 dm3 cm-1). Mass spectrum (ESI, 
+ve): m/z 723 [(17α-Ethinylestradiol)Pt(Terpy)]+. Elemental analysis: calculated for 
C37H34N3F3O4Pt- (H2O); C, 52.0; H, 4.3; N, 5.0. Found C, 52.2; H, 4.6; N, 5.3. 
 
(ET-Pt-Terpy)TFA: The chloride salt of Pt(terpyridine)Cl (20 mg, 0.04 mmol) was 
dissolved in 20 ml of dry DMF. To that, 1.1 equivalent of ethisterone (13.8 mg, 0.044 
mmol), 8% w/w of CuI (0.61 mg, 3.2 µmol) and a couple of drops of dry triethylamine 
were added. The reaction was left overnight under Argon atmosphere and at room 
temperature. Then 10 ml of dry methanol was added, and the reaction left for another 24 h 
in the same conditions. After that the solution was filtered and the solvent removed under 
vacuum, yielding a dark solid containing the chloride salt of the wanted product. This 
solid was purified by HPLC using a 40 minutes gradient of water/acetonitrile (0-100% 
acetonitrile) with TFA (0.05%), during which the chloride salt was exchanged to the TFA 
salt. After removing the solvent we obtained a bright orange solid (24.9 mg, yield 73.1%). 
1
H-NMR (500 MHz, CD3OD): δ 9.25 (d, 2H, J = 5.5 Hz, H6’), 8.47 (m, 5H, H3’,H3’’,H4’’), 
8.40 (dd, 2H, J = 8.0, 7.6 Hz, H4’), 7.78 (dd, 2H, J = 5.5, 7.6 Hz, H5’), 5.71 (s, 1H, H4), 
2.5-0.89 (m, 20H, steroid), 1.27 (s, 3H, Me19), 0.98 (s, 3H, Me18). UV / Visible 
(Dichloromethane): 242nm (ε = 26800 mol-1 dm3 cm-1). Mass spectrum (ESI, +ve): m/z 
739 [(Ethisterone)Pt(Terpy)]
+
. Elemental analysis: calculated for C38H38N3F3O4Pt-
2/3(TFA); C, 50.9; H, 4.1; N, 4.5. Found C, 51.1; H, 3.9; N, 4.1. 
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(Ph-Pt-Terpy)TFA: The chloride salt of Pt(terpyridine)Cl (20 mg, 0.04 mmol) was 
dissolved in 20 ml of dry DMF. To that, 1.1 equivalent of benzylacetinele (4.5 mg, 0.044 
mmol), 8% w/w of CuI (0.61 mg, 3.2 µmol) and a couple of drops of dry triethylamine 
were added. The reaction was left overnight under Argon atmosphere and at room 
temperature. Then 10 ml of dry methanol was added, and the reaction left for another 24 h 
in the same conditions. After that the solution was filtered and the solvent removed under 
vacuum, yielding a dark solid containing the chloride salt of the wanted product. This 
solid was purified by HPLC using a 40 minutes gradient of water/acetonitrile (0-100% 
acetonitrile) with TFA (0.05%), during which the chloride salt was exchanged to the TFA 
salt. After removing the solvent we obtained a dark brown solid (16 mg, yield 64.6%). 
1
H-NMR (500 MHz, CD3OD): δ 8.70 (d, 2H, J = 5.4 Hz, H6’), 8.2 (m, 3H, H3’’,H4’’), 8.15 
(dd, 2H, J= 7.7, 7.8 Hz, H4’), 8.09 (d, 2H, J= 7.7 Hz, H3’), 7.59 (dd, 2H, J= 5.5, 7.6 Hz, 
H5’), 7.33 (m, 3H,H2, H3), 7.21 (d, 2H, J= 6.6 Hz, H1). UV / Visible (Dichloromethane): 
248nm (ε = 18400 mol-1 dm3 cm-1). Mass spectrum (ESI, +ve): m/z 529 
[(benzylacetylen)Pt(Terpy)]
+
. Elemental analysis: calculated for C25H16F3N3O2Pt-
1.5(TFA); C, 41.4; H, 2.0; N, 5.2. Found C, 41.7; H, 2.2; N, 5.5. 
 
(EE-Terpy-Pt-Ph)TFA: The chloride salt of estradiol(terpyridine)PtCl (15 mg, 0.019 
mmol) was dissolved in 15 ml of dry DMF. To that, 1.1 equivalent of benzylacetilene (2.2 
mg, 0.021 mmol), 8% w/w of CuI (0.3 mg, 1.5 µmol) and a couple of drops of dry 
triethylamine were added. The reaction was left overnight under Argon atmosphere and at 
room temperature. Then 10 ml of dry methanol was added, and the reaction left for 
another 24 h in the same conditions. After that the solution was filtered and the solvent 
removed under vacuum, yielding a dark solid containing the chloride salt of the wanted 
product. This solid was purified by HPLC using a 40 minutes gradient of 
water/acetonitrile (0-100% acetonitrile) with TFA (0.05%), during which the chloride salt 
was exchanged to the TFA salt. After removing the solvent we obtained a brown solid (10 
mg, yield 56.5%). 
1
H-NMR (500 MHz, D2O/CD3CN): δ 8. (b, 2H,H6’), 7.95 (bt, 2H, H4’), 
7.67 (bd, 2H, H3’), 7.56 (bs, 2H, H3’’), 7.21 (m, 5H, H5’,H2’’’,H3’’’), 7.14 (d, 1H, J= 8.4 Hz, 
H1), 6.85 (b, 1H, H1’’’), 6.60 (dd, 1H, J= 8.4, 2.2 Hz, H2), 6.56 (d, 1H, J= 2.2 Hz, H4), 
2.79-1.17 (m, 18H, steroid), 0.89 (s, 3H, Me18). UV / Visible (Dichloromethane): 219nm 
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(ε = 43200 mol-1 dm3 cm-1). Mass spectrum (ESI, +ve): m/z 823 
[ET(Terpy)Pt(benzylacetylen)]
+
. Elemental analysis: calculated for C45H38N3F3O4Pt; C, 
57.7; H, 4.1; N, 4.5. Found C, 58.1; H, 3.9; N, 4.9. 
 
(ET-Terpy-Pt-Ph)TFA: The chloride salt of testosterone(terpyridine)PtCl (15 mg, 
0.018 mmol) was dissolved in 15 ml of dry DMF. To that, 1.1 equivalent of 
benzylacetilene (2 mg, 0.02 mmol), 8% w/w of CuI (0.3 mg, 1.5 µmol) and a couple of 
drops of dry triethylamine were added. The reaction was left overnight under Argon 
atmosphere and at room temperature. Then 10 ml of dry methanol was added, and the 
reaction left for another 24 h in the same conditions. After that the solution was filtered 
and the solvent removed under vacuum, yielding a dark solid containing the chloride salt 
of the wanted product. This solid was purified by HPLC using a 40 minutes gradient of 
water/acetonitrile (0-100% acetonitrile) with TFA (0.05%), during which the chloride salt 
was exchanged to the TFA salt. After removing the solvent we obtained a brown solid 
(9.5 mg, yield 53.9 %). 
1
H-NMR (300 MHz, D2O/CD3CN): δ 8.13 (b, 2H, H6’), 7.99 (b, 
2H, H4’), 7.69 (b, 2H, H3’), 7.55 (b, 2H, H3’’), 7.25 (bm, 5H, H5’,H2’’’,H3’’’), 6.84 (b, 2H, 
H1’’’), 5.73 (s, 1H, H4) 2.48-0.98 (m, 20H, steroid), 1.21 (s, 3H, Me19), 0.90 (s, 3H, Me18). 
UV / Visible (Dichloromethane): 248nm (ε = 46100 mol-1 dm3 cm-1). Mass spectrum 
(ESI, +ve): m/z 839 [ET(Terpy)Pt(benzylacetylen)]
+
. Elemental analysis: calculated for 
C46H42N3F3O4Pt-2.25(TFA); C, 50.2; H, 3.5; N, 3.5. Found C, 50.5; H, 3.0; N, 3.3. 
 
Cell test: Tissue culture flasks, 96 well plates, RPMI 1640, DMEM, L-glutamine, 
trypsin-EDTA, HEPES, sodium pyruvate and FBS were obtained from Invitrogen.  
Thiazolyl blue tetrazolium bromide (MTT) and DMSO were from Sigma, UK. Tissue 
culture flasks, 96-well plates, RPMI 1640, DMEM, L-glutamine, trypsin-EDTA, HEPES, 
sodium pyruvate and FBS were obtained from Sigma, UK.  Thiazolyl blue tetrazolium 
bromide (MTT) and DMSO were from Avocado, UK.  Cells were grown in RPMI 1640 
(T-47D, SK-OV-3) or DMEM (MDA-MB-231, A2780/cr) in 10 % FBS supplemented 
with 1% L-glutamine, 1% HEPES buffer and 1% sodium pyruvate. The MTT assay
52
 was 
carried out using 96 well plates.  Cells were harvested in logarithmic growth, 4,000 
(A2780/cr), 10,000 (SK-OV-3, MDA-MB-231) or 25,000 cells (T-47D) were seeded per 
well and left overnight to attach.  The cells were treated, in quadruplicate with 6 
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difference concentrations of complex dissolved in fresh media; the range of 
concentrations used is dependent on the complex.  The cells were incubated for 72 hours 
and 20 μl of thaizolyl blue tetrazolium bromide (5mg / ml, 0.2 μm filtered) added.  The 
cells were further incubated for 2 hours.  The media was carefully removed by aspiration 
and 200 μl of DMSO added to dissolve the purple crystals.  Absorbance was measured 
using a 96-well plate reader (BioRad) set at 590 nm.  Each cell line was investigated 
beforehand to determine the correct cell numbers to initially seed and the required amount 
of time exposed to thiazolyl blue tetrazolium bromide to ensure sensitivity and accuracy. 
 
Cellular Uptake: Two million cells (T-47D, SK-OV-3 and MDA-MB-231) were 
seeded in a 60mm diameter Petri dishes and left overnight to attach. Next day cells were 
treated with 30 µM of the different compounds for 3 hours. After that time, the medium 
was removed and cells washed three times with PBS to remove all the unwanted (non 
uptaked) Platinum complexes. Cells were collected and two aliquots of one million cells 
were taken, one of them to see whole cell uptake and the other for Cytoplasm and Nuclei 
fraction extraction (Nuclear/Cytoplasm extraction kit. BioVision). Two ml of ultrapure 
concentrated nitric acid (Traceselect Ultra, Aldrich) was added to the samples, and 
digested overnight at 90ºC. Samples were then taken to dryness at 120ºC, resuspended in 
3ml of a 2% solution of nitric acid and filtered. The amount of platinum was measured in 
a Agilent 7500CX ICP-MS (analysis was done with Pt sample cone in He and No-gas 
mode. Plasma settings: Ar.flow: 15 L/min; Neb gas: 0.8 L/min; RF power 1550W; T of 
spray chamber: 15 º C). 
 
Stability: RPMI 1640, DMEM, L-glutamine, trypsin-EDTA, HEPES, sodium 
pyruvate and FBS were obtained from Invitrogen, ultrapure water was obtained from 
Sigma. Samples were prepared as follow: Solutions of the complexes were dissolved in 
water and RPMI and DMEM medium in 10 % FBS supplemented with 1% L-
glutamine, 1% HEPES buffer and 1% sodium pyruvate, to a final complex 
concentration of 50µM. Stability was measured during 72 h at 37ºC, measuring a UV 
spectrum every hour, using a Varian Cary 5000 UV/VIS spectrophotometer with a 
Varian 6x6 Multicell Block Beltier and a Varian Cary Temperature Controller attached. 
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Gel electrophoresis: Plasmid pBR322 (New England Biolabs, UK) and varying 
amount of complex were mixed and incubated for 1 h or 24 h.  The total solution of 16 
μl consists of 1 μl (stock = 1 μg / μl ) pBR322, between 0.5 and 12.8 μl of complex 
(stock = 60 μM) and the rest with ultra-pure water.  After the incubation period, 4 μl of 
loading buffer were added and 16 μl loaded onto an agarose gel.  The loading buffer 
consisted of 30 % glycerol and 0.05% bromophenol blue in ultra-pure water.  The 
agarose (Fisher, UK) gel was prepared from 200 ml of 1x TAE buffer and 0.20 g of 
agarose (1%) the gel cast and run using a HE99X Maxi (Amersham Biosciences, UK) 
submarine gel kit.  The gel was ran using 1x TAE for 250 minutes at 5 V cm 
-1
.  The gel 
was stained after electrophoresis in TAE buffer containing ethidium bromide (0.5 µg 
ml
-1
) for 40 minutes. The gel was visualized using an UVIdoc Platinum system 
(UViDoc, Cambridge, UK) at 312 nm. 
 
ESI-MS Nucleotide binding studies: 5’-GMP and 9-ethylguanine were stored at 
4°C in a dessicator; they were dissolved freshly in 1mM sodium cacodylate buffer (pH 
6.8) before each experiment. Fresh solution of complexes in 1mM sodium cacodylate 
buffer (pH 6.8) were used and mixed with nucleotides in a 1:1 ratio. The stock solutions 
of base and complex were both 2 mM. All the solutions were incubated for three days at 
37°C in the dark.  ESI-MS spectra were taken on a a Micromass LCT time-of-flight 
mass spectrometer. 
 
Circular Dichroism: All CD spectra were recorded on a Jasco J-810 
spectropolarimeter operated with the following parameters: sensitivity, 100 mdeg; start 
wavelength, 350 or 700 nm; end wavelength, 200 or 280 nm; data pitch, 0.5 nm; scanning 
mode, continuous; scanning speed, 200 nm per min; response, 0.1 seconds; bandwidth, 
1.0; accumulation, 12. Stock solutions of ct-DNA (300 μM) with 20 mM NaCl and 0.89 
mM Sodium Cacodylate pH 6.8 was tritated with complex (500 μM), maintaining the 
concentrations. DNA:complex ratios 100:1, 60:1, 40:1, 25:1, 15:1, 10:1, and 5:1.  
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Linear Dichroism: All LD spectra were recorded on a Jasco J-810 spectropolarimeter 
modified for LD spectroscopic measurement.  The spectropolarimeter was operated in LD 
mode with the following parameters: sensitivity, 100 mdeg; start wavelength, 750 nm; 
end wavelength, 200; data pitch, 0.5 nm; scanning mode, continuous; scanning speed, 500 
nm per min; response, 0.25 seconds; bandwidth, 2.0; accumulation, 8. Stock solutions of 
ct-DNA (300 μM) with 20mM NaCl and 0.89 mM sodium cacodylate pH 6.8 was tritated 
with complex (500 μM), maintaining the concentrations. DNA:complex ratios 100:1, 
75:1, 60:1, 50:1, 40:1, 30:1, 20:1, 15:1, 10:1, 8:1, 6:1 and 5:1.  
 
Ethidium Bromide displacement: The fluorescence spectra for the ethidium bromide 
displacement experiment were recorded in a Shimadzu RF-5301 PC Fluorescence 
Spectrophotometer (λexc = 480 nm; Range emission = 500-750 nm; resolution = 0.4nm; 
Speed medium; Excitation split = 5; Emmision split = 1.5). Solutions of ethidium bromide 
(15 µM), ct-DNA (12 µM), NaCl (50 mM) and sodium cacodylate buffer (1 mM) were 
prepared, measured and titrated with the different complexes from ratios EB:complex 
200-1 to 1-1, keeping the concentration of ethidium bromide and ct-DNA constant.  
 
Hoechst 33258 displacement: The fluorescence spectra for the hoechst 33258 
(Hoechst) displacement experiment were recorded in a Shimadzu RF-5301 PC 
Fluorescence Spectrophotometer (λexc = 350 nm; Range emission = 400-600 nm; 
resolution = 0.4nm; Speed medium; Excitation split = 5; Emmision split = 1.5). Solutions 
of hoechst (1.5 µM), ct-DNA (12 µM), NaCl (50 mM) and sodium cacodylate buffer (1 
mM) were prepared, measured and titrated with the different complexes from ratios 
hoechst:complex 200-1 to 4-1, keeping the concentration of hoechst and ct-DNA 
constant. 
 
ct-DNA fluorescence: The fluorescence spectra tritation of the complexes with ct-
DNA were recorded in a Shimadzu RF-5301 PC Fluorescence Spectrophotometer (λexc = 
425 or 480 nm; Range emission = 450-800 or 500-850 nm; resolution = 0.4nm; Speed 
medium; Excitation split = 5; Emmision split = 1.5). Solutions of the different complexes 
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(25 µM) in water with NaCl (50 mM) and sodium cacodylate buffer (1 mM) were 
prepared, measured and titrated with ct-DNA (2 mM) mantaining the concentrations 
constant. DNA:complex ratios 0.05:1, 0.1:1, 0.2:1, 0.3:1, 0.4:1, 0.6:1, 0.8:1, 1:1, 2:1,3:1, 
4:1, 8:1, 10:1, 15:1 and 20:1. 
 
Cellular Imaging: 500000 cells (T-47D, SK-OV-3 and MDA-MB-231) were seeded 
in 30 mm diameter Petri dishes with glass bottom and left overnight to attach. The cells 
were treated then with 15µM of the complexes for 3hours. After that time, the medium 
was removed and the cells washed three times with PBS to remove all the unwanted 
(non uptaked) complexes. The resulting cells were observed through a Leica DMIRE2 
system with an Argon laser (operated at 405 or 488 nm) and a temperature control 
chamber (operated at 37 ºC) attached. 
 
HSA-DNA interaction: Solutions of ct-DNA (300 µM) and HSA (16 µM) in NaCl 
(50mM) and sodium cacodylate buffer (1mM), were treated with the different complexes 
(30 µM). Solutions of ct-DNA, HSA and complexes were created, adding the 
macromolecules in different order. CD spectra and fluorescence of all solutions was 
measured. All fluorescence and CD spectra were measured as previously described. 
Induced CD (ICD) spectra were obtained by subtracting the baseline corrected spectrum 
of all chiral components of any mixture from the baseline corrected spectrum of the 
mixture of the components. 
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Chapter 4: Metallosupramolecular cylinders 
 
The importance of specific DNA binding in nature is well known. Synthetic agents 
with less specific DNA binding abilities are of importance in the clinical field. A good 
example is the molecule cisplatin that binds coordinatively, principally to two 
neighbouring guanine bases of DNA (i.e. not particularly specific), and is broadly used 
to treat diverse cancers
1-3
. Non-covalent DNA interactions are commonly used in nature 
for multiple functions. For this reason metallodrugs aimed at binding to DNA in a non-
coordinative manner have recently started to receive attention
4-6
. In our lab we have 
developed metallo-supramolecular agents with similar size and shape to DNA 
recognition protein domains. They are positively charged, dimetallic iron(II) triple-
stranded helicates ([Fe2L3]
4+
) with cylindrical structure and a size of approximately 2 
nm in length and 1 nm in diameter (Fig. 4.1). Their synthesis is relatively simple (and 
cheap) and they present the correct size and shape to fit into the major groove, 
occupying a space corresponding to around five base pairs
7-12
.  
 
Figure 4.1. Structure of the triple stranded iron helicate (A, taken from Hotze et al24) and AFM image of the 
intramolecular coiling effect induced by the helicate (B, taken from Hannon et al7). 
These molecules bind strongly, non-covalently to the major groove of DNA, 
inducing unexpected and dramatic intramolecular DNA coiling (Fig. 4.1)
7, 8, 13
 and 
producing bending of around 45º per ligand
7
. Also, they unwind the double helix by 
A 
B 
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around 27º and show certain specificity for alternating purine-pyrimidine sequences
14
.  
These abilities seem to come as a result of their shape: similar but bulkier structures 
have less structural effects on DNA
13, 15
. Although all these structural changes seem to 
be a result of binding in the major groove, recently it was discovered that the complex 
can bind at the heart of a Y-shaped three way junction (Fig. 4.2)
16-18
. This is an 
unprecedented mode of DNA binding and opens the possibility of accessing new targets 
such us replication or RNA secondary structures. 
 
Figure 4.2. Image of the interaction between an iron triple helicate molecule and a DNA three way junction 
structure. Taken from Oleksy et al16. 
Similar double and triple stranded complexes with different metal centres have been 
synthesised. Copper(I) double-stranded complexes show weaker binding to DNA, but 
they present the ability to act as a nuclease
19
. Double-stranded ruthenium(II) structures 
have high cytotoxicity, although their low solubility did not allow detailed study of the 
DNA binding abilities
20
. Ruthenium(II) triple-stranded helicates (Ru2L3
4+
) present an 
analogous structure to the iron helicate (Fig. 4.3) and have similar DNA binding 
affinity, specificity and coiling properties
21-22
. This is a strong indication that most of 
the effects observed upon interaction with DNA are produced by the structural shape of 
the complex and not by the properties of the metallic centre. However, the metallic 
centre can be an important factor in this interaction: the ruthenium cylinder produces a 
much lower unwinding of the double helix (13º), can cleave the DNA when irradiated 
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with UV/VIS light, usually at a guanine base, and show fluorescent emission when 
excited in the MLCT
22
. None of these effects are observed for the iron cylinder. 
 
Figure 4.3. Overlay of the X-Ray structures of iron (yellow) and ruthenium (red) triple stranded helicates. Taken 
from Pascu et al21. 
Recent experiments have shown that the iron triple helicate has antimicrobial 
activity, showing in vivo binding to the bacterial DNA
23
. Studies in human cells show 
that our metallo-supramolecular complex inhibits proliferation in a panel of tumour 
cells and induces cytostasis and apoptosis in myeloid leukaemia cell line HL-60. More 
importantly, this activity is observed without the presence of unwanted genotoxic 
effects
24
. All of this is thought to be arising from the binding of the complex to cellular 
DNA.  However, even if strong evidence suggests this to be the case (bacterial data), no 
proof of in vivo DNA interactions or evidence of uptake into human cells had been 
observed. For this reason, studies about the uptake and cellular distribution of the triple 
stranded helicates were performed and are presented in this chapter. In addition, the 
relationship between DNA binding and cytotoxicity was probed by exploring the 
cytotoxicity of cylinders with surface modifications that will influence the DNA 
binding. 
 
4.1 Cellular toxicity 
The DNA binding capacities of our metallo-supramolecular complexes are related to 
the triple helicate ([Fe2L3]
4+
) structure. If the ability to inhibit the proliferation in cancer 
cells
24 
is linked to the interaction with the DNA we could reason that modification of 
this structure, since it affects the DNA binding, would lead to a change in cytotoxic 
 176 
properties. Complexes retaining similar shapes and structure, on the other hand, should 
maintain similar cytotoxicity. To examine this, the ruthenium (II) triple helicate 
([Ru2L3]
4+
) was tested against cell lines used previously for the iron derivative. In 
addition, the free ligand and FeCl2 were tested as well, to rule out the possibility that 
extra or intracellular degradation of the original iron complex could be the cause of the 
toxicity.    
Table 4.1. IC50 µM of iron and ruthenium cylinders against Breast and ovarian cancer cell lines. 
 HBL-100 T-47D SK-OV-3 A2780 A2780cr Rf[a] 
Ru Cylinder 22±2 53±5 Not active 72±3.3 152±4.3 2.1±0.1 
Fe Cylinder 27±5* 52±10* 35±5* ≈10& ≈12& ≈1.2& 
FeCl2(100 µM) 100% grow 90-95% grow 95-100 grow    
Parent ligand >300 >700 >400    
cisplatin 4.9±0.3 28±1.7 6±0.3 3±0.5 12.8±1.4 4.3±0.8 
* Data taken from A. C. G. Hozte, ref. 24. &Data taken from A. J. Pope, ref. 25. [a]Rf is increase in IC50 observed for 
a compound when tested in the cisplatin-resistant A2780cisR compared to A2780. 
Table 4.1 shows the results of these experiments. Immediately we can observe that 
the ruthenium cylinder possesses almost exactly the same activity as the iron cylinder in 
breast cancer cell lines (HBL-100 and T-47D). The inactivity of the free ligand and 
FeCl2, also rule out the possibility that the action is produced by the toxicity of the 
subproducts of the degradation of the complex. However, for the ovarian SK-OV-3 line, 
the ruthenium(II) derivative is not toxic, while the iron(II) compound is. This is 
probably the only difference between the two cylinders, and tells us that at certain levels 
(as seen for the DNA unwinding) the two complexes can show different actions 
(independent of its almost identical structure). To further study this, the ruthenium 
cylinder was tested against another ovarian cell line A2780, and its cisplatin resistant 
strand. Again low activity was observed for ruthenium while similar activity to cisplatin 
was observed for the iron cylinder. 
To explore whether other small modifications in the structure of the iron complex 
could produce big changes of activity in ovarian cell lines, surface-modified iron 
cylinders with small structural modifications (Fig. 4.4) were tested in the same A2780 
cell lines
26
. These complexes showed DNA binding abilities comparable with the non-
NH equivalent compounds ([Fe2(LNHD)3]
4+
 similar binding properties to the [Fe2L3]
4+
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with addition of methyl groups producing decrease in DNA binding affinities)
27
.  The 
results (Table 4.2) showed that the three complexes presented much higher toxicity than 
the [Ru2L3]
4+
 complex, with IC50 values similar to cisplatin and were more effective at 
overcoming resistance. Even more interestingly, the complex [Fe2(LNHD)3]
4+
, which 
has the most similar structure to the parent complex, showed identical activity. 
 
 
Figure 4.4. Structure of the ligands forming the different iron triple helicates (left) compared with the parent 
ligand (right). 
Table 4.2. Cell growth inhibition values (MTT assay) IC50 (µM) values of different iron triple stranded helicates 
against A2780 and A2780cr ovarian cancer cell lines. &Data taken from A. J. Pope, ref. 25. 
 A2780 A2780cr Rf 
[Fe2(LNHD)3
4+ 9.9±0.6 12.6±2.6 1.3±0.3 
[Fe2(LNH-5Me)3]
4+ 3.3±0.6 5±1 1.5±0.4 
[Fe2(LNHAc)3]
4+ 6.9±0.8 11±1 1.6±0.2 
Fe Cylinder ≈10& ≈12& ≈1.2& 
cisplatin 3±0.5 12.8±1.4 4.3±0.8 
 
In breast cancer cell lines, on the other hand, both ruthenium and iron triple helicates 
showed similar toxicity. This could indicate that in these cell lines the activity was 
H
N
NN
N N
H
N
NN
N N
H
N
NN
N N
LNHD 
LNH-5Me 
LNHAc 
NN
N N
L 
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mainly due to structural features. To study this, the activity of tetra-stranded palladium 
dinuclear ([Pd2L4]
4+
) (Fig. 4.5) complexes
28
 in breast cancer cell line T-47D was 
studied. These compounds are bigger than the [Fe2L3]
4+ 
cylinder, and their DNA 
binding properties are totally different
28
. Data in Table 4.3 show that they presented 
high activity in this cell line. Unfortunately one of them ([Pd2(LST)4]
4+
) was not 
sufficiently soluble in the required concentrations. However, for the other two 
complexes, a 6 fold improvement compared with cisplatin was observed, while the 
triple helicates were an order of magnitude less toxic.  
 
Figure 4.5. Structure of the ligands forming the different Pd tetrastranded complexes (left), crystal structure of 
[Pd2(LST)4]
4+ 28 and cell growth inhibition values (MTT assay) IC50 (µM) values against breast cancer cell line T-
47D. 
 
4.2 Cellular distribution 
While our working hypothesis is that cellular activity is related to the DNA binding, 
which will be dependent of the structure the complex, similar effects might be produced 
if the cylinder affects other macromolecules or organelles. To probe and understand 
this, it is important to know if the cylinders are taken up into the cell and where they are 
distributed once inside.  
Table 4.3. 
T-47D 
[Pd2(LS)4]
4+ 5.6±0.5 
[Pd2(LSO)4]
4+ 4.8±1.1 
[Pd2(LST)4]
4+ Not soluble enough 
cisplatin 28±1.7 
N N
N
O
N
N N
LS 
LSO 
LST 
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4.2.1 Propidium iodide displacement 
Previous Flow Cytometer analysis showed an increase in the number of apoptotic 
cells after treatment with the iron triple helicate
24
. When this was further investigated 
with dual propidium iodide (PI) and annexin-V (AV) staining (a technique that 
differenciates between early apoptotic and post-apoptotic cells), a decrease in the PI 
staining was observed in apoptotic cells treated with the complex
24
. PI is a fluorescent 
dye that increases its emission when bound to DNA. A decrease in PI DNA staining 
could suggest that it cannot bind to cellular DNA when the complex is present.  The 
observed decrease could therefore indicate the desired complex-DNA interaction on 
nuclear DNA. In order to see if this could be possible, a PI displacement assay was 
undertaken with free ct-DNA (Fig. 4.6). 
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Figure 4.6. Displacement of propidium iodide (1.5 μM) from ct-DNA (6 μM) by iron cylinder [Fe2L3]
4+. Mixing 
ratios Pi/cylinder are shown in the caption. λexc=535nm. (Normalized to the maximum of emission PI-DNA). 
Ct-DNA was loaded with PI, then aliquots of [Fe2L3]
4+
 added and the change in PI 
fluorescence monitored. As observed in Figure 4.6, the iron triple helicate can displace 
PI at very low concentrations (200-1 PI:complex). Such displacement has been observed 
before with other dyes (e.g. ethidium bromide)
13
, and indicates that the lower PI staining 
observed in the flow cytometry could indeed be due to our complex interacting with the 
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cellular DNA. Unfortunately, PI is not membrane permeable and can only enter 
apoptotic cells, which have big pores in their membrane. For that reason the observation 
does not inform on whether our helicate might have reached cellular DNA in healthy 
cells (causing apoptosis), or caused the apoptosis by a different mechanism and 
subsequently bound to the DNA of dead cells as the PI.  
4.2.2 Hoechst 33258 displacement 
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Figure 4.7. Displacement of Hoechst 33258 (1.5 μM) from ct-DNA (12 μM) by iron cylinder [Fe2L3]
4+(Left). 
Quenching of Hoechst 33258 by iron cylinder [Fe2L3]
4+(right). Mixing ratios Hoechst/cylinder are shown in the 
caption. λexc=350 nm. (Normalized to the maximum of emission Hoechst-DNA or Hoechst alone). 
nm
 
Figure 4.8. UV spectra of iron cylinder 15 µM (red), and Hoechst 33258 (black) and Hoechst 34580 (purple) 25 
µM. 
Hoechst 33258 is a nuclear staining agent that binds to the minor groove of the DNA 
and can penetrate the membrane and stain the nuclei of live cells
29-31
. When excited at 
350 nm it produces a fluorescent emission with the maximum at around 500 nm. This 
emission is increased upon binding to DNA, shifting the maximum approximately to 
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450 nm. Previous work showed that the iron cylinder could displace this molecule from 
naked DNA in vitro
13
. For that reason it looked like an interesting tool to see if our 
complexes could arrive at and bind to the nuclear DNA of live cells. When the 
experiment was repeated with the same conditions used for PI, displacement was 
observed as expected (Fig. 4.7). However, when the same experiment was measured in 
absence of DNA as a control, quenching of the Hoechst fluorescence was observed as 
well (Fig. 4.7).  
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Figure 4.9. UV titration of  Hoechst 33258 (15 µM) with iron cylinder in presence (top) or absence (middle) of 
DNA (120 µM) and decreasing ratios of emission at 450 nm and absorbance at 350 nm (bottom). Mixing ratios 
Hoechst/cylinder are shown in the caption. 
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This decrease in intensity was much bigger than the decrease observed when DNA 
was present (Fig. 4.7). We first thought that the fluorescence was quenched as a result 
of the iron cylinder band with maximum at 325 nm (Fig. 4.8) absorbing the energy 
provided for the excitation of the Hoechst molecules. However, when the same titration 
was followed by UV/VIS spectroscopy, we could observe a decrease in the absorbance 
band produced by the transition responsible of the fluorescence emmision (and others) 
similar to the decrease in fluorescence intensity observed previously (Fig. 4.9). Again 
this was stronger in the absence of DNA, but not visible in its presence. This indicated 
that somehow the DNA was protecting Hoechst 33258 from the quenching effect caused 
by the iron cylinder and the loss of fluorescence in this case was probably due to 
removal of the Hoechst from DNA.   
3.03.54.04.55.05.56.06.57.07.58.08.59.09.5
**
 
Figure 4.10. 1H NMR spectrum of iron cylinder (top), Hoechst 33258 (bottom) and mixture 1:1 of both (middle) 
in deuterated water (4.5 mM). * indicates a small percentage of complex hydrolysis. 
The fact that absorbance due to the Hoechst 33258 was disappearing during the 
titration was uncommon. Stranger was the observed reappearance of the bands 
belonging to the staining agent when a certain cylinder concentration was reached. This 
could only be explained if somehow there was a (weak?) chemical interaction between 
our iron cylinder and the Hoechst 33258, that would be stopped when enough cylinder 
to interact with themselves or the DNA were present. To explore this hypothesis, the 
NMR spectra of iron cylinder, Hoechst 33258 and of a 1:1 mixture of both were 
recorded (Fig. 4.10). Immediately we could see that the mixture produces a small shift 
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towards higher field in the signals from the free iron cylinder, and a big shift in the 
Hoechst protons. This indicated that there was interaction between both compounds and 
that the quenching was more due to chemical interaction than physical interferences (at 
least in absence of DNA).  
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Figure 4.11. UV titration of  Hoechst 34580 (15 µM) with iron cylinder in presence (top) or absence (middle) of 
DNA (120 µM) and decreasing ratios of emission at 450 nm (Hoechst 33258) and absorbance at 350 (Hoechst 33258) 
or 392 nm(Hoechst 34580) (bottom). Mixing ratios Hoechst/cylinder are shown in the caption. 
This was reinforced when a different nuclear dye from the same Hoechst family 
(Hoechst 34580, normally excited at 392 nm, a region were the iron cylinder have a 
window with low absorbance, between 390 and 410 nm; Fig. 4.8) suffered a similar UV 
absorbance quenching process (Fig. 4.11).  
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4.2.3 In vivo Hoechst 33258 displacement 
Despite these problems, we chose to continue to try and follow Hoechst displacement 
from cells. Matsuda et al have used Hoechst displacement to detect if a DNA binder 
could target nuclear DNA in vivo
32
. Cells were incubated with Hoechst 33258 for a time 
long enough to stain the cellular DNA. Then they were treated with the DNA binder for 
some time. If a decrease in the emission was observed, that meant that Hoechst was 
displaced and the compound could interact with cellular DNA. In our case, although 
cylinder can displace the dye from the DNA, this will be difficult to quantify due to the 
simultaneous quenching of free Hoechst molecules. For that reason the experiment will 
not tell us if our cylinder displaces Hoechst 33258 from cellular DNA, however, it can 
be used to observe uptake inside the cell. If, after treatment with our cylinder, the 
Hoechst emission decreases, it will tell us that the Hoechst emission is quenched or 
displaced, and our compound is therefore inside the cell. The cells used here were HL-
60, a myeloid leukemia cell line that grows in suspension. They were chosen because 
suspension growth makes easier the treatment and posterior recollection of the cells 
compared with adherent cell lines. 
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Figure 4.12. Fluorescence displacement assay for HL60 cells loaded with 10 µM Hoechst 33258 and then treated 
with varying concentrations of cylinder (concentrations indicated in the figure). λexc=350nm. (Normalized to the 
maximum of emission of cells untreated with cylinder) 
Figure 4.12 show the emission of Hoechst 33258 stained cells after treatment with 
different concentrations of iron cylinder. Immediately we can observe that the 
fluorescence coming from Hoechst decrease with the addition of cylinder and the 
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quenching of this emission seems to be dependent of the concentration of iron cylinder 
added (Fig. 4.13). As explained before, this means that the intracellular dye is been 
quenched by our complex, indicating that our compound is been taken up and that this 
uptake depends on the concentration of cylinder present in the medium.  
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Figure 4.13. Ratios of decreasing Hoechst 33258 fluorescence upon treatment with different concentrations of 
iron cylinder. 
4.2.4 Cellular uptake 
In order to explore uptake in a more rigorous manner, HL-60 cells were treated with 
drugs and uptake determined using ICP-MS. The iron cylinder, as the most interesting 
compound, and its ruthenium derivative (due to its similitude in structure and activity) 
were chosen, and cisplatin was used as a control. A short time of exposure (3 h) and a 
single concentration (50 µM)
33
 was used in order to determinate speed and efficiency of 
cell uptake for all the compounds, under the same conditions. Whole cell, cytoplasm 
(including mitochondria and the other organelles) and nucleic fractions were obtained 
from the same experiment to observe distribution through the cell. Uptake could be 
immediately observed by eye since the different fractions were coloured with the colour 
of the compound (red-brown for ruthenium cylinder; purple for iron cylinder. Fig. 4.14).  
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Figure 4.14. HL-60 whole cells (A) and nuclear fractions (B) after 3 h treatment with iron cylinder (purple), 
ruthenium cylinder (red-brown) and cisplatin (white)  
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Figure 4.15. pmols of Pt and Ru (as dinuclear) in HL-60 after 3hours of treatment with 50µM of the complexes. 
Iron cylinder (nmol/106 cells): 1.93 whole cells, 0.2 cytoplasm, 0.68 nuclei. 
Unfortunately the high background of iron in the cell did not allow us to get reliable 
data from the iron cylinder (see Fig. 4.15 caption for an example value). However, 
uptake data of ruthenium and platinum were obtained for cells treated with cisplatin and 
ruthenium cylinder (Fig. 4.15). Cisplatin was found in similar concentrations to these 
observed previously
34
 (and chapters 2.2.5 and 3.3.2), showing that most of the drug 
stays in the cytoplasm, and just one third of the platinum arrives at the nuclei (at this 
time point). However, the ruthenium cylinder was taken up 4 times more than cisplatin. 
The compound does not get stuck in the membrane as more than 80% of the compound 
is found in the cytoplasm or nucleus, and only 15% stays in the cytoplasm (against the 
A B 
 187 
two thirds of cisplatin). Over 60% of the ruthenium cylinder taken up into the cell is 
found to be in the nuclei (much higher than for cisplatin).  
If cellular volume is known, intracellular concentration can be calculated. This data 
is interesting because it can give us preliminary information about how our compound is 
taken up. If the compound is found in higher concentration than the original treatment 
solution, it can be indicative of an active uptake mechanism or binding to a cellular 
target. Lower or similar concentrations to the initial medium could indicate passive 
transport or not equilibrium reached. Two different volume values are found in the 
literature for HL-60 cells, 0.7 pl/cell
35
 (2005) or 0.05 pl/cell
36
 (1983). When the second 
value is used, internal concentrations of 3 mM and 0.75 mM for the ruthenium cylinder 
and cisplatin respectively are found. These high values would mean that in times as 
short as 3 hours our cylinder is concentrated inside the cell 60 times and cisplatin 15, 
making the calculations hard to believe. Using 0.7 pl/cell concentrations of 213.3 µM 
for the ruthenium cylinder (4 times more concentrated than the 50 µM of the treatment 
medium) and 53.4 µM for cisplatin are found. These values are more understandable 
(and similar to previous data presented for ruthenium(II) polypyridyl complexes in 
HeLa cells
37
) and could indicate that the cylinder is concentrated inside the cell (maybe 
due to active transport) while cisplatin is not (probably due to its passive transport). 
These experiments prove that the cylinders enter the cell, and arrive in contact with or 
close to cellular DNA (a similar conclusion could be reached for the iron derivative. 
Figure caption from Fig. 4.15).  
4.2.5 Single cell electrophoresis for detection of DNA strand breaks (Comet 
assay) 
As previously described, the ruthenium cylinder has the ability to act as a nuclease 
when irradiated with UV or Vis light
22
. In order to reinforce the previous experiment 
and establish whether this cylinder can interact with the nuclear DNA, HL-60 cells were 
treated with the ruthenium helicate for one hour (at the same concentration used for 
uptake experiments: 50µM). Then, some of the cells were illuminated with visible light 
using a 250 W halogen lamp giving out white light for 10 minutes, to see if our 
ruthenium cylinder could cleave the DNA under cellular conditions. Cisplatin was used 
as a control. To detect strand breaks we used the comet assay. The cells were collected 
and the nuclei isolated. These nuclei were studied with normal electrophoretic 
techniques; this will show any damaged DNA as a tail flowing out of the nuclei and 
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allow us to quantify the damage produced to the cellular DNA (as % of DNA in the 
tail)
38
. This is an increasingly used (and recognised) assay for genotoxicity. The results 
can be observed in Table 4.4 and Fig. 4.16. 
Table 4.4. % tail-DNA indicative of DNA strand breaks after 1h treatment with 50 µM of the complexes. With and 
without light irradiation. 
 No-Light Light 
Ruthenium cylinder 2.9±2 47.2±4.9 
Cisplatin 0.7±0.5 24±1 
Untreated 0.5±0.1 28±3.3 
Cisplatin did not affect the DNA more after radiation with light than seen in the 
untreated cells. However, when the cells were treated with ruthenium cylinder and 
irradiated doubled the amount of DNA damaged compared with the illuminated 
controls. In times as short as 1 hour the ruthenium cylinder can be taken up into the 
nuclei and interact with DNA and in the presence of light cleave it. 
 
Figure 4.16. Image of HL-60 nuclei treated with 50µM ruthenium cylinder for 1h with (B) and without light 
irradiation (A). 
4.2.6 Microscopy cell distribution 
Another property of the ruthenium cylinder is that it produces a fluorescence 
emission when excited in the MLCT region. The maximum wavelength for this 
excitation is at 480 nm producing a broad emission band between 600 and 800 nm with 
a maximum at around 700 nm
21
. We decided to use this property to follow cellular 
uptake and localisation. Adherent cell line T-47D (breast) was treated with the 
ruthenium complex under the same conditions used for the ICPMS uptake experiment 
A B 
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(50 µM for 3 hours), knowing that in this time the complex is internalized and arrives in 
large quantities to the nuclei. Treated cells were then visualized under a confocal 
microscope, exciting the cells with an Argon laser (λex=488 nm). The first question was 
whether our compound could be detected, as its emission is not very strong. Beyond that 
we were interested to see where the ruthenium cylinder would be concentrated or 
observed in live cells. Fig. 4.17 shows some of the images taken from this experiment.  
A B
C D
 
Figure 4.17. Confocal microscopy image under Argon laser (488 nm) or with light of cells treated (A or C) and 
untreated (B or D) with 50 µM ruthenium cylinder.  
In the pictures (Fig. 4.17A) the ruthenium cylinder can be observed in the cells. 
When a control without complex was studied under the same conditions no comparable 
(auto)fluorescence was observed (Fig. 4.17B). The confocal images allow us to confirm 
that the compound is in the cell, not merely on the membrane. We can see that the 
complex is distributed through the whole cell at this time point, but is more 
concentrated in some circular corpuscles. Small really intense dots can be observed as 
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well. We can speculate that the big circular corpuscles are nuclei and the small dots 
endosomes, but further studies are required using nuclear, endocytosis or other markers 
to confirm this. 
 
4.3 Conclusions 
As observed previously the iron cylinder has cytotoxic activity
24
. This is not unique 
to this compound but a feature of the class and the structurally similar iron and 
ruthenium compounds show similar toxicities. However, size and shape are not the only 
factors involved in their anticancer properties, as observed by the fact that the ruthenium 
cylinder doesn’t show activity in ovarian cell lines and the iron one does. Since the size 
and shape are important for DNA binding
13, 15, 21-22
, the possible relation between the 
toxicity and the structure of the complexes could indicate that their cytotoxic properties 
could depend of the interaction between the metallo-cylinders and the DNA.  
To probe the potential link between DNA binding and toxicity, uptake and cellular 
distribution of the cylinders were studied. The complexes showed the ability to quench 
Hoechst 33258 emission inside cells, suggesting that they could be taken up. ICP-MS 
studies showed that the cylinders can cross the membrane arriving in relative short 
times at the nuclei. The amount of compound that arrives there is very high compared 
with cisplatin, showing that more than 60% of uptaken cylinders arrive at the nuclei 
compared to less than 30% of cisplatin. Remarkably our compound was concentrated in 
the nuclei, arriving in large quantities close to the cellular DNA. When cells preloaded 
with ruthenium cylinder were irradiated with visible light, they presented a high 
percentage of DNA strand breaks compared with untreated and cisplatin controls. This 
could be considered as the in vivo equivalent of the in vitro DNA photocleavage activity 
observed for the same complex
22
, showing that the same or similar effects observed in 
vitro could be present in vivo. Finally, confocal microscopy showed us that the 
fluorescent emission of the ruthenium cylinder can be observed inside live cells. 
Although no detailed information was obtained, it can be an important tool for the study 
of accumulation and transport process in the future.  
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Summarizing, our metallo-supramolecular cylinders can be taken up in live cells, 
being accumulated in the nuclei. There, the complexes can interact with DNA, being the 
probable cause of their final cytotoxic activity. 
 
4.4 Experimental 
Cell test: Tissue culture flasks, 96-well plates, RPMI 1640, DMEM, L-glutamine, 
trypsin-EDTA, HEPES, sodium pyruvate and FBS were obtained from Invitrogen.  
Thiazolyl blue tetrazolium bromide (MTT) and DMSO were from Sigma, UK. Tissue 
culture flasks, 96 well plates, RPMI 1640, DMEM, L-glutamine, trypsin-EDTA, HEPES, 
sodium pyruvate and FBS were obtained from Sigma, UK.  Thiazolyl blue tetrazolium 
bromide (MTT) and DMSO were from Avocado, UK.  Cells were grown in RPMI 1640 
(HBL-100, T-47D, SK-OV-3) or DMEM (A2780/cr) in 10 % FBS supplemented with 1% 
L-glutamine, 1% HEPES buffer and 1% sodium pyruvate. The MTT assay
39
 was carried 
out using 96 well plates.  Cells were harvested in logarithmic growth, 4,000 (A2780/cr), 
10,000 (SK-OV-3, HBL-100) or 25,000 cells (T-47D) were seeded per well and left 
overnight to attach.  The cells were treated, in quadruplicate with 6 difference 
concentrations of complex dissolved in fresh media; the range of concentrations used is 
dependent on the complex.  The cells were incubated for 72 hours and 20 μl of thaizolyl 
blue tetrazolium bromide (5mg / ml, 0.2 μm filtered) added.  The cells were further 
incubated for 2 hours.  The media was carefully removed by aspiration and 200 μl of 
DMSO added to dissolve the purple crystals.  Absorbance was measured using a 96-well 
plate reader (BioRad) set at 590 nm.  Each cell line was investigated beforehand to 
determine the correct cell numbers to initially seed and the required amount of time 
exposed to thiazolyl blue tetrazolium bromide to ensure sensitivity and accuracy. 
 
Propidium Iodide displacement:The fluorescence spectra for the propidium iodide 
(PI) displacement experiment were recorded in a Shimadzu RF-5301 PC Fluorescence 
Spectrophotometer (λexc = 535 nm; Range emission = 580-800 nm; resolution = 0.4 nm; 
Speed medium; Excitation split = 10; Emmision split = 1.5). Solutions of PI (15 or 1.5 
µM), ct-DNA (12, 1.2 or 6 µM), NaCl (50 mM) and sodium cacodylate buffer (1 mM) 
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were prepared, measured and tritiated with iron parent cylinder from ratios PI:iron 
cylinder 200-1 to 4-1, keeping the concentration of PI and ct-DNA constant. 
 
Hoechst 33258 displacement: The fluorescence spectra for the Hoechst 33258 
(Hoechst) displacement experiment were recorded in a Shimadzu RF-5301 PC 
Fluorescence Spectrophotometer (λexc = 350 nm; Range emission = 400-600 nm; 
resolution = 0.4 nm; Speed medium; Excitation split = 5; Emmision split = 1.5). 
Solutions of Hoechst (1.5 µM), ct-DNA (12 µM), NaCl (50 mM) and sodium 
cacodylate buffer (1 mM) were prepared, measured and tritated with the different 
complexes from ratios Hoechst:complex 200-1 to 4-1, keeping the concentration of 
Hoechst and ct-DNA constant. 
 
Hoechst 33258 cellular displacement assay: The cellular displacement assay of 
Hoechst 33258 was done following the procedure described in Matsuba et al
31
.  
Fluorescence spectra were recorded in a PTIA fluorescence system. The illumination 
source was a PTI L-201M source using a 75W Xenon arc lamp. The detection system a 
Shimadzu R298 PMT in a PTI model analogue/photon-counting photomultiplier (λexc = 
350 nm; Range emission = 380-600 nm; speed = 3nm/s; Excitation split = 5; Emission 
split = 1.5). 50000 HL-60 cells were preincubated with 10 µM Hoechst 33258 in 0.5 ml 
culture medium RPMI 1640 (supplemented as explained before) at 37ºC for 20 min. 
The iron cylinder was then added (concentrations between 0.1 and 100 µM) followed by 
a further 20 min incubation at 37ºC. Cells were then collected, washed once with chilled 
PBS, resuspended in chilled PBS and the fluorescence measured.  
 
Cellular Uptake: Four million HL-60 cells were seeded in 100 mm diameter Petri 
dishes (medium used RPMI 1640 supplemented as explained before) and treated with 50 
µM of the different compounds for 3 hours. After that time, the medium was removed and 
cells washed three times with PBS to remove all the unwanted (non uptaked) complexes. 
Cells were collected and two aliquots of two million cells were taken, one of them to see 
whole cell uptake and the other for cytoplasm and nuclei fraction extraction 
(Nuclear/Cytoplasm extraction kit. BioVision). Two ml of ultrapure concentrated Nitric 
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Acid (Traceselect Ultra, Aldrich) was added to the samples, and digested overnight at 
90ºC. Samples were then taken to dryness at 120ºC, resuspended in 3ml of a 2% solution 
of Nitric acid and filtered. The amount of Platinum was measured in a Agilent 7500CX 
ICP-MS (analysis was done with Pt sample cone in He and No-gas mode. Plasma 
settings: Ar.flow: 15 L/min; Neb gas: 0.8 L/min; RF power 1550W; T of spray chamber: 
15 º C). 
 
Comet Assay for DNA strand breaks: This method was based on that of Singh et al
40
, 
as modified in Prof. Chipman’s laboratory41. 100000 HL-60 cells were incubated with 50 
µM Hoechst 33258 in 1 ml in supplemented phenol red-free RPMI 1640 culture medium 
for 1 hour in the dark (wrapped in silver foil). Pre-treated cells were placed on ice and 
exposed to visible light from a 250 W halogen lamp (Philips, U.K.), at a distance of 19 
cm. 10 minutes of  illumination corresponded to 111 kJ/m
2
 between 400 and 800 nm, 
equivalent to 9.3 kJ/m
2
 between 400 and 500 nm. Cells were collected and washed in cold 
PBS. Then, cells were centrifuged (200 x g, 5 min) and pellets re-suspended in PBS (150 
μl). An aliquot of re-suspended cells (15 μl) was placed into a sterile tube containing low 
melting point agarose (150 μl) and this cell suspension transferred to a glass microscope 
slide (150 μl per slide, BDH, U.K.), pre-coated with 0.5 % normal melting point agarose. 
Glass coverslips (BDH, U.K.) were added and slides placed on a metal tray over ice for 
10 min. Coverslips were removed and slides incubated for 1 h at 4 °C in lysis buffer (2.5 
M NaCl, 0.1 M Na2EDTA, 10 mM Tris base, 1 % sodium N - lauryl sarcosinate, 10 % 
DMSO and1 % Triton X-100). Following lysis slides were transferred to a horizontal 
electrophoresis tank (Pharmacia Biotech, U.S.A.) containing electrophoresis buffer (75 
mM NaOH and 1 mM Na2EDTA, pH approximately12.8) and DNA allowed to unwind 
for 10 min. DNA was subjected to electrophoresis (25 V, 0.8 Vcm
-1
, 10 min) and slides 
neutralised by washing (3 x 5 min) with neutralisation buffer (0.4 M Tris, adjusted to pH 
7.5). Slides were subsequently stained with Sybr Gold 50 μl (Invitrogen, 10 x solution). 
The slides were examined at 320 x magnification using a fluorescence microscope (Zeiss 
Axiovert 10, Germany), fitted with a 515 - 560 nm excitation filter and a barrier filter of 
590 nm. A USB digital camera (Merlin, Allied Vision Technologies) received the images, 
which were analysed using a personal computer-based image analysis system Comet 
assay IV (Perceptive instruments). Images of one hundred randomly selected nuclei were 
analyzed per slide.  
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Measurement of percent tail DNA (TD %) was chosen to assess the extent of DNA 
damage as this has been shown to suffer much less from inter-run variation than other 
comet parameters because it is independent of electrophoresis voltage and run time
38
. 
Median values of three separate experiments were analysed using ANOVA and post-hoc 
Student's t-test, as recommended by Duez et al
42
. 
 
Cellular Imaging: 500000 T-47D cells were seeded in 30 mm diameter Petri dishes 
with glass bottom and left overnight to attach. The cells were treated then with 50 µM 
of the ruthenium cylinder for 3 hours. After that time, the medium was removed and the 
cells washed three times with PBS to remove all the unwanted (non uptaked) 
complexes. The resulting cells were observed through a Leica DMIRE2 system with an 
Argon laser (operated at 488 nm) and a temperature control chamber (operated at 37 ºC) 
attached. 
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Chapter 5: Conclusions and Future Work 
 
5.1 Conclusions 
The work described in this thesis has been directed by two questions: how the use of 
steroids as delivery vectors affects the anticancer properties of different metallodrugs, 
and whether active anticancer metallosupramolecular cylinders previously synthesised 
(and which present interesting DNA interaction properties) could act through structural 
interaction with cellular DNA. Herein we showed experiments that tried to address 
these questions. 
In Chapters 2 and 3 the use of improved and new synthesis and purification routes 
allowed us to obtain in good yields a series of new and previously reported steroidal 
(estradiol and testosterone) metallodrugs (both DNA covalent and non-covalent 
binders), aiming to target their receptors (ER or AR). The procedures were quick and 
simple with standardised purification through HPLC techniques.  
Chapter 2 focused on the study of the steroidal covalent DNA-binders. The 
cytotoxicity assays of these complexes showed that the coupling of a steroid to a DNA 
covalent-binding complex conferred activity to the otherwise non-active non-steroidal 
analogues. This activity was not the result of the known cell sensitisation to platinum 
drugs that steroids induce (as shown by Lippard
1
) or the biological activity of the 
steroidal ligands used, as the performed cytotoxicity assays showed. Increase of the 
cellular uptake of the complexes upon steroid coupling was not the origin of this new 
activity either; ICP-MS experiments showed that the attachment of the steroid decreased 
the amount of complex taken up by the cells in short times. However, coupling to the 
steroid helped the complexes to cross the cellular membrane (compared with the non-
steroidal equivalents) and modified the cellular distribution; concentrating the 
complexes in the cytoplasm (showing a cytoplasm:nuclei ratio of 3:1 against 1:1 
distribution for the non-steroidal analogues).  
More remarkably, steroidal coupled compounds produced a dramatic modification of 
the mode of binding to DNA, as demonstrated by the CD (performed with ct-DNA) and 
MS and NMR (performed with mononucleotides, and that could explain the observed 
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difference in activity between cis and trans isomers) experiments herein presented and 
some previous experiments
2-5
. 
Chapter 3 studied the steroidal non-covalent metallodrugs, showing that the coupling 
of a steroidal moiety to intercalative metallodrugs produced a decrease of the anticancer 
properties of the complexes (compared with active non-steroidal analogues). This 
difference in activity was not the result of the effect on the cellular uptake; the steroidal 
complexes were not taken up by cells less when compared with the non-steroidal 
analogues, as ICP-MS experiments showed. As seen for the steroidal DNA covalent-
binding metallodrugs, the steroids again concentrated the complexes in the cytoplasm, 
showing a cytoplasm:nuclei ratio of 3:1 against a 1:1 distribution for the non-steroidal 
analogues. The ability to intercalate between the bases of ct-DNA was found to be of 
high importance for activity, as the cytoxicity decreased dramatically in complexes 
where the access to the intercalating terpyridine was hindered. LD and DNA 
fluorescence titrations proved that these hindered complexes did not show intercalating 
properties, while the compounds showing anticancer activity did (both steroidal and 
non-steroidal). The fact that the anticancer activity was produced by the intercalation of 
the platinum(II) terpyridine moiety would explain the decrease in activity when a 
steroid is coupled, as  Ethidium Bromide (EB) displacement assays showed lower 
binding affinities for steroidal complexes compared with the non-steroidal analogue.  
Concluding, we can say that the unprecedented effects observed in the anticancer 
activity (decrease or dramatic increase) upon attachment of steroid moieties to 
metallodrugs are related to the changes that this steroid molecule produce in their DNA-
binding properties. Steroidal covalent DNA-binders produce dramatic structural 
changes in the double helix as a result of the necessity to accommodate the bulk of the 
steroid (improving the cytotoxic properties of the non-steroidal complexes), while 
DNA-intercalating metallodrugs suffer a decrease in their DNA binding affinity when a 
steroid is attached (being a drawback for their anticancer abilities). 
In Chapter 4 the biological activity of iron(II) and ruthenium(II) 
metallosupramolecular cylinders were studied
24
. Both are known to show similar DNA-
binding properties, due to their almost identical size and structural shape
6-7
. When their 
cytotoxicity was studied, they presented almost identical activity against breast cancer 
cell lines, perhaps suggesting that the compounds could act through DNA interaction. 
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However, size and shape proved to be not the only factors involved in their anticancer 
properties, as observed by the fact that the ruthenium cylinder did not show activity in 
ovarian cell lines and the iron one did. Both complexes showed, also, the ability to go 
across the cellular membrane. Iron cylinders quenched the emission of intracellular 
Hoechst 33258 in HL-60 leukaemia cells, while the presence of the ruthenium complex 
inside the cell was proved by confocal fluorescence microscopy in T-47D breast cancer 
cell line. ICP-MS uptake experiments of the performed in HL-60 cell line also showed 
that surprisingly, the ruthenium cylinders were not only taken up but concentrated 
inside the cells, being mainly found in the nuclei. Once in the nuclei, the ruthenium 
compound could interact with cellular DNA; cells pre-treated with ruthenium cylinder 
showed an increase in the DNA breaks after irradiation with white light.  
In summary, the metallo-supramolecular cylinders can be taken up in live cells, and 
are accumulated in the nuclei. There, the complexes can interact with DNA, and this is 
the probable cause of their ultimate cytotoxic activity. 
 
5.2 Future work  
Although the work in this thesis much has been learnt about the design principles and 
activities through, this new knowledge brings new possibilities and raises new questions 
to be addressed. Further experiments should be taken in consideration to better 
understand how the complexes presented in this thesis work and behave in full 
organisms. For steroidal complexes information about cytoxicity in prostate and 
testicular cancers would be interesting, since testosterone and its receptor play an 
important role in these types of cancers. Work in more ordered systems presenting cells 
both with and without high quantity of steroidal receptors is desired as well, to know if 
they are really capable to fulfil their target (specificity for reproductive cancer cells 
over-expressing ER or AR). The initial studies herein showed that they do not posses 
significantly different cytotoxicity towards isolated cell lines over-expressing or not 
their receptors. However, uptake experiments show that although they are not more 
active for steroid dependent cancer types, they can be internalized better in those cells 
(compared to the ones not over-expressing their receptors).  
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Steroidal complexes can interact with proteins, although the presence of the metallic 
centre alters this ability. This should be further studied and interaction with their 
receptors and other steroid-related proteins (such metabolic and transport proteins) 
would be needed to better understand how the complexes would behave inside the body.  
Finally, the different distribution, uptake and mechanism of action of 
metallosupramolecular cylinders in different cell lines would need to be further studied. 
This could confirm if they are taken up through an active transport process, where they 
accumulate and why they show different anticancer activity against certain cell lines. 
 Figure 5.1. New Non-covalent steroidal designs for a farther DNA-steroid interaction(A) and aiming telomeric G-
quadruplexes (B). 
The coupling of steroids to coordination complexes has proven to be a very 
interesting mode of targeting metallodrugs, showing unexpected effects in their 
cytotoxicity and mode of action (both positives and negatives). This makes the design of 
new complexes that further explore targeting through steroidal coupling desired. For 
non-covalent DNA-binding metallodrugs, steroids proved to be a drawback in their 
cytotoxicity and DNA-binding abilities, probably because the steroid hindered the 
intercalation of the terpyridine moiety between the DNA bases. To overcome this 
negative effect one could synthesise complexes where the steroid is further away from 
the terpyridine unit, maybe allowing an easier intercalation with the DNA (Fig. 5.1 A). 
A different approach would be the use of extended planar terpyridines aiming not for 
intercalation between the bases of the DNA but the interaction with telomeric G-
quadruplexes
8
 (Fig. 5.1 B).  
 202 
 
 
Figure 5.2. New covalent steroidal designs with acetate leaving groups for higher solubility (A), using Click 
chemistry (B) and using bidentate ligands (C). 
New designs of DNA-covalent binders could help to address the low solubility of the 
steroidal complexes, to explore structures with different orientations or create 
bifunctional complexes (Fig. 5.2). Substitution of the Cl for an acetate leaving group 
should increase the water solubility, as observed previously for non-steroidal 
platinum(II) complexes
9
 (Fig. 5.2 A). Bidentate ligands could provide an easier 
possibility to produce bifunctional complexes (as cisplatin, transplatin and analogues) 
compared with other failed approaches tried previously
2-3
 (Fig. 5.2 C). Use of tools as 
the “Click” chemistry could help to produce easily steroidal ligands and complexes that 
would bind to DNA with different orientations, compared with the ethynyl derived 
compounds used herein. 
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  All these would be exciting possibilities to drive this work forward to create more 
compounds that could be specifically delivered directly to the location of a selected 
tumour. 
 
5.3 References 
1  Q. He, C. H. Liang, S. J. Lippard, Proc. Natl. Acad. Sci, 2000, 97, 5768. 
2  Martin Huxley, PhD Thesis, University of Warwick, 2006. 
3 Michael Browning, PhD Thesis, University of Warwick, 2006. 
4  M. Huxley, C. Sanchez-Cano, M. J. Browning, C. Navarro-Ranninger, A. G. 
Quiroga, A. Rodger, M. J. Hannon, To be submitted. 
5  M. Huxley, C. Sanchez-Cano, M. J. Browning, C. Navarro-Ranninger, A. G. 
Quiroga, A. Rodger, M. J. Hannon, To be submitted.  
6  G. I. Pascu, A. C. G. Hotze, C. Sanchez Cano, B. M. Kariuki, M. J. Hannon, 
Angew. Chem. Intl. Ed., 2007, 46, 4374. 
7   M. J. Hannon, V. Moreno, M. J. Prieto, E. Molderheim, E. Sletten, I. 
Meistermann, C. J. Isaac, K. J. Sanders, A. Rodger, Angew. Chem. Int. Ed., 2001, 40, 
879. 
8  D.-L. Ma, C.-M. Che, S-C. Yan, J. Am. Chem. Soc., 2009, 131, 1835. 
9  A. G. Quiroga, J. M. Perez, C. Alonso, C. Navarro-Ranninger, N. Farrell, J. Med. 
Chem., 2006, 49, 224.   
 
 
 
 
 
 
 
 
 
 
 204 
Appendix A 
 
      Table 1.  Crystal data and structure refinement for Di-17-α-Ethynyl-Estradiol. 
Empirical formula    C52 H74 N4 O8 
Formula weight     883.15 
Temperature     296(2) K 
Wavelength     1.54178 Å 
Crystal system, space group   Orthorhombic,   P212121 
Unit cell dimensions     a = 7.0012(16) Å   alpha = 90 deg. 
                                       b = 22.481(5) Å     beta = 90 deg. 
                                        c = 31.946(7) Å    gamma = 90 deg. 
Volume                              5028(2) Å
3
 
Z, Calculated density              4,    1.167 Mg/m
3
 
Absorption coefficient             0.624 mm
-1
 
F(000)                              1912 
Crystal size                        0.50 x 0.40 x 0.40 mm 
Theta range for data collection    2.40 to 66.01 deg. 
Limiting indices                    -8<=h<=8, -25<=k<=25, -37<=l<=35 
Reflections collected / unique     32263 / 8345 [R(int) = 0.0962] 
Completeness to theta = 66.01      97.9 % 
Max. and min. transmission         0.7883 and 0.7454 
Refinement method                  Full-matrix least-squares on F^2 
Data / restraints / parameters     8345 / 3 / 577 
Goodness-of-fit on F
2
            1.072 
Final R indices [I>2sigma(I)]      R1 = 0.0913,  wR2 = 0.2362 
R indices (all data)               R1 = 0.1252,   wR2 = 0.2650 
Absolute structure parameter       -0.2(5) 
Largest diff. peak and hole        0.578 and -0.273 e. Å
-3
 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (A2 x 103) for Di-17-α-
Ethynyl-Estradiol. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
______________________________________________ 
                      x                 y                  z               U(eq) 
______________________________________________ 
C(1)        10647(9)       3885(3)       3728(2)       60(1) 
C(2)         8934(9)       3614(2)       3669(2)       58(1) 
C(3)         7928(7)       3667(2)       3294(2)       50(1) 
C(4)         8634(7)       4016(2)       2966(1)       44(1) 
C(5)        10391(8)       4295(2)       3040(2)       57(1) 
C(6)        11374(8)       4241(3)       3414(2)       60(1) 
C(7)         5997(7)       3348(2)       3252(2)       53(1) 
C(8)         4938(7)       3465(2)       2849(2)       52(1) 
C(9)         6269(6)       3539(2)       2480(1)       41(1) 
C(10)        7573(7)       4082(2)       2553(2)       42(1) 
C(11)        8864(7)       4208(2)       2175(2)       48(1) 
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C(12)        7743(7)       4267(2)       1770(2)       45(1) 
C(13)        6461(6)       3729(2)       1687(1)       38(1) 
C(14)        5190(6)       3632(2)       2073(1)       39(1) 
C(15)        3737(7)       3159(2)       1931(2)       52(1) 
C(16)        3474(7)       3291(2)       1459(2)       50(1) 
C(17)        4890(7)       3806(2)       1346(1)       42(1) 
C(18)        7690(7)       3178(2)       1581(2)       55(1) 
C(19)       -5830(8)       6212(3)       3739(2)       59(1) 
C(20)       -4153(8)       6512(2)       3688(2)       54(1) 
C(21)       -3041(7)       6462(2)       3328(2)       46(1) 
C(22)       -3665(7)       6093(2)       3001(1)       44(1) 
C(23)       -5405(8)       5784(2)       3070(2)       52(1) 
C(24)       -6435(8)       5826(3)       3426(2)       58(1) 
C(25)       -1143(7)       6788(2)       3306(2)       49(1) 
C(26)         -28(7)       6681(2)       2905(2)       53(1) 
C(27)       -1316(7)       6599(2)       2528(1)       41(1) 
C(28)       -2560(7)       6040(2)       2597(1)       43(1) 
C(29)       -3805(7)       5901(2)       2213(2)       50(1) 
C(30)       -2663(7)       5872(2)       1810(2)       47(1) 
C(31)       -1458(6)       6428(2)       1743(1)       38(1) 
C(32)        -196(6)       6532(2)       2126(1)       38(1) 
C(33)        1208(7)       7019(2)       1985(2)       49(1) 
C(34)        1444(7)       6914(2)       1512(2)       48(1) 
C(35)          88(7)       6396(2)       1396(1)       41(1) 
C(36)       -2761(8)       6954(2)       1645(2)       56(1) 
C(37)        1134(7)       5829(2)       1409(1)       44(1) 
C(38)        2054(7)       5370(2)       1410(1)       43(1) 
C(39)        3057(7)       4844(2)       1395(1)       45(1) 
C(40)        3901(7)       4382(2)       1374(1)       43(1) 
O(1)        11524(7)       3812(2)       4110(1)       87(1) 
O(2)         5530(5)       3706(2)        927(1)       53(1) 
O(3)         -696(6)       6445(2)        989(1)       59(1) 
O(4)        -6940(7)       6260(2)       4092(1)       88(1) 
C(41)        8920(16)      5303(3)       4026(3)      119(3) 
C(42)        8033(18)      4726(6)       4654(3)      165(5) 
C(43)        6052(14)      4706(4)       4058(3)       98(2) 
C(44)        1905(16)      5421(4)        319(3)      115(3) 
C(45)        1800(30)      4384(5)        164(5)      242(10) 
C(46)        -776(16)      4869(5)        572(2)      125(4) 
C(47)        5430(20)      6725(5)        271(5)      217(8) 
C(48)        5530(20)      7680(5)        540(4)      164(5) 
C(49)        5314(18)      7404(4)       -209(2)      291(13) 
C(50)        5819(12)      3390(3)       -191(3)       95(2) 
C(51)        5570(14)      2384(4)       -503(2)       99(2) 
C(52)        5642(10)      2507(3)        248(2)       74(2) 
N(1)         7532(8)       4907(3)       4250(2)       84(2) 
N(2)          802(10)      4880(2)        356(2)       87(2) 
N(3)         5451(9)       7342(3)        200(2)       90(2) 
N(4)         5622(8)       2736(2)       -134(2)       69(1) 
O(5)         4862(11)      4378(4)       4226(2)      137(2) 
O(6)        -1753(18)      4409(6)        607(2)      278(8) 
O(7)         5683(12)      7862(5)       -392(2)      205(5) 
O(8)         5565(9)       1972(2)        313(2)       98(2) 
_____________________________________________ 
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Table 3.  Bond lengths [A] and angles [deg] for Di-17-α-Ethynyl-Estradiol. 
__________________________ 
C(1)-C(2)                     1.358(8) 
C(1)-O(1)                     1.376(7) 
C(1)-C(6)                     1.379(8) 
C(2)-C(3)                     1.394(7) 
C(3)-C(4)                     1.398(7) 
C(3)-C(7)                     1.537(7) 
C(4)-C(5)                     1.402(7) 
C(4)-C(10)                    1.521(7) 
C(5)-C(6)                     1.385(8) 
C(7)-C(8)                     1.509(7) 
C(8)-C(9)                     1.510(7) 
C(9)-C(14)                    1.518(6) 
C(9)-C(10)                    1.541(6) 
C(10)-C(11)                   1.535(7) 
C(11)-C(12)                   1.520(7) 
C(12)-C(13)                   1.528(6) 
C(13)-C(14)                   1.537(6) 
C(13)-C(18)                   1.546(6) 
C(13)-C(17)                   1.558(7) 
C(14)-C(15)                   1.540(6) 
C(15)-C(16)                   1.547(7) 
C(16)-C(17)                   1.565(7) 
C(17)-O(2)                    1.430(5) 
C(17)-C(40)                   1.471(6) 
C(19)-C(20)                   1.364(8) 
C(19)-O(4)                    1.374(7) 
C(19)-C(24)                   1.392(8) 
C(20)-C(21)                   1.394(7) 
C(21)-C(22)                   1.404(7) 
C(21)-C(25)                   1.519(7) 
C(22)-C(23)                   1.419(7) 
C(22)-C(28)                   1.509(7) 
C(23)-C(24)                   1.349(7) 
C(25)-C(26)                   1.521(7) 
C(26)-C(27)                   1.514(7) 
C(27)-C(32)                   1.512(6) 
C(27)-C(28)                   1.544(7) 
C(28)-C(29)                   1.538(7) 
C(29)-C(30)                   1.517(7) 
C(30)-C(31)                   1.523(6) 
C(31)-C(36)                   1.525(6) 
C(31)-C(32)                   1.529(6) 
C(31)-C(35)                   1.549(6) 
C(32)-C(33)                   1.539(6) 
C(33)-C(34)                   1.536(7) 
C(34)-C(35)                   1.547(6) 
C(35)-O(3)                    1.417(5) 
C(35)-C(37)                   1.471(6) 
C(37)-C(38)                   1.215(6) 
C(38)-C(39)                   1.377(7) 
C(39)-C(40)                   1.197(6) 
C(41)-N(1)                    1.499(10) 
C(42)-N(1)                    1.397(12) 
C(43)-O(5)                    1.236(10) 
C(43)-N(1)                    1.286(10) 
C(44)-N(2)                    1.445(9) 
C(45)-N(2)                    1.453(11) 
C(46)-O(6)                    1.245(11) 
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C(46)-N(2)                    1.302(11) 
C(47)-N(3)                    1.406(12) 
C(48)-N(3)                    1.324(11) 
C(49)-O(7)                    1.2097(11) 
C(49)-N(3)                    1.3193(11) 
C(50)-N(4)                    1.488(8) 
C(51)-N(4)                    1.419(8) 
C(52)-O(8)                    1.222(7) 
C(52)-N(4)                    1.325(7) 
 
C(2)-C(1)-O(1)              117.6(6) 
C(2)-C(1)-C(6)              119.0(5) 
O(1)-C(1)-C(6)              123.3(6) 
C(1)-C(2)-C(3)              121.8(5) 
C(2)-C(3)-C(4)              120.8(5) 
C(2)-C(3)-C(7)              118.7(5) 
C(4)-C(3)-C(7)              120.5(5) 
C(3)-C(4)-C(5)              115.9(5) 
C(3)-C(4)-C(10)             122.1(4) 
C(5)-C(4)-C(10)             122.0(4) 
C(6)-C(5)-C(4)              122.8(5) 
C(1)-C(6)-C(5)              119.7(5) 
C(8)-C(7)-C(3)              115.2(4) 
C(7)-C(8)-C(9)              112.4(4) 
C(8)-C(9)-C(14)             112.0(4) 
C(8)-C(9)-C(10)             109.6(4) 
C(14)-C(9)-C(10)            108.5(4) 
C(4)-C(10)-C(11)            114.4(4) 
C(4)-C(10)-C(9)             110.1(4) 
C(11)-C(10)-C(9)            112.1(4) 
C(12)-C(11)-C(10)           112.5(4) 
C(11)-C(12)-C(13)           112.4(4) 
C(12)-C(13)-C(14)           108.3(4) 
C(12)-C(13)-C(18)           110.2(4) 
C(14)-C(13)-C(18)           112.6(4) 
C(12)-C(13)-C(17)           116.6(4) 
C(14)-C(13)-C(17)            99.7(3) 
C(18)-C(13)-C(17)           109.1(4) 
C(9)-C(14)-C(13)            114.7(3) 
C(9)-C(14)-C(15)            119.2(4) 
C(13)-C(14)-C(15)           104.1(4) 
C(14)-C(15)-C(16)           103.5(4) 
C(15)-C(16)-C(17)           106.9(4) 
O(2)-C(17)-C(40)            110.0(4) 
O(2)-C(17)-C(13)            114.6(4) 
C(40)-C(17)-C(13)           112.8(4) 
O(2)-C(17)-C(16)            107.3(3) 
C(40)-C(17)-C(16)           109.8(4) 
C(13)-C(17)-C(16)           101.8(4) 
C(20)-C(19)-O(4)            123.1(5) 
C(20)-C(19)-C(24)           119.0(5) 
O(4)-C(19)-C(24)            117.8(5) 
C(19)-C(20)-C(21)           122.6(5) 
C(20)-C(21)-C(22)           119.3(5) 
C(20)-C(21)-C(25)           119.2(4) 
C(22)-C(21)-C(25)           121.5(4) 
C(21)-C(22)-C(23)           116.1(4) 
C(21)-C(22)-C(28)           121.6(4) 
C(23)-C(22)-C(28)           122.3(4) 
C(24)-C(23)-C(22)           123.8(5) 
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C(23)-C(24)-C(19)           119.1(5) 
C(21)-C(25)-C(26)           114.3(4) 
C(27)-C(26)-C(25)           112.5(4) 
C(32)-C(27)-C(26)           112.2(4) 
C(32)-C(27)-C(28)           109.4(4) 
C(26)-C(27)-C(28)           108.8(4) 
C(22)-C(28)-C(29)           114.1(4) 
C(22)-C(28)-C(27)           110.3(4) 
C(29)-C(28)-C(27)           111.8(4) 
C(30)-C(29)-C(28)           112.8(4) 
C(29)-C(30)-C(31)           112.1(4) 
C(30)-C(31)-C(36)           109.5(4) 
C(30)-C(31)-C(32)           109.4(4) 
C(36)-C(31)-C(32)           113.0(4) 
C(30)-C(31)-C(35)           116.7(4) 
C(36)-C(31)-C(35)           108.0(4) 
C(32)-C(31)-C(35)           100.1(3) 
C(27)-C(32)-C(31)           113.4(4) 
C(27)-C(32)-C(33)           120.7(4) 
C(31)-C(32)-C(33)           104.0(4) 
C(34)-C(33)-C(32)           104.3(4) 
C(33)-C(34)-C(35)           106.6(4) 
O(3)-C(35)-C(37)            106.7(4) 
O(3)-C(35)-C(34)            113.5(4) 
C(37)-C(35)-C(34)           109.9(4) 
O(3)-C(35)-C(31)            112.4(4) 
C(37)-C(35)-C(31)           111.6(4) 
C(34)-C(35)-C(31)           102.8(3) 
C(38)-C(37)-C(35)           177.4(5) 
C(37)-C(38)-C(39)           177.5(5) 
C(40)-C(39)-C(38)           178.4(5) 
C(39)-C(40)-C(17)           178.5(5) 
O(5)-C(43)-N(1)             123.0(8) 
O(6)-C(46)-N(2)             122.0(11) 
O(7)-C(49)-N(3)             123.62(16) 
O(8)-C(52)-N(4)             122.6(6) 
C(43)-N(1)-C(42)            122.8(8) 
C(43)-N(1)-C(41)            120.2(8) 
C(42)-N(1)-C(41)            116.7(8) 
C(46)-N(2)-C(44)            120.9(7) 
C(46)-N(2)-C(45)            128.2(9) 
C(44)-N(2)-C(45)            110.7(8) 
C(49)-N(3)-C(48)            138.9(8) 
C(49)-N(3)-C(47)            105.3(8) 
C(48)-N(3)-C(47)            115.8(9) 
C(52)-N(4)-C(51)            123.2(6) 
C(52)-N(4)-C(50)            119.8(6) 
C(51)-N(4)-C(50)            116.8(6) 
______________________________ 
Symmetry transformations used to generate equivalent atoms 
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Table 4.  Anisotropic displacement parameters (A2 x 103) for Di-17-α-Ethynyl-Estradiol. The anisotropic 
displacement factor exponent takes the form: -2 pi2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
_____________________________________________________ 
            U11        U22        U33        U23        U13        U12 
________________________________________________________ 
C(1)     61(3)      66(3)      53(3)     -10(3)     -16(3)      11(3) 
C(2)     70(4)      59(3)      45(3)       2(2)      -6(3)       2(3) 
C(3)     50(3)      43(3)      57(3)      -8(2)       2(3)       3(2) 
C(4)     48(3)      46(3)      38(3)      -6(2)      -1(2)       3(2) 
C(5)     53(3)      63(3)      55(3)      -3(3)      -1(3)      -2(3) 
C(6)     49(3)      76(4)      56(3)     -14(3)     -12(3)       0(3) 
C(7)     49(3)      53(3)      57(3)       4(2)       2(3)      -1(2) 
C(8)     41(3)      65(3)      51(3)       7(2)       2(2)      -3(2) 
C(9)     36(2)      36(2)      52(3)       3(2)       3(2)       0(2) 
C(10)    41(2)      34(2)      51(3)       0(2)      -5(2)      -2(2) 
C(11)    42(3)      49(3)      53(3)       6(2)      -2(2)     -12(2) 
C(12)    45(3)      41(2)      48(3)       2(2)      -5(2)     -11(2) 
C(13)    31(2)      33(2)      52(3)      -4(2)       6(2)       1(2) 
C(14)    31(2)      39(2)      48(3)      -1(2)       6(2)       0(2) 
C(15)    38(2)      54(3)      63(3)       3(2)       4(2)     -12(2) 
C(16)    44(3)      46(3)      61(3)      -5(2)      -1(2)      -8(2) 
C(17)    45(3)      40(2)      40(2)      -6(2)       1(2)       1(2) 
C(18)    47(3)      54(3)      63(3)      -8(2)       6(3)      14(2) 
C(19)    56(3)      74(4)      47(3)      11(3)      14(3)      10(3) 
C(20)    63(3)      60(3)      40(3)      -1(2)       7(3)       2(3) 
C(21)    48(3)      47(3)      44(3)       4(2)       0(2)       3(2) 
C(22)    50(3)      44(2)      37(2)       4(2)       0(2)       2(2) 
C(23)    52(3)      57(3)      48(3)       1(2)       3(3)       1(3) 
C(24)    53(3)      68(3)      52(3)       6(3)      10(3)      -6(3) 
C(25)    45(3)      54(3)      48(3)      -1(2)      -3(2)      -5(2) 
C(26)    47(3)      60(3)      51(3)      -5(2)      -5(2)      -2(2) 
C(27)    38(2)      41(2)      45(3)      -2(2)      -4(2)       3(2) 
C(28)    46(3)      40(2)      43(3)       0(2)       1(2)       0(2) 
C(29)    47(3)      53(3)      50(3)      -5(2)       0(2)     -10(2) 
C(30)    45(3)      50(3)      47(3)      -7(2)       1(2)      -8(2) 
C(31)    37(2)      33(2)      43(2)      -1(2)      -3(2)       3(2) 
C(32)    35(2)      33(2)      45(3)      -4(2)      -6(2)      -1(2) 
C(33)    43(3)      45(3)      57(3)      -4(2)       0(2)      -7(2) 
C(34)    45(3)      43(3)      58(3)       0(2)      -1(2)      -5(2) 
C(35)    47(3)      39(2)      36(2)       3(2)      -5(2)       3(2) 
C(36)    51(3)      54(3)      63(3)       3(2)      -3(3)      16(3) 
C(37)    48(3)      46(3)      37(2)      -2(2)       4(2)       2(2) 
C(38)    49(3)      41(2)      39(3)      -1(2)       2(2)      13(2) 
C(39)    53(3)      45(3)      36(2)      -9(2)      -8(2)       9(2) 
C(40)    46(3)      42(3)      42(3)      -7(2)      -8(2)       3(2) 
O(1)     98(3)     104(3)      58(3)      -3(2)     -28(3)       9(3) 
O(2)     63(2)      54(2)      40(2)     -12(1)       7(2)      -5(2) 
O(3)     70(2)      67(2)      41(2)       7(2)     -10(2)       4(2) 
O(4)     97(3)     112(4)      57(3)      -6(2)      30(3)      -5(3) 
C(41)   149(8)      76(5)     131(7)      10(5)      50(7)       4(6) 
C(42)   138(9)     268(15)     90(7)       6(8)      -6(7)      -9(10) 
C(43)    98(6)     112(6)      85(5)      -3(5)     -26(5)       0(5) 
C(44)   152(9)     112(6)      81(5)      -1(4)      18(5)     -48(6) 
C(45)   330(20)     99(8)     300(19)    -53(10)    177(18)     20(11) 
C(46)   137(8)     181(9)      58(4)      -6(5)      12(5)     -85(8) 
C(47)   188(14)     97(8)     370(20)     -4(11)    -79(15)     12(9) 
C(48)   185(12)    151(9)     157(10)    -53(8)     -55(10)     17(9) 
C(49)   156(11)    610(40)    113(9)     204(16)     51(8)     162(18) 
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C(50)    94(5)      69(4)     123(6)      16(4)      -4(5)      11(4) 
C(51)   123(6)     107(6)      65(4)     -27(4)      -2(4)     -17(5) 
C(52)    85(5)      82(5)      54(4)       2(3)       8(3)      -5(4) 
N(1)     79(4)     105(4)      67(4)     -22(3)      -9(3)      17(4) 
N(2)    117(5)      65(3)      78(4)      -8(3)      11(4)      -9(3) 
N(3)     92(4)     106(5)      73(4)       7(3)     -10(3)     -15(4) 
N(4)     74(3)      77(3)      57(3)      -1(2)      10(3)      11(3) 
O(5)    112(5)     174(7)     124(5)     -27(5)     -30(4)     -16(5) 
O(6)    354(16)    366(15)    113(6)     -12(7)      45(7)    -295(14) 
O(7)    128(6)     290(11)    197(8)     152(8)     -12(6)      28(7) 
O(8)    129(4)      85(3)      80(3)      12(2)      14(3)     -14(3) 
_______________________________________________________ 
  
 
Table 5.  Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2 x 103) for Di-17-α-Ethynyl-
Estradiol. 
_________________________________________ 
 
                      x                  y                z           U(eq) 
_________________________________________ 
H(2)         8418          3387          3884          70 
H(5)        10920          4527          2829          69 
H(6)        12519          4443          3454          72 
H(7A)        6213          2923          3276          64 
H(7B)        5189          3467          3484          64 
H(8A)        4174          3822          2880          63 
H(8B)        4075          3136          2794          63 
H(9)         7063          3182          2455          49 
H(10)        6731          4427          2584          51 
H(11A)       9568          4573          2225          58 
H(11B)       9784          3888          2147          58 
H(12A)       8630          4312          1539          54 
H(12B)       6961          4622          1783          54 
H(14)        4461          4001          2109          47 
H(15A)       2539          3201          2081          62 
H(15B)       4230          2761          1975          62 
H(16A)       2169          3411          1403          61 
H(16B)       3758          2940          1295          61 
H(18A)       8363          3246          1324          82 
H(18B)       6878          2837          1551          82 
H(18C)       8591          3109          1802          82 
H(20)       -3736          6761          3902          65 
H(23)       -5861          5539          2858          63 
H(24)       -7535          5599          3461          69 
H(25A)       -362          6666          3542          59 
H(25B)      -1380          7211          3334          59 
H(26A)        815          7016          2855          63 
H(26B)        759          6329          2938          63 
H(27)       -2154          6946          2504          50 
H(28)       -1681          5704          2631          52 
H(29A)      -4445          5523          2256          60 
H(29B)      -4779          6206          2186          60 
H(30A)      -3532          5825          1576          57 
H(30B)      -1834          5527          1817          57 
H(32)         568          6170          2159          45 
H(33A)        690          7412          2039          58 
H(33B)       2422          6980          2128          58 
H(34A)       2756          6810          1448          58 
H(34B)       1107          7269          1357          58 
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H(36A)      -3584          7027          1880          84 
H(36B)      -3519          6865          1403          84 
H(36C)      -1999          7301          1592          84 
H(1)        12539          3994          4111         130 
H(2A)        6275          3970           859          79 
H(3)          168          6441           816          89 
H(4)        -6427          6487          4258         133 
H(41A)       9007          5184          3738         178 
H(41B)      10154          5270          4155         178 
H(41C)       8487          5707          4042         178 
H(42A)       7783          5043          4847         248 
H(42B)       9367          4627          4661         248 
H(42C)       7295          4383          4730         248 
H(43)        5869          4814          3780         118 
H(44A)       1422          5712           511         173 
H(44B)       1806          5570            38         173 
H(44C)       3219          5339           382         173 
H(45A)       3021          4333           296         363 
H(45B)       1984          4463          -129         363 
H(45C)       1060          4028           197         363 
H(46)       -1185          5216           703         150 
H(47A)       5425          6520             7         326 
H(47B)       4298          6621           425         326 
H(47C)       6537          6613           428         326 
H(48A)       6819          7700           638         246 
H(48B)       4728          7511           753         246 
H(48C)       5083          8073           473         246 
H(49)        4913          7079          -366         349 
H(50A)       6076          3574            74         143 
H(50B)       4654          3548          -305         143 
H(50C)       6853          3470          -381         143 
H(51A)       6851          2308          -596         148 
H(51B)       4885          2594          -717         148 
H(51C)       4940          2014          -444         148 
H(52)        5717          2763           476          88 
_________________________________________ 
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Figure B.1. Relation between pmols of Pt uptaked and cytotoxicity in T-47D, SK-OV-3 and MDA-MB-231 of  cis 
and trans-[Pt(2ET)Cl(NH3)2]
+, cis and trans-[Pt(Py)Cl(NH3)2]
+ and cisplatin. 
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Figure B.2. Relation between pmols of Pt uptaked and cytotoxicity in T-47D, SK-OV-3 and MDA-MB-231 of  EE, 
ET and Ph-Pt-Terpy and cisplatin.  
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